



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07D 233/22	A1	(11) International Publication Number: WO 91/18885 (43) International Publication Date: 12 December 1991 (12.12.91)
(21) International Application Number: PCT/US91/03727 (22) International Filing Date: 4 June 1991 (04.06.91) (30) Priority data: 533,241 4 June 1990 (04.06.90) US (71) Applicant: THE DU PONT MERCK PHARMACEUTICAL COMPANY [US/US]; 1007 Market Street, Wilmington, DE 19898 (US). (72) Inventors: BILLHEIMER, Jeffrey, Thomas ; 1618 East Lafayette Drive, West Chester, PA 19382 (US). GILLIES, Peter, John ; 55 Quail Hollow Drive, Hockessin, DE 19707 (US). HIGLEY, C., Anne ; 17 Ballad Drive, Newark, DE 19702 (US). MADUSKUIE, Thomas, Peter, Jr. ; 613 Foulkstone Road, Wilmington, DE 19803 (US). WEXLER, Ruth, Richmond ; 2205 Patwynn Road, Wilmington, DE 19810 (US).		(74) Agents: FATO, Gildo, E. et al.; The Du Pont Merck Pharmaceutical Company, Legal/Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US). (81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), SE (European patent). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: IMIDAZOLES FOR THE TREATMENT OF ATHEROSCLEROSIS (57) Abstract This invention relates to imidazoles as inhibitors of acyl-CoA: cholesterol acyltransferase (ACAT), processes for their preparation, and their use as antihypercholesterolemic agents or antiatherosclerotic.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

TitleImidazoles for the Treatment of AtherosclerosisCross-Reference to Related Application

5 This application is a continuation-in-part of U.S.S.N. 07/416,606 filed October 10, 1989, which is a continuation-in-part of U.S.S.N. 07/279,981, filed December 5, 1988, both of which are incorporated herein by reference.

10 Field of the Invention

This invention relates to imidazoles as inhibitors of acyl-CoA: cholesterol acyltransferase (ACAT), pharmaceutical compositions containing them, processes for their preparation, and their use as
15 antihypercholesterolemic and/or antiatherosclerotic agents.


Background of the Invention

Hypercholesterolemia is an established risk factor in the development of atherosclerosis. Therapeutic
20 agents which control the level of serum cholesterol have proven to be effective in the treatment of coronary artery disease. While agents exist that can modulate circulating levels of cholesterol carrying lipoproteins, these agents have little or no effect on the intestinal
25 absorption of cholesterol. Dietary cholesterol can increase the level of serum cholesterol to levels which place an individual at increased risk for the development or exacerbation of atherosclerosis. Since much of the free or unesterified cholesterol that is
30 absorbed by intestinal mucosal cells must first be esterified by ACAT prior to its incorporation and secretion into the bloodstream in large lipoprotein particles called chylomicrons, inhibition of ACAT can reduce the absorption of dietary cholesterol. In
35 addition, the accumulation and storage of cholesteryl

esters in the arterial wall is associated with increased activity of ACAT. Inhibition of the enzyme is expected to inhibit the formation or progression of atherosclerotic lesions in mammals.

5 There are a limited number of patents in the literature disclosing compounds which are useful as ACAT inhibitors in particular and antiatherosclerotic agents in general. For example, U.S. Patent No. 4,623,662, issued to De Vries on November 18, 1986, discloses ureas and thioureas as ACAT inhibitors useful for reducing the
10 cholesterol ester content of an arterial wall, inhibiting atherosclerotic lesion development, and/or treatment of mammalian hyperlipidemia. U.S. Patent No. 4,722,927, issued to Holmes on February 2, 1988,
15 discloses disubstituted pyrimidineamides of oleic and linoleic acids as ACAT inhibitors useful for inhibiting intestinal absorption of cholesterol.

U.S. Patent No, 4,460,598, issued to Lautenschläger et al. on July 17, 1984, discloses compounds of the
20 formula:



wherein


25 R¹, R², R³, R⁴, R⁵ and R⁶ independently are H, F, Cl, Br, I, alkyl, alkoxy, or CF₃, with the proviso

that one or several of R^1 and R^2 , R^3 and R^4 , or R^5 and R^6 taken together represent methylenedioxy;
 R^7 is H, alkali metal ion, alkyl of 1 to 6 carbon atoms, or benzyl; and

5 n is 0 to 10.

The synthesis and the use of these compounds in the treatment of thromboembolic, inflammatory and/or atherosclerotic diseases is disclosed.

U.S. Patent No. 4,654,358, issued to Lautenschläger
 10 et al. on March 31, 1987, discloses compounds of the formula:



15 wherein

k is 0, 1, or 2,

R^1 , R^2 and R^3 independently are H, F, Cl, CH_3 , CH_3O , or CF_3 ;

20 R^4 is H, Na, K, CH_3 , CH_3CH_2 , $(CH_3)_2CH$, $CH_3(CH_2)_2$, or butyl;


A is $C(CH_3)_2$, $CH(CH_2)_mCH_3$, $(CH_2)_n$, or $(CH_2)_{n-2}CH(CH_3)$;

m is 0 to 8; and

n is 2 to 10.


The synthesis and the use of these compounds in the treatment of inflammatory diseases, diseases of lipid metabolism, and/or hyperlipidemic diseases is disclosed.

German Laid Open Application No. DE 3504679,
 5 Lautenschläger et al., published August 14, 1986,
 discloses compounds of the formula:



10 wherein


R^1 , R^2 and R^3 independently are H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 1 to 6 carbon atoms, or



15

R^4 and R^5 independently are H, C_6H_5 , or alkyl of 1 to 9 carbon atoms;

20 R^6 and R^7 independently are H, OH, saturated or unsaturated alkyl, cycloalkyl, or hydroxyalkyl of 1 to 10 carbon atoms,



R^8 , R^9 , R^{10} , R^{11} , R^{12} and R^{13} independently are H, F, Cl, Br, NO_2 , CH_3CONH , OH, alkyl of 1 to 3 carbon atoms, CF_3 , and alkoxy of 1 to 3 carbon atoms, with the proviso that R^8 and R^9 , R^{10} and R^{11} , or R^{12} and R^{13} taken together represent methylenedioxy;

R^{14} is alkyl of 1 to 2 carbon atoms;

m and n taken together represent a whole number from 0 to 9;


p is 0 to 2;

s is 0 to 2; and

t is 0 or 2.


The synthesis and the use of these compounds in the treatment of thromboembolic, inflammatory, atherosclerotic, and lipid metabolism diseases in general is disclosed.

German Laid Open Application No. DE 3504680, Lautenschläger et al., published August 14, 1986, discloses compounds of the formula:



wherein


R^1 , R^2 and R^3 independently are H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 1 to 6 carbon atoms, or



R¹ and R² can be taken together with the carbon atoms in the 4 and 5 position of the imidazole ring to represent a carbocyclic five- or six-membered aromatic or partially hydrogenated ring which may be substituted by R⁸ or R⁹;

R⁴ and R⁵ independently are H, C₆H₅, or alkyl of 1 to 9 carbon atoms;

R⁶ is alkyl, cycloalkyl, or hydroxyalkyl of 1 to 20 carbon atoms, H, alkali metal if X is -COO-, 1-phenethyl, or



R⁷ is H, OH if X is -CONR⁷-, or alkyl of 1 to 4 carbon atoms;

R⁸, R⁹, R¹⁰ and R¹¹ are independently H, Cl, F, Br, NO₂, CH₃CONH, OH, alkyl of 1 to 3 carbon atoms, CF₃, or alkoxy of 1 to 3 carbons, or R⁸ and R⁹ or R¹⁰ and R¹¹ taken together represent methylene-dioxy;

X is a bond, O, OC(=O)O, C(=O)O, CONR⁷, OC(=O), or OC(=O)NR⁷;

m and n taken together represent a whole number from 0 to 9;


p is 0 to 2;

s is 0 to 2; and


t is 0 or 2.

The synthesis and the use of these compounds in the treatment of thromboembolic, inflammatory, atherosclerotic, and lipid metabolism diseases in general is disclosed.

Durant et al., U.S. Patent 4,228,291, issued October 14, 1980, teaches compounds of the formula:




5 wherein A together with the carbon atom form an unsaturated heterocyclic nucleus which may be an imidazole, pyrazole, pyrimidine, pyrazine, pyridazine, thiazole, isothiazole, oxazole, isoxazole, triazole, thiadiazole, benzimidazole, or 5,6,7,8-tetrahydro-
 10 imidazol[1,5-a]pyridine ring; X_1 is H, lower alkyl, hydroxyl, trifluoromethyl, benzyl, halogen, amino, or



15 X_2 is H, or when X_1 is lower alkyl, lower alkyl or halogen; k is 0 to 2 and m is 2 or 3, provided that the sum of k and m is 3 or 4; Y is O, S, or NH; E is NR_2 ; R_1 is H, lower alkyl or di-lower alkyl amino-lower alkyl;
 20 and R_2 is H, nitro, or cyano. The compounds are said to be antihistamines of the H_2 receptor blocking type, as well as having anti-inflammatory activity.

White, U.S. Patent 4,413,130, November 1, 1983, discloses histamine H_2 receptor antagonists of the
 25 formula:



where A together with the carbon atom form an unsaturated heterocyclic nucleus which may be an imidazole, pyridine, thiazole, isothiazole, oxazole, isoxazole, pyrazole, triazole, thiadiazole, pyrimidine, pyrazine or pyridazine; X₁ and X₂ may be H, lower alkyl, trifluoromethyl, hydroxyl, halogen, amino, or X₁ and X₂ and at least two of the atoms comprising A may form a further ring; k is 0 to 2 and m is 2 or 3, provided that the sum of k and m is 3 or 4; E is O, S, or NR₂; R₁ is H, lower alkyl, acyl, or dialkylaminoalkyl; and R₂ is H, NO₂, CN, alkansulphonyl or arenesulphonyl.


There are no known literature references disclosing the imidazoles of this invention, their use as ACAT inhibitors, or their use to lower cholesterol or in the treatment of atherosclerosis.

The compounds of this invention are very potent ACAT inhibitors. As shown by the data presented below in Table 6, the compounds of this invention inhibit ACAT activity in vitro with at least ten times the potency of any ACAT inhibitors described in the current literature. As shown by the data presented below in Table 8, the compounds of this invention cause a reduction in the serum cholesterol level in cholesterol-fed hamsters. The compounds of this invention are thus expected to be useful in pharmaceutical formulations for the treatment of atherosclerosis. The compounds of this invention have been shown to lower serum cholesterol, and this invention should not be construed as limited to any particular antihypercholesterolemic mechanism of action.

Summary of the Invention

The present invention provides novel compounds of Formula (I), processes for their preparation, pharmaceutical compositions containing such imidazoles, and therapeutic methods for their use as antihypercholesterolemic and/or antiatherosclerotic agents.


This invention provides compounds of Formula (I):



wherein

R¹ and R² are selected independently from H, C₁-C₈ alkyl, C₃-C₈ branched alkyl, C₃-C₇ cycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₇-C₁₄ araalkyl, 2-, 3- or 4-pyridinyl, 2-thienyl, 2-furanyl, phenyl optionally substituted with 1 to 3 groups selected from F, Cl, Br, OH, C₁-C₄ alkoxy, C₁-C₄ alkyl, C₃-C₈ branched alkyl, CH₃S(O)_r, NO₂, CF₃, or NR⁷R⁸; or

R¹ and R² can also be taken together as



where L is O, $O(CH_2)_{m+1}O$, or $(CH_2)_m$ where m is 0-4;
 R^3 is H, C_1 - C_6 alkyl, allyl, benzyl, or phenyl
optionally substituted with F, Cl, CH_3 , CH_3O , or
 CF_3 ;

- 5 R^4 is straight chain C_1 - C_8 alkyl optionally
substituted with F; C_3 - C_8 branched alkyl, C_3 - C_7
cycloalkyl, C_4 - C_{10} cycloalkylalkyl, C_7 - C_{14} araalkyl
where the aryl group is optionally substituted
with 1 to 3 groups selected from C_1 - C_4 alkyl or
10 alkoxy, F, Br, Cl, NH_2 , OH, CN, CO_2H , CF_3 , NO_2 , C_1 -
 C_4 carboalkoxy, NR^7R^8 , or $NCOR^7$; C_3 - C_6 alkenyl or
alkynyl, C_1 - C_3 perfluoroalkyl, phenyl optionally
substituted with 1 to 3 groups selected from C_1 - C_4
15 alkyl, C_3 - C_8 branched alkyl, C_1 - C_4 alkoxy, F, Br,
Cl, NH_2 , OH, CN, CO_2H , CF_3 , NO_2 , C_1 - C_4 carboalkoxy,
 NR^7R^8 or $NCOR^7$; pentafluorophenyl, benzyl
optionally substituted with 1 to 3 groups selected
from C_1 - C_4 alkyl or alkoxy, F, Br, Cl, NH_2 , OH,
CN, CO_2H , CF_3 , NO_2 , C_1 - C_4 carboalkoxy, NR^7R^8 , or
20 $NCOR^7$; 2-, 3- or 4- pyridinyl, pyrimidinyl, or
biphenyl;
 R^5 is H, C_1 - C_6 alkyl, or benzyl;
 R^6 is C_1 - C_8 alkyl, C_3 - C_8 branched alkyl, C_3 - C_7
cycloalkyl, C_3 - C_8 alkenyl or alkynyl, phenyl
25 optionally substituted with 1 to 3 groups selected
from C_1 - C_4 alkyl or alkoxy, F, Br, Cl, NH_2 , OH,
CN, CO_2H , CF_3 , NO_2 , C_1 - C_4 carboalkoxy, NR^7R^8 , or
 $NCOR^7$; pentafluorophenyl, benzyl optionally
substituted with 1 to 3 groups selected from C_1 - C_4
30 alkyl or alkoxy, F, Br, Cl, NH_2 , OH, CN, CO_2H ,
 CF_3 , NO_2 , C_1 - C_4 carboalkoxy, NR^7R^8 , or $NCOR^7$;
 R^7 and R^8 are selected independently from H or C_1 - C_4
alkyl;
 X is $S(O)_r$, O, NR^5 , CH_2 ;

A is C₂-C₁₀ alkyl, C₃-C₁₀ branched alkyl, C₃-C₁₀ alkenyl, or C₃-C₁₀ alkynyl;

Y is O, S, H₂, NH;

Z is NHR⁴, OR⁴, or R⁴;

5 r is 0-2,

or a pharmaceutically acceptable salt thereof.


Preferred are compounds of Formula (I) wherein:

R¹ and R² are selected independently from C₁-C₈

10 alkyl, C₃-C₈ branched alkyl, C₃-C₇ cycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₇-C₁₄ araalkyl, 2-, 3-, or 4-pyridinyl, 2-thienyl, 2-furanyl, phenyl optionally substituted with 1 to 2 groups selected from F, Cl, Br, OH, C₁-C₄ alkoxy, C₁-C₄ alkyl, C₃-C₈

15 branched alkyl, CH₃S(O)_r, NO₂, or NR⁷R⁸; or

R¹ and R² can also be taken together as



20 where L is O, O(CH₂)_{m+1}O, or (CH₂)_m where m is 0-4.

More preferred are compounds of Formula (I)

wherein:

R³ is H, CH₃, phenyl;

R⁶ is C₁-C₈ alkyl, C₃-C₈ branched alkyl, C₃-C₇

25 cycloalkyl, phenyl optionally substituted with 1 to 3 groups selected from CH₃, CH₃O, F, Br, Cl, NH₂, OH, CN, CO₂H, CF₃, or di(C₁-C₄)alkylamino; or benzyl optionally substituted with 1 to 3 groups

selected from CH₃, CH₃O, F, Br, Cl, NH₂, OH, CN, CO₂H, CF₃, or di(C₁-C₄)alkylamino;


X is S(O)_r, CH₂;

A is C₂-C₁₀ alkyl, C₄-C₉ branched alkyl.

5

More specifically preferred because of their biological activity are compounds of Formula (I) wherein:

10 R¹ and R² are selected independently from C₁-C₈ alkyl, C₃-C₈ branched alkyl, C₃-C₇ cycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₇-C₁₄ araalkyl, 2-, 3-, or 4-pyridinyl, 2-thienyl, or phenyl optionally substituted with 1 to 2 groups selected from F, Br, Cl, C₁-C₄ alkyl, C₃-C₈ branched alkyl, CH₃O, 15 CH₃S(O)_r, NO₂, or di(C₁-C₄)alkylamino; or R¹ and R² can also be taken together as



20 where L is O or OCH₂O;

R³ is H;

25 R⁴ is C₁-C₈ alkyl, C₃-C₈ branched alkyl, C₃-C₇ cycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₇-C₁₄ araalkyl, phenyl substituted with 1 to 3 groups selected from CH₃, F, Cl, CH₃O, CN; or benzyl optionally substituted with 1 to 3 groups selected from CH₃, CH₃O, F, Cl, or CN;

R⁶ is C₁-C₈ alkyl or phenyl optionally substituted with 1 to 3 groups selected from CH₃, CH₃O, F, Cl, or CN;

A is C₄-C₉ alkyl;

5 X is S(O)_r.

Specifically preferred are:

N'-(2,4-difluorophenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea

10 N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-phenylurea

N'-(2,4-difluorophenyl)-N-[8-(4,5-diphenyl-1H-imidazol-2-ylthio)octyl]-N-heptylurea

N-butyl-N'-(2,4-difluorophenyl)-N-[8-(4,5-diphenyl-1H-imidazol-2-ylthio)octyl]urea

15 N'-(2,4-dimethoxyphenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea

N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-methylurea

20 N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-propylurea

N'-(2,4-difluorophenyl)-N-[5-[(4,5-diphenyl-1H-imidazol-2-yl)sulfonyl]pentyl]-N-heptylurea

N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N'-(3-fluorophenyl)-N-heptylthiourea

25 N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N'-(3-fluorophenyl)-N-heptylurea

N'-(2,4-difluorophenyl)-N-heptyl-N-[5-(4-phenyl-1H-imidazol-2-ylthio)pentyl]urea

30 N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-(2,4,6-trifluorophenyl)thiourea

N'-(2,6-dichlorophenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea

N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-(1-methylethyl)urea

- N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-2,4-difluoro-N-heptylbenzeneacetamide
- N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-propylthiourea
- 5 N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-octylurea
- N'-cyclohexyl-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea
- N'-(2,4-difluorophenyl)-N-[5-[(4,5-diphenyl-1H-imidazol-2-yl) sulfinyl]pentyl]-N-heptylurea
- 10 N'-(2,4-difluorophenyl)-N-[2-(4,5-diphenyl-1H-imidazol-2-ylthio)ethyl]-N-heptylurea
- N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylbutanamide
- 15 N-[5-[4,5-bis(4-methoxyphenyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea
- N-[5-[4,5-bis(1-methylethyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea
- N'-(2,4-difluorophenyl)-N-[5-(4,5-dipropyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea
- 20 N-[5-[4,5-bis(4-fluorophenyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea
- N-[5-(1H-dibenz[2,3:6,7]oxedino[4,5-d]imidazol-2-ylthio)pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea
- 25 N-[5-[4,5-bis(2-thienyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea
- N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylpentanamide
- N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl[1,1'-biphenyl]-4-acetamide
- 30 N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-(2,4,6-trifluorophenyl)urea
- N-[5-[4,5-bis(2-pyridinyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea

- N'-(2,4-difluorophenyl)-N-[6-(4,5-diphenyl-1H-imidazol-2-yl)hexyl]-N-heptylurea
N-[5-[4,5-bis(4-methylphenyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea
5 N-[5-[4,5-bis(4-methoxyphenyl)-1H-imidazol-2-ylthio]pentyl]-N-heptylbutanamide
N-[5-[4,5-bis(4-hydroxyphenyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea
N-[5-[4,5-bis(1-methylethyl)-1H-imidazol-2-ylthio]pentyl]-N-heptylcyclohexaneacetamide
10 N-[5-[4,5-bis(3-methoxyphenyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea
N-[5-[4,5-bis(2-methoxyphenyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea
15 N'-[(1,1'-biphenyl)-4-yl]-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea
N-(2,4-difluorophenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N'-octylurea
Propyl [5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]heptylcarbamate
20 (Phenylmethyl) [5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]heptylcarbamate
Phenyl [5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]heptylcarbamate
25 (2-Methylpropyl) [5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]heptylcarbamate
Ethyl [5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]heptylcarbamate
Octyl [5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]heptylcarbamate
30 N-[5-[4,5-bis[4-(dimethylamino)phenyl]-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea

- N-[5-(4,5-dicyclohexyl-1H-imidazol-2-ylthio)pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea
(4-fluorophenyl) [5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]heptylcarbamate
- 5 N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N'-octyl-N-phenylurea
- N-[5-(1H,9H-dibenz[4,5:8,9][1,3]dioxonino[6,7-d]imidazol-2-ylthio)-pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea
- 10 N'-(4-cyanophenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea
- N-[5-[4,5-bis(4-methoxyphenyl)-1H-imidazol-2-ylthio]pentyl]-2,4-difluoro-N-heptylbenzeneacetamide
- 15 Phenyl [5-[4,5-bis(4-(dimethylamino)phenyl)-1H-imidazol-2-ylthio]pentyl]heptylcarbamate
- N-[5-[4,5-bis(4-methoxyphenyl)-1H-imidazol-2-ylthio]pentyl]-N-heptyl-N'-(1-methylethyl)urea
- N-[5-[4,5-bis[4-(dimethylamino)phenyl]-1H-imidazol-2-ylthio]pentyl]-N-heptyl-N'-(1-methylethyl)urea
- 20 or a pharmaceutically acceptable salt thereof.

Detailed Description of the Invention

Synthesis


- The novel compounds of Formula (I) may be prepared
- 25 using the reactions and techniques described in this section. The reactions are performed in solvents appropriate to the reagents and materials employed and suitable for the transformation being effected. It is understood by those skilled in the art of organic
- 30 synthesis that the functionality present on the imidazole and other portions of the molecule must be compatible with the reagents and reaction conditions

proposed. Not all compounds of Formula (I) falling into a given class may be compatible with some of the reaction conditions required in some of the methods described. Such restrictions to the substituents which
5 are compatible with the reaction conditions will be readily apparent to one skilled in the art and alternative methods described must then be used.

The compounds of Formula (I) wherein X is O, S or NH can be prepared by the route shown in Scheme 1. The
10 esters of Formula (3) wherein X is O or S can be prepared by converting the requisite 4-imidazolin-2-one (1) where X is O, or 4-imidazolin-2-thione (1) where X is S, into the corresponding alkali metal salt by addition of a base such as sodium hydride, and the salt
15 is alkylated with a compound of the formula M-(A')CO₂R, wherein R is CH₃ or C₂H₅, M is a halogen or a tosylate group, and A' is a moiety having one less methylene group than A, in a polar solvent such as N,N-dimethylformamide. Alternatively, the esters of Formula
20 (3) wherein X is S may be prepared by direct alkylation of the requisite 4-imidazolin-2-thione with M-(A')CO₂R, without the addition of a suitable base, in a polar solvent such as N,N-dimethylformamide at a temperature from ambient temperature to the reflux temperature of the solvent. The esters of Formula (3) wherein X is NH
25 can be prepared by the reaction of the requisite 2-aminoimidazole of Formula (2) with a compound of the formula M-(A')CO₂R wherein R, M, and A' are as defined above, in a suitable solvent such as N,N-dimethylformamide. Compounds of Formula (2) wherein R³
30 is H are preferentially alkylated at a ring nitrogen atom. Therefore, in order to prepare compounds of Formula (I) wherein X is NH and R³ is H, it is usually necessary to protect the ring nitrogen atom. The

protecting group is preferably stable under basic conditions and easily removed under acidic conditions, e.g., a silyl or trityl group. The protected 2-aminoimidazole can then be used to prepare esters of Formula (3) wherein R^3 is a protecting group. The protecting group can be removed at any suitable stage in the synthetic sequence for the preparation of the compounds of Formula (I) wherein X is NH and R^3 is H.

10

Scheme 1

The esters of Formula (3) are hydrolyzed to the corresponding carboxylic acids of Formula (4) by methods which are well known in the chemical literature. For

example, the hydrolysis can be accomplished by reaction with an alkali metal hydroxide in aqueous or organic solvents such as water, alcohols, ethers or mixtures thereof, followed by acidification with a mineral acid.

5 The methods used to prepare compounds of Formula (4) are substantially similar to the methods described in U.S. 4,654,358, U.S. 4,460,598 and in co-assigned Application U.S. Serial No. 244,170 (BP-6339) filed September 14, 1988, the teaching of which is incorporated by
10 reference. Compounds of Formula (4) wherein R^1 and R^2 are phenyl or substituted phenyl, R^3 is H, X is S, A' is $(CH_2)_{n-1}$ and n is 8 to 21 are claimed as antihypercholesterolemic compounds in co-assigned application, U.S.S.N. 244,170 (BP-6339).


15 The amides of Formula (5) are prepared by coupling the carboxylic acids of Formula (4) with a primary amine by amide bond forming reactions which are well known in the chemical literature. One method for amide bond formation is to use a coupling reagent which generates a
20 reactive intermediate such as a mixed anhydride or active ester. Examples of such coupling agents are disubstituted carbodiimides, N,N'-carbonyldiimidazole, diphenylphosphoryl azide, and the like. For example, the coupling can be carried out with a disubstituted
25 carbodiimide such as dicyclohexylcarbodiimide in an appropriate solvent such as methylene chloride, acetonitrile, toluene, or N,N-dimethylformamide. Nucleophilic hydroxy compounds such as 1-hydroxy-1H-benzotriazole, which form highly active esters, may be
30 added to catalyze the reaction.

There are several alternate approaches to the preparation of the amides of Formula (5). For example, the boron trifluoride etherate catalyzed reaction of the carboxylic acids of Formula (4) with a primary amine,

with azeotropic removal of water, affords the amides of Formula (5). Another approach is to convert the carboxylic acids of Formula (4) to the corresponding acid chloride using thionyl chloride, oxalyl chloride or the like and then to react the acid chloride with a primary amine in the presence of a base such as triethylamine to afford the amides of Formula (5). Alternatively, the esters of Formula (3) can be directly converted to the amides of Formula (5) by ester aminolysis in the presence of strong alkali metal catalysts such as sodium amide, sodium hydride, sodium methoxide, Grignard reagents or butyllithium, or in the presence of milder catalysts such as 2-pyridone, boron tribromide, or dimethylaluminum amides.

The amines of Formula (6) can be prepared by reduction of the corresponding amides of Formula (5) by a variety of methods well known to those skilled in the art. For example, reagents such as lithium aluminum hydride, diborane, sodium bis(2-methoxyethoxy)aluminum hydride (Red-Al®), and diisobutylaluminum hydride can be used to reduce an amide to an amine. Such reactions are typically conducted in an appropriate anhydrous aprotic solvent such as ether, toluene or tetrahydrofuran at a temperature from room temperature to the boiling point of the solvent for a period of 2-48 hours.

Alternatively amines of Formula (6), wherein X is NH can be prepared by the route shown in Scheme 2. The primary amines (2) can be prepared by reacting 2-bromoimidazoles of Formula (8) with an appropriately elaborated diamine under neat, thermal conditions or in an appropriate solvent such as N,N-dimethylformamide, toluene, acetonitrile or tetrahydrofuran, at or below the boiling point of the solvent.

Scheme 2

5 The secondary amines of Formula (6) wherein X is NH can be prepared by direct alkylation of the primary amines of Formula (9) with an appropriately substituted alkyl halide. Or, the secondary amines (6) are prepared by acylation of the primary amines of Formula (9) with
 10 an acid chloride or activated carboxylic acid derivative to give the amide of Formula (10) and reduction of the amide (10) to the amines (6) by well known methods previously described.


 The compounds of Formula (7) where Y is O and Z is
 15 NR^4 , OR^4 , R^4 are prepared by the reaction of the secondary amines (6) with the requisite isocyanates, chloroformates, acid chlorides, activated urea or activated carboxylic acid derivatives in an appropriate solvent such as hexane, toluene, diethyl ether, diphenyl
 20 ether, methylene chloride or tetrahydrofuran at a

temperature at or below the boiling point of the solvent.

The guanidines of Formula (7), where in Y is NH and Z is NR^4 are prepared by the reaction of the secondary amines (6) with an appropriately substituted S-methyl carbamimidothioate salt (C. R. Rasmussen, F. J. Villani, et al., *Synthesis*, 460, 1988), in acetonitrile or dioxane at reflux.


The amines of Formula (7), wherein Y is H_2 are prepared by reaction of the corresponding ureas or amides of Formula (7) wherein Y is O, with a reducing agent such as lithium aluminum hydride or other such reagents in an appropriate anhydrous aprotic solvent such as hexane, toluene, diethylether or tetrahydrofuran at temperatures at or below the boiling point of the solvent.

As shown in Scheme 3, the thioureas of Formula (12) wherein X is S, O or NH and Z is NHR^4 can be prepared in an analogous manner by the reaction of the secondary amines of Formula (6) with the requisite isothiocyanate. Alternatively, the thioureas or thioamides where Z is R^4 of Formula (12) can be prepared from the ureas or amides of Formula (7) by the reaction with Lawesson's reagent or diphosphorus pentasulfide in an appropriate solvent such as toluene.

Scheme 3

5 As shown in Scheme 4, alternatively the amides of Formula (5) can be prepared by the alkylation of (1) or (2) with compounds of the formula M-(A')CONHR⁶ wherein M is a halogen or tosylate group, as described for compounds of Formula (3), Scheme 1.

10

Scheme 4

15 Alternatively, compounds of Formula (7), where X is O, S, or NH can be prepared by the route shown in Scheme 5. The compounds of Formula (13) can be prepared from a lactone or an hydroxyalkylcarboxylic ester and an appropriate amine, neat or in an inert solvent such as

N,N-dimethylformamide at ambient or elevated temperatures. The amines of Formula (14) are prepared by reduction of the corresponding amide of Formula (13) by a variety of well known methods, as illustrated above. The compounds of Formula (15) are prepared by the reaction of the secondary amine (14) with the requisite isocyanates, chloroformates, acid chlorides, activated ureas or activated carboxylic acid derivatives as described for the preparation of compounds of Formula (7), Scheme 1.


The compounds of Formula (7), wherein A is branched alkyl, can be prepared by a route analogous to that shown in Scheme 5. The requisite lactones with branching substituents can be prepared by functionalization of the parent unsubstituted lactones. Alternatively, branched cyclic α,ω -diacid anhydrides can be reduced to the corresponding branched lactone using agents such as sodium borohydride. Synthesis of compounds of Formula (16) then proceeds exactly as described in the preceding paragraph, and alkylation of compounds of Formula (1) affords compounds of Formula (7), wherein A is branched alkyl.

The compound of Formula (16) can be prepared by conversion of the hydroxy group to a halogen moiety by a variety of well known methods. Examples of these methods are phosphorous tribromide, phosphorous oxychloride, thionyl chloride, or triphenylphosphine and carbon tetrabromide. Or, compounds of Formula (16) where M is a tosylate or similar functionality, can be prepared from toluene sulfonyl chloride and triethylamine, in an appropriate aprotic solvent such as methylene chloride, tetrahydrofuran or toluene.

The compounds of Formula (7) can be prepared by converting the requisite 4-imidazolin-2-one (1) where X

is 0, or 4-imidazolin-2-thione (1) where X is S into the corresponding alkali metal salt by addition of a base such as sodium hydride, and alkylating with the compounds of Formula (16) in a polar aprotic solvent such as N,N-dimethylformamide at an appropriate temperature.

Scheme 5




10

The compounds of Formula (7) wherein X is CH_2 are prepared by the route shown in Scheme 6. The compounds of Formula (18) are prepared by converting the requisite imidazoles of Formula (17) where R^3 is alkyl or an appropriate protecting group, into the corresponding alkali metal salt, by addition of a base such as n-butyl lithium, and alkylating with an appropriate alkyl halide in a solvent such as tetrahydrofuran under an inert

15

atmosphere and reduced temperatures. The compounds of Formula (19) are prepared from compounds of Formula (18) by reaction with an appropriately substituted amine, in an inert solvent such as toluene, acetonitrile, tetrahydrofuran or N,N-dimethylformamide, at a temperature at or below the boiling point of the solvent. The imidazole compounds of Formula (20) are prepared by the reaction of the secondary amines of Formula (19) with the requisite isocyanate, chloroformate, acid chloride or other activated carboxylic acid derivative as previously described. Or, the imidazole compounds of Formula (20) can be prepared by reacting the alkali metal salt of compounds of Formula (17) with the elaborated compounds of Formula (16) in analogous conditions described above. The compounds of Formula (7) wherein X is CH₂ and R³ is H, are prepared by deprotecting compounds of Formula (20), where R³ is a protecting group. For example, when R³ is a silyl protecting group, removal with tetrabutylammonium fluoride in tetrahydrofuran at reflux, affords compounds of Formula (7) where X is CH₂.

Likewise, compounds of Formula (7) wherein X is O, S, NH or CH₂ and Y is H₂ may be prepared by reacting compounds similar to compounds of Formula (18) with an appropriately functionalized secondary amine, HNCH₂ZR⁶, in a solvent such as toluene, acetonitrile, tetrahydrofuran, or N,N-dimethylformamide at a temperature at or below the boiling point of the solvent.

Scheme 6


- 5 The linked phenyl compounds of Formula (24) are prepared as shown in Scheme 7. The linked bis-benzaldehyde compounds of Formula (21) are prepared by bis alkylation of an appropriately functionalized dihaloalkyl, with a substituted salisaldehyde, using an
- 10 alkali base, such as sodium hydride in an inert solvent, such as N,N-dimethylformamide. The α -hydroxyketones of Formula (22) are prepared by standard literature benzoin forming reaction conditions, Walter S. Ide, Johannes S. Buck, Organic Reactions, Vol. IV, p. 269, utilizing
- 15 potassium cyanide in ethanol:water, at reflux.

The imidazoles of Formula (23) are prepared by methods well known in the literature, Klaus Hoffman, The Chemistry of Heterocyclic Compounds, Imidazoles, Part I, by condensing the α -hydroxyketone compounds of Formula

5 (22) with thiourea, or ammonium thiocyanate, or an appropriately substituted thiourea in a suitable solvent such as N,N-dimethylformamide, ethanol or hexanol, at a temperature at or below the boiling point of the solvent.


10 The compounds of Formula (24) are prepared by alkylating the alkali metal salt of imidazole (23) with the compound of Formula (16), as described previously to give the compounds of Formula (24) directly or with a compound of formula $M(A')CO_2R$ when R is CH_3 or C_2H_5 , M is
15 halogen or a tosylate group and A' is a moiety having one less methylene group than A, as described in Scheme 1.

29

Scheme 7

- 5 The compounds of Formula (1), Scheme 8, wherein X is S are available from commercial sources or can be prepared by methods as described above.


Scheme 8




5 Alternatively, the compounds of Formula (1) where X
 is S, Scheme 8, can be prepared from the corresponding
 4-imidazolin-2-ones of Formula (1) where X is O, Org.
Syn. Coll., Vol. II, 231, by reaction with Lawesson's
 reagent or diphosphorus pentasulfide in a suitable
 10 solvent such as toluene.

As shown in Scheme 9, the 2-aminoimidazoles of
 Formula (2) can be prepared by the reaction of the
 appropriately substituted α -aminoketones of Formula (27)
 with cyanamide (28). Compounds of Formula (2) can be
 15 used in the preparation of compounds of Formula (I) as
 previously described in Scheme 1.

Scheme 9




5 As shown in Scheme 10, the compounds of Formula (I)
wherein X is $\text{S}(\text{O})_r$ and r is 1 or 2 can be prepared by
the oxidation of the compounds of Formula (29) by
methods which are well known in the chemical literature.
For example, the oxidation of (29) with one equivalent
10 of a peracid such as m-chloroperoxybenzoic acid in a
suitable solvent such as methylene chloride at a low
temperature affords primarily the sulfoxides of Formula
(30), and the oxidation of (29) with an oxidant such as
potassium hydrogen persulfate, or Oxone®, in a suitable
15 solvent such as methanol affords the sulfones of Formula
(31).

Scheme 10

- 5 Alternatively, compounds of Formula (I) where R³ is not H, Scheme 11, can be prepared by direct alkylation of compounds of Formula (I) when R is H, in the presence or absence of a base such as potassium carbonate, pyridine, sodium hydride, triethylamine, or potassium t-butoxide in an appropriate solvent such as N,N-
- 10 dimethylformamide, glyme, tetrahydrofuran, pyridine or methylene chloride.

Scheme 11

15



Preparation of pharmaceutically suitable salts of Formula (I) can be carried out in accordance with well known techniques for forming salts. Physiologically acceptable salts include acid addition salts, e.g.,
5 hydrochloric, sulfuric, acetic, trifluoroacetic, succinic, citric, and benzene sulfonic acid salts.

The compounds of this invention and their preparation can be further understood by the following examples, which exemplify but do not constitute a
10 limitation of the invention. In these examples, unless otherwise indicated, all temperatures are in degrees centigrade and parts and percentages are by weight.

EXAMPLE 1

15 Preparation of N'-(2,4-difluorophenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea
Part A. To a solution of 4,5-diphenyl-2-imidazoethiol (25.2 g, 0.1 mol) in N,N-dimethylformamide (250 mL) was added, dropwise, a solution of ethyl 5-bromopentanoate
20 (23.73 mL, 31.35 g, 0.15 mol) in N,N-dimethylformamide (80 mL), and the reaction mixture was stirred at reflux under nitrogen for 18 hours. The reaction mixture was cooled, poured into 5% sodium bicarbonate and ice, and then extracted with ethyl acetate. The combined organic
25 extracts were washed sequentially with 5% sodium bicarbonate, water, saturated sodium chloride solution, dried over magnesium sulfate, and concentrated under vacuum. The residue was chromatographed with 7:3 hexane-ethyl acetate, and the resulting solid was
30 recrystallized from acetonitrile and triturated with hexane to give 5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentanoic acid ethyl ester (25.95 g, 0.068 mol) as a white solid, mp 87-89°. ¹H NMR (DMSO-d₆) δ 7.55-7.15 (m, 11H), 4.0 (q, 2H, J=8Hz), 2.9 (t, 2H, J=7Hz),
35 2.3 (t, 2H, J=7Hz), 1.9-1.6 (m, 4H), 1.2 (t, 3H, J=8Hz).

Additional esters which can be used as intermediates in the preparation of compounds of Formula (I) are prepared similarly as taught in co-assigned application, U.S.S.N. 244,170 (BP-6339).

5

Part B. To a solution of 5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentanoic acid ethyl ester (7.6 g, 0.02 mol) in ethanol (200 mL), was added dropwise a solution of sodium hydroxide (7.6 g) in water (200 mL), and the reaction mixture was stirred at reflux under nitrogen for 3 hours. The reaction mixture was concentrated to half the original volume and then extracted with ether. The ether extracts were discarded. The reaction mixture was acidified to pH 1 with 1 N hydrochloric acid and extracted with ether, and the combined organic extracts were dried over magnesium sulfate and concentrated under vacuum. The resulting solid was recrystallized from acetonitrile and triturated with hexane to give 5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentanoic acid (3.88 g, 0.011 mol) as a white solid, mp 190-195°. ¹H NMR (DMSO-d₆) δ 12.6(s,1H), 7.6-7.1(m,10H), 3.3-3.1(m,2H), 2.3-2.1(m,3H), 1.8-1.6(m,4H).

Additional acids which can be used as intermediates in the preparation of compounds of Formula (I) are prepared similarly and are claimed in co-assigned application, U.S.S.N. 244,170.

Part C, Method 1. To a solution of 5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentanoic acid (2.0 g, 0.0057 mol) in N,N-dimethylformamide (25 mL) was added 1-hydroxybenzotriazole hydrate (0.93 g, 0.0069 mol) followed by a solution of heptylamine (1.10 mL, 0.86 g, 0.0074 mol) in N,N-dimethylformamide (10 mL). The reaction mixture was cooled to 0° and dicyclohexylcarbodiimide (1.42 g, 0.0069 mol) was added

portionwise as a solid. The reaction mixture was stirred for 2 hours at 0° and then stirred for 48 hours at ambient temperature. The solids were filtered and washed with N,N-dimethylformamide. The filtrate was concentrated and the residue was chromatographed with 1:1 hexane-ethyl acetate. The resulting solid was recrystallized from acetonitrile and triturated with hexane to give 5-(4,5-diphenyl-1H-imidazol-2-ylthio)-N-heptylpentanamide (2.21 g, 0.0049 mol) as a white solid, mp 104-106°. ¹H NMR (CDCl₃) δ 11.6(s,1H), 7.6-7.1(m,10H), 6.1-6.0(m,1H), 3.1-2.8(m,4H), 2.2(t,2H,J=7Hz), 1.9-1.7(m,2H), 1.7-1.5(m,2H), 1.4-1.1(m,10H), 0.9(t,3H,J=8Hz).

Part C, Method 2. To a solution of 5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentanoic acid (2.0 g, 0.0057 mol) in toluene (35 mL) was added heptylamine (1.63 mL, 1.27 g, 0.011 mol) and then boron trifluoride etherate (1.35 mL, 1.56 g, 0.011 mol) and the reaction mixture was stirred at reflux for 120 hours using a Dean-Stark moisture trap. The reaction mixture was cooled, extracted with 0.1 N NaOH, 0.1 N HCl, and water, and the combined organic extracts were dried over magnesium sulfate and concentrated under vacuum. The residue was chromatographed and worked-up as described in Part C, Method 1, to give 5-(4,5-diphenyl-1H-imidazol-2-ylthio)-N-heptylpentanamide (2.35 g, 0.005 mol) as a white solid.

Part D. To a solution of lithium aluminum hydride, (1.52 g, 0.04 mol) in dry tetrahydrofuran (50 mL) was added, dropwise, a solution of 5-(4,5-diphenyl-1H-imidazol-2-ylthio)-N-heptylpentanamide (4.04 g, 0.009 mol) in tetrahydrofuran (25 mL) and the reaction mixture was stirred at reflux for 18 hours. The reaction

mixture was cooled to 0°, quenched by the slow and careful sequential addition of water (1.52 mL), 15% sodium hydroxide (4.56 mL), and water (4.56 mL), and then stirred at 0° for 30 minutes. The solution was
5 then dried over magnesium sulfate and concentrated under vacuum, and the residue was chromatographed with a gradient of 1:0 to 3:1 to 1:1 ethyl acetate-methanol. The resulting yellow oil was triturated with cold hexane to give N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-
10 1-heptanamine as a white solid. A solution of this amine (0.80 g, 0.0018 mol) in ether (20 mL) was treated with a sufficient amount of ethereal HCl (about 25 mL) to cause complete precipitation of the amine as the hydrochloride salt. The reaction mixture was stirred
15 for 15 minutes, and the supernatant liquid was decanted to afford a gummy solid, which was triturated with hot acetonitrile and then with cold hexane to give N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-1-heptanamine hydrochloride (0.82 g, 0.0017 mol) as a white solid, mp
20 187-190°. ¹H NMR (CDCl₃) δ 9.3(s, 2H), 7.7-7.3(m, 10H), 3.7-3.5(m, 2H), 3.0-2.7(m, 4H), 2.0-1.2(m, 16H), 0.9(t, 3H, J=8Hz).

Part E. To a solution of N-[5-(4,5-diphenyl-1H-imidazol-
25 2-ylthio)pentyl]-1-heptanamine (1.0 g, 0.0024 mol) in hexane (50 mL) was added, dropwise, a solution of 2,4-difluorophenylisocyanate (0.296 mL, 0.388 g, 0.0025 mol) in hexane (25 mL), and the reaction mixture was stirred at ambient temperature for 3 hours. The reaction
30 mixture was concentrated under vacuum and the residue was chromatographed with 7:3 hexane-ethyl acetate to give the title compound (0.86 g, 0.0015 mol) as a white solid, mp 96-98°. ¹H NMR (CDCl₃) δ 10.8(s, 1H), 7.7-
7.1(m, 14H), 3.4(t, 2H, J=7Hz), 3.2(t, 2H, J=7Hz),
35 3.0(t, 2H, J=7Hz), 1.9-1.4(m, 16H), 0.9(t, 3H, J=8Hz).

EXAMPLE 2

Preparation of N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-phenylurea

5 To a solution of N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-1-heptanamine (1.0 g, 0.0024 mol) in hexane (50 mL) was added, dropwise, a solution of phenylisocyanate (0.27 mL, 0.298 g, 0.0025 mol) in hexane (25 mL) and the reaction mixture was stirred at
10 ambient temperature for 4 hours. The reaction mixture was concentrated under vacuum and the residue was chromatographed with 6:4 hexane-ethyl acetate to give the title compound (0.5 g, 0.009 mol) as a yellow amorphous solid. ¹H NMR (CDCl₃) δ 11.0(s,1H), 7.7-
15 6.9(m,14H), 6.4(s,1H), 3.4(t,2H,J=7Hz), 3.2(t,2H,J=7Hz), 3.0(t,2H,J=7Hz), 1.9-1.1(m,16H), 0.9(t,3H,J=8Hz).

EXAMPLE 3

Preparation of N'-(2,4-difluorophenyl)-N-[8-(4,5-diphenyl-1H-imidazol-2-ylthio)octyl]-N-heptylurea

20 Part A. To a solution of 8-(4,5-diphenyl-1H-imidazol-2-ylthio)octanoic acid (8.44 g, 0.02 mol) in methylene chloride (100 mL) at 0° was added, portionwise as a solid, dicyclohexylcarbodiimide (4.12 g, 0.02 mol), and
25 the reaction mixture was stirred at 0° for 30 minutes. To this reaction mixture was added, dropwise, heptylamine (2.96 mL, 2.3 g, 0.02 mol) and the reaction mixture was stirred at reflux for 72 hours. The reaction mixture was cooled, and the solids were
30 filtered and washed with chloroform. The filtrate was concentrated under vacuum and the residue was chromatographed with a gradient of 7:3 to 1:1 hexane-ethyl acetate. The resulting solid was recrystallized from acetonitrile and triturated with hexane to give 8-
35 (4,5-diphenyl-1H-imidazol-2-ylthio)-N-heptyloctanamide

(3.28 g, 0.0067 mol) as a white solid, mp 119-120°. ¹H NMR (DMSO-d₆) δ 12.5(s,1H), 7.8-7.1(m,10H), 3.2-2.9(m,4H), 2.0(t,2H,J=7Hz), 1.75-1.0(m,21H), 1.0-0.8(m,3H).

5

Part B. To a solution of lithium aluminum hydride (0.96 g, 0.025 mol) in dry tetrahydrofuran (30 mL) was added, dropwise, a solution of 8-(4,5-diphenyl-1H-imidazole-2-ylthio)-N-heptyloctanamide (2.82 g, 0.0057 mol) in tetrahydrofuran (15 mL) and the reaction mixture was stirred at reflux for 18 hours. The reaction mixture was cooled to 0°, quenched by the slow and careful sequential addition of water (0.96 mL), 15% sodium hydroxide (2.88 mL), and water (2.88 mL), and then stirred at 0° for 30 minutes. The solution was then dried over magnesium sulfate and concentrated, and the residue was chromatographed with 1:1 hexane:ethyl acetate and then with a gradient of 1:0 to 3:1 to 1:1 ethyl acetate-methanol to give 8-(4,5-diphenyl-1H-imidazol-2-ylthio)-N-heptyl-1-octanamine (1.07 g, 0.0022 mol) as a white solid, mp 87-89°. ¹H NMR (CDCl₃) δ 7.6-7.2(m,11H), 3.1(t,2H,J=7Hz), 2.7-2.5(m,2H), 1.8-1.1(m,25H), 0.9(t,3H,J=8Hz).

Part C. To a solution of 8-(4,5-diphenyl-1H-imidazol-2-ylthio)-N-heptyl-1-octanamine (0.5 g, 0.001 mol) in hexane (25 mL) was added, dropwise, a solution of 2,4-difluorophenylisocyanate (0.15 mL, 0.194 g, 0.00125 mol) in hexane (10 mL), and the reaction mixture was stirred at ambient temperature for 3 hours. The reaction mixture was concentrated under vacuum and the residue was chromatographed using 8:2 hexane-ethyl acetate to give a solid which was triturated with cold ethyl acetate and then hexane to give the title compound (0.18 g, 0.00028 mol) as a white solid, mp 89-91°. ¹H NMR

(DMSO-d₆) δ 12.5(s,1H), 7.9(s,1H), 7.5-7.1(m,10H), 3.3-3.1(m,5H), 1.8-1.2(m,17H), 0.9(t,3H,J=8Hz).

EXAMPLE 4

5 Preparation of N-butyl-N'-(2,4-difluorophenyl)-N-[8-(4,5-diphenyl-1H-imidazol-2-ylthio)octyl]urea

Part A. To a solution of 8-(4,5-diphenyl-1H-imidazol-2-ylthio)octanoic acid (4.4 g, 0.0125 mol) in methylene chloride (65 mL) at 0° was added, portionwise as a
10 solid, dicyclohexylcarbodiimide (2.3 g, 0.011 mol) and the reaction mixture was stirred at 0° for 30 minutes. To this reaction mixture was added, dropwise, a solution of butylamine (1.24 mL, 0.92 g, 0.012 mol) in methylene chloride (15 mL) and the reaction mixture was stirred at
15 reflux for 18 hours. The reaction mixture was cooled, and solids were filtered and washed with methylene chloride. The filtrate was concentrated under vacuum and the residue was chromatographed with a gradient of 7:3 to 1:1 hexane-ethyl acetate. The resulting solid
20 was recrystallized from acetonitrile and triturated with hexane to give N-butyl-8-(4,5-diphenyl-1H-imidazol-2-ylthio)octanamide (1.43 g, 0.003 mol) as a white solid, mp 136-137°. ¹H NMR (DMSO-d₆) δ 12.5(s,1H), 7.8-7.7(m,1H), 7.7-7.1(m,10H), 3.2-2.9(m,4H),
25 2.0(t,2H,J=7Hz), 1.8-1.1(m,14H), 0.9(t,3H,J=8Hz).

Part B. To a solution of lithium aluminum hydride (0.46 g, 0.012 mol) in dry tetrahydrofuran (15 mL) was added, dropwise, a solution of N-butyl-8-(4,5-diphenyl-1H-imidazol-2-ylthio)octanamide (1.20 g, 0.0027 mol) in
30 tetrahydrofuran (8 mL) and the reaction mixture was stirred at reflux for 18 hours. The reaction mixture was cooled to 0°C and quenched by the slow and careful sequential addition of water (0.46 mL), 15% sodium
35 hydroxide (1.38 mL), and water (1.38 mL) and then the

reaction mixture was stirred at 0° for 30 minutes. The solution was dried over magnesium sulfate and concentrated under vacuum, and the residue was chromatographed with 1:1 hexane-ethyl acetate and then with a gradient of 1:0 to 8:2 to 1:1 ethyl acetate-methanol. The resulting solid was triturated with hexane to give N-butyl-8-(4,5-diphenyl-1H-imidazol-2-ylthio)octanamine (0.45 g, 0.001 mol) as a white solid, mp 75-78°. ¹H NMR (CDCl₃) δ 7.6-7.1(m,10H), 3.1(t,2H,J=7Hz), 2.5(t,2H,J=7Hz), 1.7-1.0(m,16H), 0.9(t,3H,J=8Hz).

Part C. To a solution of N-butyl-8-(4,5-diphenyl-1H-imidazol-2-ylthio)octanamine (0.2 g, 0.00045 mol) in hexane (15 mL) was added, dropwise, a solution of 2,4-difluorophenylisocyanate (0.065 mL, 0.085 g, 0.00055 mol) in hexane (5 mL) and the reaction mixture was stirred at ambient temperature for 3 hours. The reaction mixture was concentrated under vacuum and the residue was chromatographed with 7:3 hexane-ethyl acetate and the resulting solid was recrystallized from acetonitrile and triturated with hexane to give the title compound (0.138 g, 0.00023 mol) as a white solid, mp 114-115°. ¹H NMR (CDCl₃) δ 8.1-7.9(m,1H), 7.6-7.2(m,11H), 6.95-6.75(m,2H), 6.5-6.4(m,1H), 3.4-3.1(m,6H), 1.8-1.3(m,16H), 1.0(t,3H,J=8Hz).

EXAMPLE 5

Preparation of N'-(2,4-dimethoxyphenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea

To a solution of N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-1-heptanamine (0.75 g, 0.0017 mol), prepared according to the procedure of Example 1, Part D, in hexane (40 mL) was added, dropwise, a solution of 2,4-dimethoxyphenylisocyanate (0.358 g, 0.002 mol) in

hexane (20 mL) and the reaction mixture was stirred at ambient temperature for 4.5 hours. The reaction mixture was concentrated under vacuum and the residue was chromatographed with 7:3 hexane-ethyl acetate. The resulting solid was triturated with hexane to give the title compound (0.83 g, 0.0014 mol) as a glassy solid. ^1H NMR (CDCl_3) δ 7.7-7.1(m,10H), 6.8-6.1(m,3H), 3.8(s,3H), 3.7(s,3H), 3.45(s,1H), 3.4-3.3(m,2H), 3.2(t,2H,J=7Hz), 3.0(t,2H,J=7Hz), 1.8-1.1(m,16H), 0.9(t,3H,J=8Hz).

EXAMPLE 6

Preparation of N'-(2,4-difluorophenyl)-N-heptyl-N-[5-(1-methyl-4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]urea

To a solution of potassium carbonate (0.056 g, 0.00042 mol) in dry tetrahydrofuran (10 mL) was added, portionwise as a solid, N'-(2,4-difluorophenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea (0.25 g, 0.00042 mol) and the reaction mixture was stirred at ambient temperature for 10 minutes. To this reaction mixture was added, dropwise, methyl iodide (0.039 mL, 0.0895 g, 0.00063 mol) and the reaction mixture was stirred for 18 hours at ambient temperature. The reaction mixture was then treated with N,N-dimethylformamide (1.0 mL) and methyl iodide (0.1 mL) and the reaction mixture was stirred at reflux for an additional 24 hours. The reaction mixture was cooled, poured into water and extracted with ethyl acetate. The combined organic extracts were dried over magnesium sulfate and concentrated under vacuum. The residue was chromatographed with 3:7 hexane-ethyl acetate to give the title compound (0.13 g, 0.00022 mol) as a yellow oil. ^1H NMR (CDCl_3) δ 8.1-8.0(m,1H), 7.5-7.1(m,10H), 6.9-6.7(m,2H), 6.4(s,1H), 3.5(s,3H), 3.4-3.2(m,5H), 1.9-1.2(m,17H), 0.9(t,3H,J=8Hz).

EXAMPLE 7

Preparation of N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-methylurea

5 To a solution of N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-1-heptanamine (0.30 g, 0.0007 mol) in hexane (15 mL) was added methylisocyanate (0.06 mL, 0.057 g, 0.001 mol) and the reaction mixture was stirred at ambient temperature for 18 hours. The reaction
10 mixture was concentrated under vacuum and the residue was chromatographed with 1:1 hexane-ethyl acetate. The resulting oil was triturated with hexane to give the title compound (0.23 g, 0.00047 mol) as a white solid, mp 93-96°. ¹H NMR (CDCl₃) δ 7.6-7.2(m, 11H), 4.35-
15 2.7(m, 9H), 1.9-1.2(m, 16H), 0.9(t, 3H, J=8Hz).

EXAMPLE 8

Preparation of N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-propylurea

20 To a solution of N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-1-heptanamine (0.36 g, 0.0008 mol) in hexane (15 mL) was added propylisocyanate (0.094 mL, 0.085 g, 0.001 mol), and the reaction mixture was stirred at ambient temperature for 4 hours. The
25 reaction mixture was then treated with additional propylisocyanate (0.094 mL, 0.085 g, 0.001 mol) and stirred at ambient temperature overnight and then at reflux for 72 hours. The reaction mixture was concentrated under vacuum and the residue was
30 chromatographed using 2:8 hexane-ethyl acetate. The resulting oil was triturated with hexane to give the title compound (0.8 g, 0.00015 mol) as a white solid, mp 78-80°. ¹H NMR (CDCl₃) δ 7.6-7.2(m, 10H), 4.4(t, 1H, J=7Hz), 3.4-2.9(m, 8H), 1.9-1.1(m, 19H), 1.0-0.75(m, 6H).
35

EXAMPLE 9

Preparation of N'-(2,4-difluorophenyl)-N-[2-(4,5-diphenyl-1H-imidazol-2-ylthio)ethyl]-N-propylurea

Part A. To a solution of bromoacetylchloride (25.51 mL, 48.67 g, 0.31 mol) in methylene chloride (200 mL) at -15° was added, dropwise, a solution of propylamine (24.62 mL, 17.7 g, 0.3 mol) in methylene chloride (100 mL) and the reaction mixture was stirred at 0° for 30 minutes and then stirred at ambient temperature for 30 minutes. The reaction mixture was poured into water and then extracted with methylene chloride. The combined organic extracts were dried over magnesium sulfate and concentrated under vacuum. The residue was distilled to give bromo-N-propylacetamide as a clear liquid, bp 138-142°. ¹H NMR (CDCl₃) δ 7.1(s,1H), 3.9(d,2H,J=6Hz), 3.3(m,2H), 1.6(m,2H), 0.9(t,3H,J=7Hz).

Part B. A portion of sodium hydride, 60% in mineral oil (0.4 g, 0.01 mol), was washed twice with hexane (10 mL) and the hexane was replaced with N,N-dimethylformamide (100 mL). To this solution was added, portionwise as a solid, sodium iodide (0.4 g, 0.003 mol) and then, dropwise, a solution of diphenylimidazole (2.52 g, 0.01 mol) in N,N-dimethylformamide (10 mL) followed by the dropwise addition of a solution of bromo-N-propylacetamide (1.80 g, 0.01 mol) in N,N-dimethylformamide (10 mL). The reaction mixture was stirred at reflux for 18 hours, then cooled and poured, carefully, into ice water, and then extracted with ethyl acetate. The combined organic extracts were backwashed with brine, dried over magnesium sulfate and concentrated under vacuum. The residue was chromatographed using 1:1 hexane-ethyl acetate and the resulting solid was recrystallized from acetonitrile to give 2-(4,5-diphenyl-1H-imidazol-2-ylthio)-N-

propylacetamide as a white solid, mp 183-185°. ¹H NMR (DMSO-d₆) δ 12.6(s,1H), 8.3(s,1H), 7.5-7.1(m,10H), 3.8(s,2H), 3.0(q,2H,J=7.5Hz), 1.4(sextet, 2H,J=9Hz), 0.8(t,3H,J=6Hz).

5

Part C. Employing the method of Example 1, Part D, but using 2-(4,5-diphenyl-1H-imidazol-2-ylthio)-N-propylacetamide, N-[2-(4,5-diphenyl-1H-imidazol-2-ylthio)ethyl]-1-propanamine (0.28 g, 0.00083 mol) was
10 obtained as an oil. ¹H NMR (CDCl₃) δ 7.9-7.6(m,2H), 7.5-7.1(m,10H), 3.1(s,4H), 2.6(t,2H,J=6Hz), 1.4(sextet, 2H,J=12Hz), 0.8(t,3H,J=9Hz).

Part D. Employing the method of Example 1, Part E, but
15 using N-[2-(4,5-diphenyl-1H-imidazol-2-ylthio)ethyl]-1-propanamine, the title compound (0.20 g, 0.00045 mol) was obtained as a white solid, mp 189-190°. ¹H NMR (CDCl₃) δ 11.6-11.2(s,1H), 7.8-7.6(s,1H), 7.6-6.9(m,10H), 6.8-6.6(m,2H), 3.8(t,2H,J=7Hz),
20 3.4(t,2H,J=6.5Hz), 3.2(t,2H,J=6Hz), 1.8-1.6(m,4H), 1.0(t,3H,J=7.5Hz).

EXAMPLE 90

Preparation of N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)-N-heptyl-N'-(2-pyridinyl)-urea
25

A mixture of N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-1-heptanamine (4.35 g; 0.01 mol) and pyridyltosylurea (3.2 g; 0.011 mol; Frigola Conatansa, Jordi; ES 534,782) in diphenyl ether (35 mLs) was
30 stirred under nitrogen at 180°C for 30 minutes. The cooled solution was chromatographed with 1:1 hexane:ethyl acetate to give the title compound (4.03 g; 0.0073 mol) as an orange oil. ¹H NMR (CDCl₃) δ 8.15-8.05(m,1H), 7.9(d,1H,J=8.4Hz), 7.6-7.4(m,5H), 7.3-7.1(m,8H), 6.9-6.8(m,1H), 3.32(t,2H,J=7.2Hz),
35

3.25 (t, 2H, J=7.9Hz), 3.05 (t, 2H, J=6.6Hz), 1.8-1.45 (m, 8H),
1.4-1.2 (m, 8H), 0.9 (t, 3H, J=6.8Hz).

EXAMPLE 118

5 Preparation of N-[5-[4,5-bis(4-methoxyphenyl)-1H-
imidazol-2-ylthiol-pentyl]-N'-(2,4-difluorophenyl)-N-
10 heptylurea

Part A. A solution of γ -valerolactone (25.0 g, 0.249
mol) in toluene (50 mL) and n-heptylamine (35.96 g,
10 0.312 mol) was heated to reflux for 18 hours under a
nitrogen atmosphere. The reaction mixture was allowed
to cool to ambient temperature, diluted with ethyl
acetate (300 mL), washed with 1 N aqueous HCl (50 mL),
water, brine, dried over magnesium sulfate and
15 concentrated to give a white solid. The product was
crystallized from ethyl ether:hexane to give N-heptyl-5-
hydroxypentanamide (41.8 g, 0.194 mol) as white plates,
mp 55-6°. ¹H NMR (CDCl₃) δ 6.06(bs, 1H), 3.61(t, 2H),
3.24(q, 2H), 3.19(bs, 1H), 2.19(t, 2H), 1.80-1.23(m, 14H),
20 0.866(t, 3H).

Part B. To a solution of lithium aluminum hydride (6.7
g, 0.176 mol) in dry tetrahydrofuran (300 mL), a
solution of N-heptyl-5-hydroxypentanamide (19.0 g, 0.088
25 mol) in dry tetrahydrofuran (100 mL) under a nitrogen
atmosphere was added dropwise. The reaction mixture was
heated to reflux for 18 hours, allowed to cool to room
temperature and was poured slowly into a stirred
mixture of 10% aqueous sodium sulfate (400 mL) and ice
30 (200 mL). The resulting slurry was filtered through a
bed of Celite® and the filtrate was extracted with ethyl
acetate (2 x 500 mL). The combined organic layer was
washed with water, brine, dried over magnesium sulfate
and concentrated to give a viscous yellow oil. The
35 product was crystallized from hexane to give N-(5-

hydroxypentyl)-N-heptylamine (15.2 g, 0.075 mol) as a white powder, mp 47-8°. ¹H NMR (CDCl₃) δ 3.63(t,2H), 2.63(q,4H), 2.39(bs,2H), 1.66-1.24(m,16H), 0.905(t,3H).

- 5 Part C. To a solution of N-(5-hydroxypentyl)-N-heptylamine (11.65 g, 0.0578 mol) in methylene chloride (75 mL) under a nitrogen atmosphere cooled to 0°, 2,4-difluorophenylisocyanate (8.97 g, 0.0578 mol) was added slowly. The reaction mixture was stirred for 1 hour,
- 10 poured into 1 N aqueous HCl (200 mL) and was extracted with ethyl acetate (300 mL). The combined organic layer was washed with water, brine, dried over magnesium sulfate and was concentrated to give N'-(2,4-
- 15 yellow oil (20.0 g, 0.056 mol). ¹H NMR (CDCl₃) δ 8.03(m,1H), 6.88-6.59(m,2H), 6.45(bs,1H), 3.68(t,2H), 3.33(m,4H), 1.81-1.22(m,16H), 0.907(t,3H).

- Part D. To a solution of N'-(2,4-difluorophenyl)-N-heptyl-N-5-hydroxypentylurea (15.0 g, 0.042 mol) and carbon tetrabromide (16.75 g, 0.051 mol) in methylene chloride (350 mL) under a nitrogen atmosphere at ambient temperature, a solution of triphenylphosphine (13.24 g, 0.051 mol) in methylene chloride (100 mL) was added
- 25 slowly. The reaction mixture was stirred for 3 hours and was concentrated in vacuo to give crude viscous oil. The product was purified by flash chromatography on silica gel (400 mL) eluting with hexane:ethyl acetate (90:10 v:v) to give N-(5-bromopentyl)-N'-(2,4-
- 30 difluorophenyl)-N-heptylurea as a viscous colorless oil (17.5 g, 0.042 mol). ¹H NMR (CDCl₃) δ 8.14-8.00(m,1H), 6.92-6.79(m,2H), 6.35(bs,1H), 3.49-3.25(m,6H), 1.99-1.26(m,16H), 0.915(t,3H).

Part E. To a suspension of sodium hydride (0.88 g, 60% mineral oil dispersion, 0.0022 mol) (washed free of mineral oil with hexane) in N,N-dimethylformamide (15 mL) under a nitrogen atmosphere, cooled to 0°, a solution of 4,5-[bis-(4-methoxyphenyl)-1H-imidazol]-2-thione (0.63 g, 0.002 mol) in N,N-dimethylformamide (5 mL) was added slowly. The reaction mixture was stirred for 2 hours and then a solution of N-(5-bromopentyl)-N'-(2,4-difluorophenyl)-N-heptylurea (0.845 g, 0.002 mol) in N,N-dimethylformamide (3 mL) was added. The reaction mixture was allowed to warm to ambient temperature, stirred an additional 2 hours, poured into water (50 mL) and extracted with ethyl acetate (2 x 50 mL). The combined organic extracts were washed with water, brine, dried over magnesium sulfate and concentrated to give a viscous oil. The product was purified by flash chromatography on silica gel (100 mL) eluting with hexane:ethyl acetate (70:30 v:v) to give the title compound as a pure yellow foam (0.98 g, 0.0015 mol). ¹H NMR (CDCl₃) δ 10.15(bs,1H), 7.87-7.76(m,1H), 7.51(d,2H), 7.3(d,2H), 6.86-6.6(m,6H), 6.42(d,1H), 3.8(s, 6H), 3.4(t,2H), 3.26(t,2H), 2.99(t,2H), 1.84-1.25(m,16H), 0.89(t,3H).

25

EXAMPLE 207

Preparation of N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N'-octyl-N-phenylurea

To a solution of N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]benzeneamine (0.41 g, 0.001 mol) in toluene (25 mL) was added n-octylisocyanate (0.23 g, 0.0015 mol). The reaction mixture was stirred at reflux for 18 hours and then the solvent was removed under vacuum. The residue (1.0 g) was chromatographed with 7:3 hexane-ethyl acetate. The resulting solid was triturated with hexane to give the title compound (0.32

g, 0.00056 mol) as a white solid, mp 74-76°. ¹H NMR (CDCl₃) 11.8(s,1H), 7.75-7.1(m,15H), 4.3(t,1H,J=6.0Hz), 3.8(t,2H,J=7.0Hz), 3.0(quintet,4H,J=6.0Hz), 1.9-0.90(m,18H), 0.8(t,3H,J=7.0Hz).

5

EXAMPLE 209

Preparation of N-[5-[4,5-bis(4-hydroxyphenyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea

10 To a stirred solution of N-[5-[4,5-bis(4-methoxyphenyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea (0.78 g, 0.0012 mol) in methylene chloride (30 mL) cooled to -78° under a nitrogen atmosphere, 1M boron tribromide in methylene
15 chloride (3.6 mL) was added. The reaction mixture stirred for 1 hour at 0°, was poured over ice (100 mL) and extracted with ethyl acetate (2 x 50 mL). The combined organic layer was washed with 10% aqueous NaHCO₃ (50 mL), water, brine, dried over magnesium
20 sulfate, and concentrated in vacuo to give the crude oil. The product was purified by flash chromatography on silica gel (100 mL) eluting with hexane:ethyl acetate (40:60 v:v) to give a white foam, mp 110-12° (0.5 g, 0.00008 mol). ¹H NMR (DMSO-d₆) δ 12.22 (bs,1H),
25 9.55(bs,1H), 9.32(bs,1H), 7.92(s,1H), 7.45-6.6(m,11H), 3.24(m,4H), 3.06(t,2H), 1.77-1.17(m,16H), 0.88(t,3H).

EXAMPLE 211

Preparation of N-[5-(1H,9H-dibenz-

30 [4,5:8,9][1,3]dioxonino-[6,7-dlimidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea

Part A. To a suspension of sodium hydride (washed free of mineral oil with hexane) (2.45 g, 80% oil dispersion, 0.081 mol) in dry N,N-dimethylformamide (50 mL) under a
35 nitrogen atmosphere, cooled to 0°, a solution of

salisaldehyde (10.0 g, 81.9 mmol) in dry N,N-dimethylformamide (10 mL) was added slowly. The reaction mixture was stirred at 0° for 2 hours and diiodomethane (11.3 g, 0.041 mol) was added. The
5 reaction mixture was allowed to warm to ambient temperature for 18 hours and then was warmed to 60° for 20 hours. The reaction was allowed to cool to ambient temperature, poured into 1 N aqueous HCl (100 mL) and extracted with ethyl acetate (2 x 100 mL). The combined
10 organic extract was washed with water, brine, dried over magnesium sulfate and concentrated to give a solid. The product was purified by flash chromatography on silica gel (300 mL) eluting with methylene chloride (100%) to give 2,2'-(methylenedioxy)-bis-(2-benzaldehyde) as a
15 white crystalline solid, mp 131 to 3° (5.1 g, 0.0199 mol). ¹H NMR (CDCl₃) δ 10.47(s, 2H), 7.87(d, 2H), 7.68-7.54(m, 2H), 7.21(d, 2H), 7.15(t, 2H), 6.02(s, 2H).

Part B. A mixture of 2,2'-(methylenedioxy)-bis-(2-benzaldehyde) (5.0 g, 0.0195 mol), potassium cyanide (0.63 g, 0.0975 mol) in ethanol (75 mL) and water (50 mL) was heated to reflux for 6 hours. The reaction mixture was allowed to cool to ambient temperature, was concentrated in vacuo and the resultant aqueous residue
25 was partitioned between ethyl acetate and water. The organic layer was washed with water, brine, dried over magnesium sulfate and concentrated to give a viscous oil. The product was purified by flash chromatography on silica gel (250 mL) eluting with hexane:ethyl acetate
30 (80:20 v:v) to give 13-hydroxydibenzo[d,h][1,3]-dioxonino-12(13H)-one as a crystalline solid, mp 129-30° (2.5 g, 0.0975 mol). ¹H NMR (DMSO-d₆) δ 7.49(t, 2H), 7.29-7.08(m, 6H), 6.40(d, 1H), 5.97(d, 1H), 5.92(d, 1H), 5.24(d, 1H).

Part C. A solution of 13-hydroxy-dibenzo[d,h][1,3]-dioxonino-12(13H)-one (2.0 g, 0.0078 mol), thiourea (0.82 g, 0.0108 mol) and hexanol (25 mL), equipped with a column of 4Å sieves and a condenser, was heated to 160° for 20 hours under a nitrogen atmosphere. The reaction mixture was allowed to cool to ambient temperature and was diluted with ethyl ether (100 mL) to give a solid. The solid was washed with ethyl ether and dried to give N-(1H,9H-dibenz-[4,5:8,9][1,3]dioxonino-[6,7-d]imidazol)-2-thione as a white crystalline powder (1.6 g, 0.00539 mol), mp >250°. ¹H NMR (DMSO-d₆) δ 12.5(s,2H), 7.43-7.08(m,8H), 6.2-5.0(bd,2H).

Part D. Employing the method of Example 118, Part E, but using N-(1H,9H-dibenz-[4,5:8,9][1,3]dioxonino-[6,7-d]imidazol)-2-thione, the title compound was isolated as a white foam, mp 65-70° (0.85 g, 0.00134 mol). ¹H NMR (CDCl₃) δ 10.35-10.10(bs,1H), 7.56(m,1H), 7.30-6.95(m,10H), 6.4(d,1H), 5.70-5.20(bs,2H), 3.40-3.19(m,4H), 3.08(t,2H), 1.85-1.23(m,16H), 0.88(t,3H).

EXAMPLE 212

Preparation of N'-[5-(1H-dibenz[2,3:6,7]oxedino[4,5-d]imidazol-2-ylthio)pentyl]-N-(2,4-difluorophenyl)-N-heptylurea

Employing the method of Example 118, Part E, but using 1H-dibenz[2,3:6,7]oxedino[4,5-d]imidazol)-2-thione, the title compound was isolated as a white powder, mp 82-7° (0.36 g, 0.00059 mol). ¹H NMR (CDCl₃) δ 9.75-8.5(bs, 2H), 7.84-7.59(m,3H), 7.43-7.05(m,6H), 5.13-6.53(m,3H), 3.43-3.13(m,6H), 1.75-1.20(m,16H), 0.88(t,3H).

Additional ureas, which are listed in Tables 1 and 2, were prepared or could be prepared analogously according to the procedures listed above.

Table 1

Ex. No.	<u>R¹</u>	<u>R²</u>	<u>R³</u>	<u>R⁴</u>	<u>n</u>	<u>R⁶</u>	<u>mp °C</u>
1	C ₆ H ₅	C ₆ H ₅	H	2, 4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	96-98
2	C ₆ H ₅	C ₆ H ₅	H	C ₆ H ₅	5	(CH ₂) ₆ CH ₃	amorphous
3	C ₆ H ₅	C ₆ H ₅	H	2, 4-diFC ₆ H ₃	8	(CH ₂) ₆ CH ₃	solid
4	C ₆ H ₅	C ₆ H ₅	H	2, 4-diFC ₆ H ₃	8	(CH ₂) ₃ CH ₃	89-91
5	C ₆ H ₅	C ₆ H ₅	H	2, 4-diCH ₃ OC ₆ H ₃	5	(CH ₂) ₆ CH ₃	114-115
6	C ₆ H ₅	C ₆ H ₅	CH ₃	2, 4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	glassy
7	C ₆ H ₅	C ₆ H ₅	H	CH ₃	5	(CH ₂) ₆ CH ₃	solid
8	C ₆ H ₅	C ₆ H ₅	H	n-C ₃ H ₇	5	(CH ₂) ₆ CH ₃	oil
9	C ₆ H ₅	C ₆ H ₅	H	2, 4-diFC ₆ H ₃	2	(CH ₂) ₂ CH ₃	93-96
10	C ₆ H ₅	C ₆ H ₅	H	2, 4-diFC ₆ H ₃	10	(CH ₂) ₃ CH ₃	78-80
							189-190




Table 1 (continued)

Ex. No.	<u>R¹</u>	<u>R²</u>	<u>R³</u>	<u>R⁴</u>	<u>n</u>	<u>R⁶</u>	<u>mp °C</u>
11	C ₆ H ₅	C ₆ H ₅	H	2,4-diFC ₆ H ₃	5	CH ₂ CH ₃	
12	C ₆ H ₅	C ₆ H ₅	H	2,4-diFC ₆ H ₃	3	(CH ₂) ₈ CH ₃	
13	C ₆ H ₅	C ₆ H ₅	H	2,4-diFC ₆ H ₃	3	(CH ₂) ₁₀ CH ₃	
14	C ₆ H ₅	C ₆ H ₅	H	2,4-diFC ₆ H ₃	10	(CH ₂) ₁₀ CH ₃	
15	C ₆ H ₅	C ₆ H ₅	CH ₃	2,4-diFC ₆ H ₃	8	(CH ₂) ₃ CH ₃	
16	C ₆ H ₅	C ₆ H ₅	n-C ₃ H ₇	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
17	C ₆ H ₅	C ₆ H ₅	n-C ₆ H ₁₃	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
18	C ₆ H ₅	C ₆ H ₅	CH ₂ CH=CH ₂	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
19	C ₆ H ₅	C ₆ H ₅	CH ₂ C ₆ H ₅	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
20	C ₆ H ₅	C ₆ H ₅	C ₆ H ₅	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	99-101
21	C ₆ H ₅	C ₆ H ₅	C ₆ H ₅	2,4-diFC ₆ H ₃	8	(CH ₂) ₃ CH ₃	
22	C ₆ H ₅	C ₆ H ₅	4-FC ₆ H ₄	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
23	C ₆ H ₅	C ₆ H ₅	4-CH ₃ C ₆ H ₄	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
24	C ₆ H ₅	C ₆ H ₅	4-CH ₃ OC ₆ H ₄	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
25	C ₆ H ₅	C ₆ H ₅	4-CF ₃ C ₆ H ₄	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
26	C ₆ H ₅	C ₆ H ₅	4-ClC ₆ H ₄	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
27	C ₆ H ₅	C ₆ H ₅	3-FC ₆ H ₄	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
28	C ₆ H ₅	C ₆ H ₅	2-FC ₆ H ₄	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	

Table 1 (continued)

Ex. No.	<u>R¹</u>	<u>R²</u>	<u>R³</u>	<u>R⁴</u>	<u>n</u>	<u>R⁶</u>	<u>mp °C</u>
29	C ₆ H ₅	C ₆ H ₅	3-CH ₃ OC ₆ H ₄	3-FC ₆ H ₄	5	(CH ₂) ₆ CH ₃	
30	C ₆ H ₅	C ₆ H ₅	3-CH ₃ OC ₆ H ₄	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
31	C ₆ H ₅	C ₆ H ₅	2-CF ₃ C ₆ H ₄	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
32	C ₆ H ₅	C ₆ H ₅	4-FC ₆ H ₄	2,4-diFC ₆ H ₃	8	(CH ₂) ₃ CH ₃	
33	C ₆ H ₅	C ₆ H ₅	2-FC ₆ H ₄	2,4-diFC ₆ H ₃	8	(CH ₂) ₃ CH ₃	
34	C ₆ H ₅	C ₆ H ₅	3-CH ₃ OC ₆ H ₄	2,4-diFC ₆ H ₃	8	(CH ₂) ₃ CH ₃	
35	C ₆ H ₅	C ₆ H ₅	4-CH ₃ OC ₆ H ₄	2,4-diFC ₆ H ₃	8	(CH ₂) ₃ CH ₃	
36	C ₆ H ₅	C ₆ H ₅	4-CH ₃ OC ₆ H ₄	C ₆ H ₅	5	(CH ₂) ₅ CH ₃	
37	C ₆ H ₅	C ₆ H ₅	H	2-CF ₃ C ₆ H ₄	8	(CH ₂) ₆ CH ₃	
38	C ₆ H ₅	C ₆ H ₅	H	3-CF ₃ C ₆ H ₄	5	(CH ₂) ₆ CH ₃	
39	C ₆ H ₅	C ₆ H ₅	H	4-CF ₃ C ₆ H ₄	5	(CH ₂) ₆ CH ₃	
40	C ₆ H ₅	C ₆ H ₅	H	2-CH ₃ C ₆ H ₄	5	(CH ₂) ₆ CH ₃	
41	C ₆ H ₅	C ₆ H ₅	H	3-CH ₃ C ₆ H ₄	5	(CH ₂) ₆ CH ₃	
42	C ₆ H ₅	C ₆ H ₅	H	4-CH ₃ C ₆ H ₄	5	(CH ₂) ₆ CH ₃	
43	C ₆ H ₅	C ₆ H ₅	H	3-C ₂ H ₅ C ₆ H ₄	5	(CH ₂) ₆ CH ₃	
44	C ₆ H ₅	C ₆ H ₅	H	3-(CH ₃) ₂ CHC ₆ H ₄	5	(CH ₂) ₆ CH ₃	
45	C ₆ H ₅	C ₆ H ₅	H	2-BrC ₆ H ₄	5	(CH ₂) ₆ CH ₃	
50	C ₆ H ₅	C ₆ H ₅	H	3-BrC ₆ H ₄	5	(CH ₂) ₆ CH ₃	

Table 1 (continued)

Ex. No.	<u>R¹</u>	<u>R²</u>	<u>R³</u>	<u>R⁴</u>	<u>n</u>	<u>R⁶</u>	<u>mp °C</u>
51	C ₆ H ₅	C ₆ H ₅	H	4-BrC ₆ H ₄	5	(CH ₂) ₆ CH ₃	
52	C ₆ H ₅	C ₆ H ₅	H	2-FC ₆ H ₄	5	(CH ₂) ₆ CH ₃	
53	C ₆ H ₅	C ₆ H ₅	H	3-FC ₆ H ₄	5	(CH ₂) ₆ CH ₃	124-126
54	C ₆ H ₅	C ₆ H ₅	H	4-FC ₆ H ₄	5	(CH ₂) ₆ CH ₃	
55	C ₆ H ₅	C ₆ H ₅	H	3-ClC ₆ H ₄	5	(CH ₂) ₆ CH ₃	
56	C ₆ H ₅	C ₆ H ₅	H	4-n-C ₄ H ₉ C ₆ H ₄	5	(CH ₂) ₆ CH ₃	
57	C ₆ H ₅	C ₆ H ₅	H	4-CH ₃ OC ₆ H ₄	5	(CH ₂) ₆ CH ₃	
58	C ₆ H ₅	C ₆ H ₅	H	4-CH ₃ CH ₂ O ₂ CC ₆ H ₄	5	(CH ₂) ₆ CH ₃	
59	C ₆ H ₅	C ₆ H ₅	H	2,3-diCH ₃ C ₆ H ₃	5	(CH ₂) ₆ CH ₃	
60	C ₆ H ₅	C ₆ H ₅	H	2,5-diCH ₃ C ₆ H ₃	5	(CH ₂) ₆ CH ₃	
61	C ₆ H ₅	C ₆ H ₅	H	2,6-diCH ₃ C ₆ H ₃	5	(CH ₂) ₆ CH ₃	
62	C ₆ H ₅	C ₆ H ₅	H	2,4-diCH ₃ C ₆ H ₃	5	(CH ₂) ₆ CH ₃	
63	C ₆ H ₅	C ₆ H ₅	H	2,3-diClC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
64	C ₆ H ₅	C ₆ H ₅	H	2,6-diClC ₆ H ₃	5	(CH ₂) ₆ CH ₃	90-92
65	C ₆ H ₅	C ₆ H ₅	H	2,4-diClC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
66	C ₆ H ₅	C ₆ H ₅	H	2,5-diClC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
67	C ₆ H ₅	C ₆ H ₅	H	2,3-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
68	C ₆ H ₅	C ₆ H ₅	H	2,5-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	

Table 1 (continued)

Ex. No.	<u>R¹</u>	<u>R²</u>	<u>R³</u>	<u>R⁴</u>	<u>n</u>	<u>R⁶</u>	<u>mp °C</u>
69	C ₆ H ₅	C ₆ H ₅	H	2,4,6-triClC ₆ H ₂	5	(CH ₂) ₆ CH ₃	
70	C ₆ H ₅	C ₆ H ₅	H	2,4,5-triClC ₆ H ₂	5	(CH ₂) ₆ CH ₃	
71	C ₆ H ₅	C ₆ H ₅	H	2,4,6-triFC ₆ H ₂	5	(CH ₂) ₆ CH ₃	78-80
72	C ₆ H ₅	C ₆ H ₅	H	2,4,5-triFC ₆ H ₂	5	(CH ₂) ₆ CH ₃	
73	C ₆ H ₅	C ₆ H ₅	H	3,4,5-triCH ₃ OC ₆ H ₂	5	(CH ₂) ₆ CH ₃	
74	C ₆ H ₅	C ₆ H ₅	H	2,4,6-triCH ₃ C ₆ H ₂	5	(CH ₂) ₆ CH ₃	
75	C ₆ H ₅	C ₆ H ₅	H	4-Cl,2-CH ₃ C ₆ H ₃	5	(CH ₂) ₆ CH ₃	
76	C ₆ H ₅	C ₆ H ₅	H	4-Cl,2,5-diCH ₃ C ₆ H ₂	5	(CH ₂) ₆ CH ₃	
77	C ₆ H ₅	C ₆ H ₅	H	4-Cl,3-CF ₃ C ₆ H ₃	5	(CH ₂) ₆ CH ₃	
78	C ₆ H ₅	C ₆ H ₅	H	4-Cl,2,6-diCH ₃ C ₆ H ₂	5	(CH ₂) ₆ CH ₃	
79	C ₆ H ₅	C ₆ H ₅	H	3-Cl,4-CH ₃ C ₆ H ₃	5	(CH ₂) ₆ CH ₃	
80	C ₆ H ₅	C ₆ H ₅	H	3-Cl,4-FC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
81	C ₆ H ₅	C ₆ H ₅	H	5-Cl,2-CH ₃ OC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
82	C ₆ H ₅	C ₆ H ₅	H	2-Cl,5-CF ₃ C ₆ H ₃	5	(CH ₂) ₆ CH ₃	
83	C ₆ H ₅	C ₆ H ₅	H	4-F,2-CH ₃ C ₆ H ₃	5	(CH ₂) ₆ CH ₃	
84	C ₆ H ₅	C ₆ H ₅	H	4-NO ₂ C ₆ H ₄	5	(CH ₂) ₆ CH ₃	
85	C ₆ H ₅	C ₆ H ₅	H	4-CNC ₆ H ₄	5	(CH ₂) ₆ CH ₃	68-70
86	C ₆ H ₅	C ₆ H ₅	H	4-NH ₂ C ₆ H ₄	5	(CH ₂) ₆ CH ₃	

Table 1 (continued)

Ex. No.	<u>R¹</u>	<u>R²</u>	<u>R³</u>	<u>R⁴</u>	<u>n</u>	<u>R⁶</u>	<u>mp °C</u>
87	C ₆ H ₅	C ₆ H ₅	H	4-CH ₃ NHC ₆ H ₄	5	(CH ₂) ₆ CH ₃	
88	C ₆ H ₅	C ₆ H ₅	H	4-(CH ₃) ₂ NC ₆ H ₄	5	(CH ₂) ₆ CH ₃	
89	C ₆ H ₅	C ₆ H ₅	H	4-HOC ₆ H ₄	5	(CH ₂) ₆ CH ₃	
90	C ₆ H ₅	C ₆ H ₅	H	2-pyridinyl	5	(CH ₂) ₆ CH ₃	oil
91	C ₆ H ₅	C ₆ H ₅	H	3-pyridinyl	5	(CH ₂) ₆ CH ₃	
92	C ₆ H ₅	C ₆ H ₅	H	4-pyridinyl	5	(CH ₂) ₆ CH ₃	
93	C ₆ H ₅	C ₆ H ₅	H	2,6-pyrimidinyl	5	(CH ₂) ₆ CH ₃	
94	C ₆ H ₅	C ₆ H ₅	H	C ₆ H ₁₁	5	(CH ₂) ₆ CH ₃	95-97
95	C ₆ H ₅	C ₆ H ₅	H	C ₅ H ₉	5	(CH ₂) ₆ CH ₃	
96	C ₆ H ₅	C ₆ H ₅	H	n-C ₆ H ₁₃	5	(CH ₂) ₆ CH ₃	
97	C ₆ H ₅	C ₆ H ₅	H	n-C ₈ H ₁₇	5	(CH ₂) ₆ CH ₃	oil (a)
98	C ₆ H ₅	C ₆ H ₅	H	n-C ₃ H ₇	5	(CH ₂) ₆ CH ₃	
99	C ₆ H ₅	C ₆ H ₅	H	CF ₃	5	(CH ₂) ₆ CH ₃	
100	C ₆ H ₅	C ₆ H ₅	H	CH ₂ CH=CHCH ₃	5	(CH ₂) ₆ CH ₃	
101	C ₆ H ₅	C ₆ H ₅	H	CH ₂ CH=CH ₂	5	(CH ₂) ₆ CH ₃	
102	C ₆ H ₅	C ₆ H ₅	H	CH ₂ CH=CHCH ₂ CH ₃	5	(CH ₂) ₆ CH ₃	
103	C ₆ H ₅	C ₆ H ₅	H	CH ₂ C≡CCH ₃	5	(CH ₂) ₆ CH ₃	
104	C ₆ H ₅	C ₆ H ₅	H	n-C ₄ H ₉	5	(CH ₂) ₆ CH ₃	

Table 1 (continued)

Ex. No.	R^1	R^2	R^3	R^4	n	R^6	mp°C
105	C ₆ H ₅	C ₆ H ₅	H	CH(CH ₃) ₂	5	(CH ₂) ₆ CH ₃	84-86
106	C ₆ H ₅	C ₆ H ₅	H	CF ₂ CF ₃	5	(CH ₂) ₆ CH ₃	
107	2-pyridinyl	2-pyridinyl	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	oil (b)
108	3-pyridinyl	3-pyridinyl	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
109	4-pyridinyl	4-pyridinyl	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
110	2-thienyl	2-thienyl	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	75-80
111	C ₆ H ₅ CH ₂	C ₆ H ₅ CH ₂	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
112	C ₆ H ₅ (CH ₂) ₂	C ₆ H ₅ (CH ₂) ₂	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
113	C ₆ H ₅ (CH ₂) ₅	C ₆ H ₅ (CH ₂) ₅	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
114	4-FC ₆ H ₄	4-FC ₆ H ₄	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	82-84
115	4-FC ₆ H ₄	4-FC ₆ H ₄	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
116	4-FC ₆ H ₄	4-FC ₆ H ₄	H	2,4-diFC ₆ H ₃	8	(CH ₂) ₆ CH ₃	
117	4-FC ₆ H ₄	4-FC ₆ H ₄	H	n-C ₃ H ₇	8	(CH ₂) ₆ CH ₃	
118	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	2,4,6-triFC ₆ H ₂	5	(CH ₂) ₆ CH ₃	
119	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	55-59
120	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	2,4-diFC ₆ H ₃	8	(CH ₂) ₆ CH ₃	
121	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	n-C ₃ H ₇	8	(CH ₂) ₆ CH ₃	
122	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	2,4,6-triFC ₆ H ₂	5	(CH ₂) ₆ CH ₃	
	4-CH ₃ C ₆ H ₄	4-CH ₃ C ₆ H ₄	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	63-65 (c)

Table 1 (continued).

Ex. No.	<u>R¹</u>	<u>R²</u>	<u>R³</u>	<u>R⁴</u>	<u>n</u>	<u>R⁶</u>	<u>mp °C</u>
123	4-CH ₃ C ₆ H ₄	4-CH ₃ C ₆ H ₄	H	2,4-diFC ₆ H ₃	8	(CH ₂) ₆ CH ₃	
124	4-CH ₃ C ₆ H ₄	4-CH ₃ C ₆ H ₄	H	n-C ₃ H ₇	8	(CH ₂) ₆ CH ₃	
125	4-CH ₃ C ₆ H ₄	4-CH ₃ C ₆ H ₄	H	2,4,6-triFC ₆ H ₂	5	(CH ₂) ₆ CH ₃	
126	4-(CH ₃) ₂ NC ₆ H ₄	4-(CH ₃) ₂ NHC ₆ H ₄	H	CH ₃	8	(CH ₂) ₆ CH ₃	
127	4-NO ₂ C ₆ H ₄	4-NO ₂ C ₆ H ₄	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
128	C ₆ H ₅	4-CH ₃ SC ₆ H ₄	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
129	C ₆ H ₅	4-CH ₃ SOC ₆ H ₄	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
130	C ₆ H ₅	4-CH ₃ SO ₂ C ₆ H ₄	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
131	4-ClC ₆ H ₄	4-ClC ₆ H ₄	H	2,4-diCH ₃ OC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
132	4-BrC ₆ H ₄	4-BrC ₆ H ₄	H	2,4-diCH ₃ C ₆ H ₃	8	(CH ₂) ₆ CH ₃	
133	C ₆ H ₅	4-FC ₆ H ₄	H	2,4,6-triFC ₆ H ₂	8	(CH ₂) ₆ CH ₃	
134	4-CF ₃ C ₆ H ₄	4-CF ₃ C ₆ H ₄	H	4-FC ₆ H ₄	5	(CH ₂) ₆ CH ₃	
135	2-ClC ₆ H ₄	2-ClC ₆ H ₄	H	2,4,6-triFC ₆ H ₂	4	(CH ₂) ₇ CH ₃	
136	3-ClC ₆ H ₄	3-ClC ₆ H ₄	H	2,4-diCH ₃ OC ₆ H ₃	6	(CH ₂) ₈ CH ₃	
137	4-ClC ₆ H ₄	4-ClC ₆ H ₄	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	55-57 (d)
138	4-FC ₆ H ₄	3-ClC ₆ H ₄	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
139	4-nC ₄ H ₉ C ₆ H ₄	4-nC ₄ H ₉ C ₆ H ₄	H	C ₆ H ₅	5	(CH ₂) ₆ CH ₃	
140	3,4-diClC ₆ H ₃	C ₆ H ₅	H	n-C ₃ H ₇	6	(CH ₂) ₆ CH ₃	

Table 1 (continued).

Ex. No.	<u>R¹</u>	<u>R²</u>	<u>R³</u>	<u>R⁴</u>	<u>n</u>	<u>R⁶</u>	<u>mp °C</u>
141	C ₆ H ₅	3-pyridinyl	H	C ₆ H ₁₁	5	(CH ₂) ₆ CH ₃	
142	C ₆ H ₅	3-pyridinyl	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
143	C ₆ H ₅	3-pyridinyl	H	2,4-diFC ₆ H ₃	8	(CH ₂) ₆ CH ₃	
144	C ₆ H ₅	3-pyridinyl	H	n-C ₃ H ₇	8	(CH ₂) ₆ CH ₃	
145	4-FC ₆ H ₄	3-pyridinyl	H	2,4,6-triFC ₆ H ₂	5	(CH ₂) ₆ CH ₃	
146	4-CH ₃ OC ₆ H ₄	3-pyridinyl	H	2,4,6-triFC ₆ H ₂	6	(CH ₂) ₆ CH ₃	
147	C ₆ H ₅	2-thienyl	H	2,4-diFC ₆ H ₃	4	(CH ₂) ₇ CH ₃	
148	4-FC ₆ H ₄	2-thienyl	H	C ₆ H ₅	5	(CH ₂) ₆ CH ₃	
149	4-CH ₃ OC ₆ H ₄	2-thienyl	H	2,4-diCH ₃ OC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
150	C ₆ H ₅	4-pyridinyl	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
151	4-FC ₆ H ₄	4-pyridinyl	H	C ₆ H ₅	5	(CH ₂) ₆ CH ₃	
152	4-CH ₃ OC ₆ H ₄	4-pyridinyl	H	2,4-diCH ₃ C ₆ H ₃	6	(CH ₂) ₇ CH ₃	
153	C ₆ H ₅	2-pyridinyl	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
154	3-F, 4-ClC ₆ H ₃	C ₆ H ₅	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
155	4-CH ₃ OC ₆ H ₄	4-FC ₆ H ₄	H	C ₆ H ₅	8	(CH ₂) ₆ CH ₃	
156	4-FC ₆ H ₄	C ₆ H ₅	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
157	4-BrC ₆ H ₄	C ₆ H ₅	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
158	4-CH ₃ OC ₆ H ₄	C ₆ H ₅	H	2,4-diCH ₃ OC ₆ H ₃	8	(CH ₂) ₆ CH ₃	

Table 1 (continued)

Ex. No.	<u>R¹</u>	<u>R²</u>	<u>R³</u>	<u>R⁴</u>	<u>n</u>	<u>R⁶</u>	<u>mp °C</u>
159	3,4-diCH ₃ OC ₆ H ₃	3,4-diCH ₃ OC ₆ H ₃	H	C ₆ H ₅	9	(CH ₂) ₅ CH ₃	
160	C ₆ H ₅	H	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	oil (e)
161	C ₆ H ₅	H	H	2,4-diCH ₃ OC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
162	C ₆ H ₅	H	H	2,4-diFC ₆ H ₃	8	(CH ₂) ₆ CH ₃	
163	C ₆ H ₅	H	H	n-C ₃ H ₇	5	(CH ₂) ₆ CH ₃	
164	4-FC ₆ H ₄	H	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
165	4-CH ₃ OC ₆ H ₄	H	H	2,4-diFC ₆ H ₃	8	(CH ₂) ₆ CH ₃	
166	C ₆ H ₅	H	H	C ₆ H ₅	8	(CH ₂) ₆ CH ₃	
167	C ₆ H ₅	CH ₃	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
168	C ₆ H ₅	CH ₃	H	2,4-diFC ₆ H ₃	8	(CH ₂) ₆ CH ₃	
169	C ₆ H ₅	CH ₃	H	n-C ₃ H ₇	8	(CH ₂) ₆ CH ₃	
170	C ₆ H ₅	CH ₃	H	2,4-diCH ₃ OC ₆ H ₃	8	(CH ₂) ₆ CH ₃	
171	4-FC ₆ H ₄	CH ₃	H	2,5-diClC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
172	C ₆ H ₅	n-C ₄ H ₉	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
173	C ₆ H ₅	n-C ₄ H ₉	H	2,4-diFC ₆ H ₃	8	(CH ₂) ₆ CH ₃	
174	C ₆ H ₅	n-C ₄ H ₉	H	2,4-diCH ₃ OC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
175	C ₆ H ₅	n-C ₄ H ₉	H	n-C ₃ H ₇	7	(CH ₂) ₆ CH ₃	
176	C ₆ H ₅	n-C ₈ H ₁₇	H	n-C ₃ H ₇	9	(CH ₂) ₅ CH ₃	

Table 1 (continued)

Ex. No.	<u>R¹</u>	<u>R²</u>	<u>R³</u>	<u>R⁴</u>	<u>n</u>	<u>R⁶</u>	<u>mp°C</u>
177	C ₆ H ₅	n-C ₈ H ₁₇	H	2,4-diClC ₆ H ₃	4	(CH ₂) ₇ CH ₃	
178	C ₆ H ₅	C ₅ H ₉	H	2,4-diFC ₆ H ₃	8	(CH ₂) ₆ CH ₃	
179	C ₆ H ₅	C ₅ H ₉	H	2,4,5-triClC ₆ H ₂	5	(CH ₂) ₆ CH ₃	
180	4-CH ₃ OC ₆ H ₄	C ₆ H ₁₁	H	C ₆ H ₅	5	(CH ₂) ₈ CH ₃	
181	C ₆ H ₅	C ₆ H ₁₁ -CH ₂	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
182	C ₆ H ₅	C ₆ H ₁₁ -(CH ₂) ₂	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
183	CH ₃	CH ₃	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
184	CH ₃	CH ₃	H	n-C ₃ H ₇	8	(CH ₂) ₆ CH ₃	
185	n-C ₄ H ₉	n-C ₄ H ₉	H	2,4,6-triFC ₆ H ₂	8	(CH ₂) ₆ CH ₃	
186	H	H	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	oil (f)
187	H	H	H	2,4-diFC ₆ H ₃	8	(CH ₂) ₆ CH ₃	
188	(CH ₃) ₂ CH	(CH ₃) ₂ CH	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	91-93
189	C ₆ H ₅	C ₆ H ₅	H	2,4-diFC ₆ H ₃	2	(CH ₂) ₆ CH ₃	144-146
190	C ₆ H ₅	C ₆ H ₅	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₂ CH ₃	68-70
191	C ₆ H ₅	C ₆ H ₅	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₇ CH ₃	
192	C ₆ H ₅	C ₆ H ₅	H	(C ₆ H ₄) (C ₆ H ₅)	5	(CH ₂) ₆ CH ₃	119-121
193	CH ₃ CH ₂ CH ₂	CH ₃ CH ₂ CH ₂	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	78-80
194	2-pyridinyl	2-pyridinyl	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	80-83 (HCl salt)

Table 1 (continued)

Ex. No.	R ¹	R ²	R ³	R ⁴	n	R ⁶	mp°C
195	3-CH ₃ OC ₆ H ₄	3-CH ₃ OC ₆ H ₄	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	100-102
196	2-CH ₃ OC ₆ H ₄	2-CH ₃ OC ₆ H ₄	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	oil (g)
197	4-(CH ₃) ₂ NC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	68-70 (h)
198	4-(CH ₃) ₂ NC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	142-145
199	C ₆ H ₁₁	C ₆ H ₁₁	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	(HCl salt)
200	C ₆ H ₅	4-(CH ₃) ₂ NC ₆ H ₄	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	55-58 (i)
201	2-furanyl	2-furanyl	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	oil (j)
202	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	CH ₂ (CH ₃) ₂	5	(CH ₂) ₆ CH ₃	liq (k)
203	4-(t-C ₄ H ₉)C ₆ H ₄	4-(t-C ₄ H ₉)C ₆ H ₄	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	oil (l)
204	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	78-80 (m)
205	4-(CH ₃) ₂ NC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	H	2,4-diFC ₆ H ₃	5	CH ₃	65-75 (n)
206	C ₆ H ₅	C ₆ H ₅	H	CH(CH ₃) ₂	5	(CH ₂) ₆ CH ₃	70-72 (o)
207	C ₆ H ₅	C ₆ H ₅	H	(CH ₂) ₇ CH ₃	5	2,4-diFC ₆ H ₃	oil (p)
208	C ₆ H ₅	C ₆ H ₅	H	(CH ₂) ₇ CH ₃	5	C ₆ H ₅	74-76
209	4-HOC ₆ H ₄	4-HOC ₆ H ₄	H	(CH ₂) ₇ CH ₃	5	2,4,6-triFC ₆ H ₂	99-101
210	(CH ₃) ₂ CH	(CH ₃) ₂ CH	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	110-112
				CH(CH ₃) ₂	5	(CH ₂) ₆ CH ₃	oil (q)

Table 1 (continued)

Ex. No.	R ¹	R ²	R ³	R ⁴	n	R ⁶	mp°C
211	C ₆ H ₄ -2-OCH ₂ O-2'-C ₆ H ₄		H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	65-70
212	C ₆ H ₄ OC ₆ H ₄		H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	82-87
213	n-C ₃ H ₇	n-C ₃ H ₇	H	n-C ₃ H ₇	5	(CH ₂) ₆ CH ₃	
214	2-pyridinyl	2-pyridinyl	H	C ₆ H ₁₁	5	(CH ₂) ₆ CH ₃	
215	3-pyridinyl	3-pyridinyl	H	2,4-diCH ₃ OC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
216	4-pyridinyl	4-pyridinyl	H	2,4,6-triFC ₆ H ₂	5	(CH ₂) ₆ CH ₃	
217	2-CH ₃ OC ₆ H ₄	2-CH ₃ OC ₆ H ₄	H	3-FC ₆ H ₄	5	(CH ₂) ₆ CH ₃	
218	3-CH ₃ OC ₆ H ₄	3-CH ₃ OC ₆ H ₄	H	CH(CH ₃) ₂	5	(CH ₂) ₆ CH ₃	
219	C ₆ H ₁₁	C ₆ H ₁₁	H	C ₆ H ₅	5	(CH ₂) ₆ CH ₃	
220	C ₆ H ₅	4-(CH ₃) ₂ NC ₆ H ₄	H	(CH ₂) ₇ CH ₃	5	(CH ₂) ₆ CH ₃	
221	2-furanyl	2-furanyl	H	2,6-diClC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
222	4-(t-C ₄ H ₉)C ₆ H ₄	4-(t-C ₄ H ₉)C ₆ H ₄	H	CH ₃	5	(CH ₂) ₆ CH ₃	
223	2-thienyl	2-thienyl	H	(C ₆ H ₄) (C ₆ H ₅)	5	(CH ₂) ₆ CH ₃	
224	4-HO-C ₆ H ₄	4-HO-C ₆ H ₄	CH ₃	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
225	(CH ₃) ₂ CH	(CH ₃) ₂ CH	CH ₃	C ₆ H ₁₁	5	(CH ₂) ₆ CH ₃	
226	C ₆ H ₅ -CH ₂	C ₆ H ₅ -CH ₂	CH ₃	C ₆ H ₅	5	(CH ₂) ₆ CH ₃	
227	C ₆ H ₄ -2-OCH ₂ O-2'-C ₆ H ₄		H	2,4-diFC ₆ H ₃	3	(CH ₂) ₆ CH ₃	
228	C ₆ H ₄ OC ₆ H ₄		H	C ₆ H ₁₁	3	(CH ₂) ₆ CH ₃	

Table 1 (continued)

Ex. No.	<u>R¹</u>	<u>R²</u>	<u>R³</u>	<u>R⁴</u>	<u>n</u>	<u>R⁶</u>	<u>mp°C</u>
229	4-CH ₃ OC ₆ H ₄	4-CH ₃ C ₆ H ₄	H	2,4-diFC ₆ H ₃	8	(CH ₂) ₆ CH ₃	
230	4-CH ₃ OC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	H	C ₆ H ₁₁	8	(CH ₂) ₆ CH ₃	
231	4-CH ₃ OC ₆ H ₄	C ₆ H ₁₁	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₃ CH ₃	
232	4-CH ₃ OC ₆ H ₄	(CH ₃) ₂ CH	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₈ CH ₃	
233	4-(CH ₃) ₂ NC ₆ H ₄	C ₆ H ₁₁	H	2,4-diFC ₆ H ₃	5	CH ₃	
234	4-(CH ₃) ₂ NC ₆ H ₄	(CH ₃) ₂ CH	H	2,4-diFC ₆ H ₃	5	C ₆ H ₅	
235	C ₆ H ₁₁	(CH ₃) ₂ CH	CH ₂ CH ₃	2,4-diFC ₆ H ₃	5	3-FC ₆ H ₄	
236	C ₆ H ₅	4-CH ₃ OC ₆ H ₄	C ₆ H ₅	(CH ₂) ₇ CH ₃	5	(CH ₂) ₃ CH ₃	
237	C ₆ H ₅	4-(CH ₃) ₂ NC ₆ H ₄	CH ₂ C ₆ H ₅	(CH ₂) ₇ CH ₃	5	C ₆ H ₅	
238	C ₆ H ₅	C ₆ H ₁₁	H	n-C ₃ H ₇	5	(CH ₂) ₆ CH ₃	
239	C ₆ H ₅	(CH ₃) ₂ CH	H	C ₆ H ₁₁	5	(CH ₂) ₆ CH ₃	
240	4-CH ₃ SC ₆ H ₄	4-CH ₃ SC ₆ H ₄	H	2,4-diCH ₃ OC ₆ H ₃	5	(CH ₂) ₆ CH ₃	
241	4-CH ₃ SC ₆ H ₄	4-CH ₃ SC ₆ H ₄	H	2,4,6-triFC ₆ H ₂	5	(CH ₂) ₆ CH ₃	
242	4-CH ₃ SO ₂ C ₆ H ₄	4-CH ₃ SO ₂ C ₆ H ₄	H	3-FC ₆ H ₄	5	(CH ₂) ₆ CH ₃	
243	C ₆ H ₅	4-CH ₃ SC ₆ H ₄	H	CH(CH ₃) ₂	5	(CH ₂) ₆ CH ₃	
244	C ₆ H ₅	4-CH ₃ SOC ₆ H ₄	H	C ₆ H ₅	5	(CH ₂) ₆ CH ₃	
245	C ₆ H ₅	4-CH ₃ SO ₂ C ₆ H ₄	H	(CH ₂) ₇ CH ₃	5	(CH ₂) ₆ CH ₃	
246	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	n-C ₃ H ₇	5	(CH ₂) ₆ CH ₃	
247	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	C ₆ H ₁₁	5	(CH ₂) ₆ CH ₃	

Table 1 (continued)

Ex. No.	R ¹	R ²	R ³	R ⁴	n	R ⁶	mp °C
248	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	C ₆ H ₅	5	(CH ₂) ₆ CH ₃	
249	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	2,4-diFC ₆ H ₃	3	(CH ₂) ₆ CH ₃	
250	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	C ₆ H ₁₁	8	(CH ₂) ₆ CH ₃	
251	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	(CH ₂) ₇ CH ₃	5	C ₆ H ₅	
252	4-(CH ₃) ₂ NC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	H	n-C ₃ H ₇	5	(CH ₂) ₆ CH ₃	
253	4-(CH ₃) ₂ NC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	H	C ₆ H ₁₁	5	(CH ₂) ₆ CH ₃	
254	4-(CH ₃) ₂ NC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	H	C ₆ H ₅	5	(CH ₂) ₆ CH ₃	
255	4-(CH ₃) ₂ NC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	H	2,4-diFC ₆ H ₃	3	(CH ₂) ₆ CH ₃	
256	4-(CH ₃) ₂ NC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	H	C ₆ H ₁₁	8	(CH ₂) ₆ CH ₃	
257	4-(CH ₃) ₂ NC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	H	(CH ₂) ₇ CH ₃	5	C ₆ H ₅	
258	4-CF ₃ C ₆ H ₄	4-CF ₃ C ₆ H ₄	H	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	oil (r)
259	C ₆ H ₅	H	C ₆ H ₅	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	oil (s)
260	H	C ₆ H ₅	C ₆ H ₅	2,4-diFC ₆ H ₃	5	(CH ₂) ₆ CH ₃	oil (t)
261	C ₆ H ₅	C ₆ H ₅	H	CH(CH ₃) ₂	5	C ₆ H ₅	55-59
262	C ₆ H ₅	C ₆ H ₅	H	CH(CH ₃) ₂	8	(CH ₂) ₃ CH ₃	110-112
263	C ₆ H ₅	C ₆ H ₅	H	CH(CH ₃) ₂	5	2,4-diFC ₆ H ₃	46-50
264	4-CH ₃ O-C ₆ H ₄	4-CH ₃ O-C ₆ H ₄	H	CH(CH ₃) ₂	5	4-(CH ₃) ₂ NC ₆ H ₄	76-80
265	C ₆ H ₅	C ₆ H ₅	H	CH(CH ₃) ₂	5	4-(CH ₃) ₂ NC ₆ H ₄	166-167
266	C ₆ H ₅	C ₆ H ₅	H	2,6-di[(CH ₃) ₂ CH]C ₆ H ₃	5	(CH ₂) ₆ CH ₃	185-187

Footnotes to Table 1

- (a) ^1H NMR (CDCl_3) δ 11.6(s, 1H), 7.7-7.1(m, 10H), 4.4(t, 1H, J=5Hz), 3.4(t, 2H, J=6.7Hz), 3.2-2.9(m, 5H), 1.8-1.0(m, 29H), 1.0-0.8(m, 7H).
- 5 (b) ^1H NMR (CDCl_3) δ 8.79-7.63(m, 7H), 7.29-7.12(m, 2H), 6.87-6.73(m, 2H), 6.44(bs, 1H), 3.34-3.08(m, 6H), 1.83-1.18(m, 16H), 0.86(t, 3H).
- 10 (c) ^1H NMR (CDCl_3) δ 10.6-10.0(bs, 1H), 7.80(m, 1H), 7.35-7.00(m, 8H), 6.8-6.57(m, 2H), 6.4(bs, 1H), 3.89(t, 2H), 3.25(t, 2H), 3.00(t, 2H), 2.33(s, 3H), 2.32(s, 3H), 1.79-1.29(m, 16H), 0.88(t, 3H).
- 15 (d) ^1H NMR (CDCl_3) δ 11.1-11.0(bs, 1H), 7.64(m, 1H), 7.5(d, 2H), 7.27(m, 6H), 6.75(m, 1H), 6.53(m, 1H), 6.33(bs, 1H), 3.45(t, 2H), 3.26(t, 2H), 2.98(t, 2H), 1.82-1.25(m, 16H), 0.90(t, 3H).
- 20 (e) ^1H NMR (CDCl_3) δ 10.8-10.7(m, 1H), 8.0-7.2(m, 7H), 6.9-6.6(m, 2H), 6.0-5.9(m, 1H), 3.4(t, 2H, J=6.6Hz), 3.3(t, 2H, J=7.6Hz), 3.0(t, 2H, J=6.5Hz), 1.9-1.2(m, 18H), 0.9(t, 3H, J=7.2Hz).
- 25 (f) ^1H NMR (CDCl_3) δ 10.4-10.1(m, 1H), 8.0-7.8(m, 1H), 7.2-6.9(m, 2H), 6.9-6.75(m, 2H), 6.5-6.4(m, 1H), 3.4-3.2(m, 4H), 3.0(t, 2H, J=7Hz), 1.9-1.1(m, 19H), 0.9(t, 3H, J=8Hz).
- 30 (g) ^1H NMR ($\text{DMSO}-d_6$) δ 12.17(bs, 1H), 7.94(bs, 1H), 7.43-6.77(m, 11H), 3.57(s, 3H), 3.24(m, 4H), 3.19(s, 3H), 3.07(t, 2H), 1.76-1.18(m, 16H), 0.85(t, 3H).
- (h) ^1H NMR (CDCl_3) δ 10.03-9.55(bs, 1H), 7.86(m, 1H), 7.58-7.20(bm, 4H), 6.82-6.61(m, 6H), 6.42(bs, 1H), 3.30-3.21(m, 2H), 2.94(bs, 14H), 1.78-1.26(m, 16H), 0.88(t, 3H).
- (i) ^1H NMR (CDCl_3) δ 9.50-9.18(bs, 1H), 7.97(m, 1H), 6.80(m, 2H), 6.41(bs, 1H), 3.31(m, 4H), 2.86(t, 2H), 2.68-2.37(m, 2H), 1.91-1.13(m, 36H), 0.89(t, 3H).

Footnotes to Table 1 (continued)

- (j) ^1H NMR (CDCl_3) δ 10.2-9.8(bs,1H), 7.85(m,1H), 7.70-7.16(m,7H), 6.75(m,1H), 6.89(d,3H), 6.39(bs,1H), 3.38(t,2H), 3.25(t,2H), 3.01(t,2H), 2.95(s,6H), 1.85-1.25(m,16H), 0.9(t,3H).
- (k) ^1H NMR (CDCl_3) δ 10.35-10.15(bs,1H), 7.95(m,1H), 7.50-7.36(m,2H), 6.98-6.69(m,4H), 6.49-6.38(m,3H), 3.35(t,2H), 3.25(t,2H), 3.05(t,2H), 1.79-1.27(m,16H), 0.90(t,3H).
- (l) ^1H NMR (CDCl_3) δ 7.47(d,4H), 6.84(d,4H), 4.12(d,1H), 3.84(m,1H), 3.80(s,6H), 3.33(t,2H), 3.07(t,2H), 2.96(t,2H), 1.8-1.24(m,16H), 1.08(d,6H), 0.90(t,3H).
- (m) ^1H NMR (CDCl_3) δ 10.15-10.0(bs,1H), 7.82(m,1H), 7.53(m,2H), 7.31(m,6H), 6.73(m,1H), 6.61(m,1H), 3.4(t,2H), 3.26(t,2H), 3.00(t,2H), 1.82-1.49(m,12H), 1.33(bs,22H), 0.9(t,3H).
- (n) ^1H NMR (CDCl_3) δ 10.8-10.76(bs,1H), 7.70(m,1H), 7.15(m,2H), 7.31(m,2H), 6.82(m,4H), 6.73(m,1H), 6.58(m,1H), 6.40(bs,1H), 3.8(s,6H), 3.46(t,2H), 3.01(s,3H), 2.94(t,2H), 1.78-1.44(m,6H).
- (o) ^1H NMR (CDCl_3) δ 7.56-7.33(bs,4H), 6.67(d,4H), 4.11(d,1H), 3.89(m,1H), 3.3(t,2H), 3.08(t,2H), 2.95(bs,14H), 1.84-1.25(m,16H), 1.1(d,6H), 0.9(t,3H).
- (p) ^1H NMR (CDCl_3) δ 7.7-6.9(m,14H), 4.1(t,1H, $J=5.4\text{Hz}$), 3.8-3.65(m,2H), 3.1-2.9(m,4H), 1.9-1.0(m,18H), 0.85(t,3H, $J=6.7\text{Hz}$).
- (q) ^1H NMR ($\text{DMSO}-d_6$) δ 11.58(s,1H), 5.71(d,1H), 3.75(m,1H), 3.07(t,4H), 2.95-2.78(m,4H), 1.57-1.1(m,16H), 1.14(d,6H), 1.10(d,6H), 1.03(d,6H), 0.85(t,3H).
- (r) ^1H NMR (CDCl_3) δ 11.68(bs,1H), 7.67-7.2(m,9H), 6.68(m,1H), 6.48(m,1H), 6.33(m,1H), 3.46(t,2H), 3.27(t,2H), 2.99(t,2H), 1.83-1.2(m,16H), 0.90(t,3H).

Footnotes to Table 1 (continued)

- (s) NMR (CDCl₃) δ 8.0(s, 1H), 7.85-7.80(m, 2H), 7.55-7.40(m, 7H), 7.3-7.2(m, 2H), 6.9-6.8(m, 2H), 6.4(d, 1H, J=3.3Hz), 3.25(sextet, 4H, J=5.1Hz), 3.15(t, 2H, J=7.2Hz), 1.8-1.2(m, 16H), 0.9-0.8(m, 3H).
- (t) NMR (CDCl₃) δ 8.1-8.0(m, 1H), 7.5-7.3(m, 3H), 7.3-7.1(m, 4H), 7.1-7.0(m, 1H), 6.9-6.8(m, 1H), 6.5(d, 1H, J=3.3Hz), 3.3(q, 4H, J=7.4Hz), 3.1(t, 2H, J=7.2Hz), 1.8-1.2(m, 18H), 0.9-0.8(m, 3H).

EXAMPLE 267

Preparation of N'-(2,4-difluorophenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylthiourea

- Employing the method of Example 1, Part E, using 2,4-difluorophenylisothiocyanate (0.14 g, 0.0008 mol), the title compound (0.19 g, 0.00031 mol) was obtained as a white solid, mp 116-118°. ¹H NMR (CDCl₃) δ 9.5-9.4(s, 1H), 7.8-7.1(m, 11H), 7.0-6.7(m, 3H), 3.8(t, 2H, J=7.6Hz), 3.6(t, 2H, J=7.8Hz), 3.1(t, 2H, J=7Hz), 1.9-1.1(m, 18H), 0.9(t, 3H, J=4Hz).

EXAMPLE 278

Preparation of N'-(2,4-difluorophenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylsulfinyl)pentyl]-N-heptylurea

- To a solution of N'-(2,4-difluorophenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea (0.59 g, 0.001 mol) in methylene chloride (50 mL) cooled to -78° was added, dropwise, a solution of meta-chloroperbenzoic acid (0.286 g, 0.0017 mol) in methylene chloride (10 mL). The reaction mixture was stirred at -78° for 1 hour and then allowed to warm to ambient temperature. The reaction mixture was then cooled to 0° and then added, dropwise, was a solution of saturated sodium bisulfite. The layers were separated and the organic layer was washed with saturated sodium

bisulfite. The layers were separated and the sodium chloride solution dried over magnesium sulfate and concentrated under vacuum. The residue (0.76 g) was chromatographed with 1:1 hexane-ethyl acetate to give the title compound (0.43 g, 0.00071 mol) as a yellow solid, mp 77-79°. ¹H NMR (CDCl₃) δ 8.1-7.9(m, 1H), 7.6-7.2 (m, 10H), 6.9-6.7(m, 2H), 6.4(d, 1H, J=3.3Hz), 3.4-3.1(m, 6H), 2.0-1.1(m, 18H), 0.9(t, 3H, J=6.4Hz).

10

EXAMPLE 281

Preparation of N'-(2,4-difluorophenyl)-N-[5-[(4,5-diphenyl-1H-imidazol-2-yl)sulfonyl]pentyl]-N-heptylurea

To a solution of N'-(2,4-difluorophenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea (0.11 g, 0.00019 mol) in methanol (5 mL) was added, portionwise as a solid, OxoneTM (0.234 g, 0.00038 mol) and the reaction mixture was stirred at ambient temperature for 7 hours. The solids were filtered and washed with methanol. The filtrate was concentrated under vacuum and the residue was chromatographed with 6:4 hexane-ethyl acetate to give the title compound (0.06 g, 0.000096 mol) as a glassy, colorless solid, mp 66-68°. ¹H NMR (CDCl₃) δ 7.85-7.75(m, 1H), 7.6-7.1(m, 11H), 6.8-6.6(m, 2H), 6.4(s, 1H), 3.4(t, 4H, J=10Hz), 3.25(t, 2H, J=7Hz), 1.9-1.75(m, 2H), 1.75-1.4(m, 6H), 1.4-1.1(m, 8H), 0.9(t, 3H, J=8Hz).

20

25

EXAMPLE 338

Preparation of N'-(2,4-difluorophenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylamino)pentyl]-N-heptylurea

30

Part A. A solution of 2-bromo-4,5-diphenyl-1H-imidazole (3.5 g, 0.0117 mol) in 1,5-diaminopentane (20 mL) was heated to reflux for 48 hours. The reaction mixture was concentrated in vacuo to give a viscous oil which was taken up in methylene chloride (60 mL) and washed with

35

10% aqueous NaHCO_3 , water (2 x 50 mL), brine, dried over magnesium sulfate and concentrated in vacuo to give 5-(4,5-diphenyl-1H-imidazol-2-ylamino)aminopentane as a viscous oil (3.5 g, 0.0109 mol). ^1H NMR (CDCl_3) δ 7.55-7.09(m,10H), 4.79-3.79(bs,3H), 3.14(t,2H), 2.59(t,2H), 1.79-1.22(m, 6H).

Part B. To a solution of 5-(4,5-diphenyl-1H-imidazol-2-ylamino)-aminopentane (1.7 g, 0.00531 mol) and triethylamine (0.58 g, 0.0058 mol) in methylene chloride cooled to 0° under a nitrogen atmosphere, heptanoyl chloride (0.788 g, 0.00531 mol) was added slowly. The reaction mixture was stirred for 1 hour at 0° , poured into water and extracted with methylene chloride (2 x 50 mL). The combined organic extract was washed with water, brine, dried over magnesium sulfate and concentrated to give N-[5-(4,5-diphenyl-1H-imidazol-2-ylamino)pentyl]heptanamide as a viscous oil. The product was purified by flash chromatography on silica gel (250 mL) eluting methylene chloride:methanol (95:5 v:v), to give an amber foam (1.3 g, 0.003 mol). ^1H NMR (CDCl_3) δ 7.43-7.15(m,10H), 6.3(m,1H), 3.24-3.1(m,4H), 2.09(t,2H), 1.6-1.16(m,14H), 0.84(t,3H).

Part C. Employing the method of Example 118, Part B, but using N-[5-(4,5-diphenyl-1H-imidazol-2-ylamino)pentyl]heptanamide, N-[5-(4,5-diphenyl-1H-imidazol-2-ylamino)pentyl]-N-heptylamine was obtained as an amber oil (1.00 g, 0.00238 mol). ^1H NMR (CDCl_3) δ 7.56-6.85(m,10H), 3.23(m,2H), 2.49(m,4H), 1.68-0.90(m,16H), 0.88(t,3H).

Part D. Employing the method of Example 118, Part C, but using N-[5-(4,5-diphenyl-1H-imidazol-2-ylamino)pentyl]-N-heptylamine, the title compound was obtained as a yellow foam (0.395 g, 0.000688 mol). ¹H NMR (CDCl₃) δ 8.37-7.1(m,11H), 6.9-6.67(m,2H), 6.44(d,1H), 4.53(bs,1H), 3.27(m,6H), 1.74-1.23(m,16H), 0.89(t,3H).

EXAMPLE 339

10 Preparation of N'-(2,4-difluorophenyl)-N-[6-(4,5-diphenyl-1H-imidazol-2-yl)hexyl]-N-heptylurea

Part A. To a solution of 4,5-diphenyl-1-[(trimethylsilyl)ethoxymethyl]-1H-imidazole (2.5 g, 0.00734 mol) (B. Lipshutz, B. Huff, W. Hazen, Tetrahedron Letters, 29, 3411-14, 1988), in dry tetrahydrofuran (50 mL) cooled to -78° under a nitrogen atmosphere, n-butyl lithium in hexane (2.5 M, 0.00734 mol) was added slowly. The reaction mixture was stirred for 1 hour and 1,6-dibromohexane (2.68 g, 0.0011 mol) was added rapidly, stirred for 1/2 hour and was allowed to warm to ambient temperature and stirred for 2 additional hours. The reaction mixture was poured into water and extracted with ethyl acetate (2 x 50 mL). The combined organic layer was washed with water, brine, dried over magnesium sulfate and concentrated to give a viscous oil. The product was purified by flash chromatography on silica gel (250 mL) eluting with hexane:ethyl acetate (70:30 v:v) to give 6-bromo-1-(4,5-diphenyl-1-[(trimethylsilyl)ethoxymethyl]imidazol-2-yl)hexane as an oil (2.18 g, 0.00424 mol). ¹H NMR (CDCl₃) δ 7.53-7.16(m,10H), 5.10(s,2H), 3.48(t,2H), 3.34(t,2H), 2.90(t,2H), 1.99-1.5(m,8H), 0.875(t,2H), 0.008(s,9H).

Part B. A solution of 6-bromo-1-(4,5-diphenyl-1-[(trimethylsilyl)ethoxymethyl]-1H-imidazol-2-yl)hexane


(1.0 g, 0.00195 mol) and n-heptylamine (0.45 g, 0.00389 mol) in acetonitrile (25 mL) was heated to 60° for 8 hours. The reaction mixture was poured into 10% aqueous sodium bicarbonate and extracted with ethyl acetate (2 x 50 mL). The combined organic extract was washed with water, brine, dried over magnesium sulfate and concentrated to give N-[6-(4,5-diphenyl-1-[(trimethylsilyl)ethoxymethyl]-1H-imidazol-2-yl)hexyl]-N-heptylamine as a colorless viscous oil (1.04 g, 0.00189 mol). ¹H NMR (CDCl₃) δ 7.52-7.2(m,10H), 5.11(s,2H), 4.7-4.2(bs,1H), 3.3(t,2H), 2.93-2.70(m,6H), 1.95-1.34(m,18H), 0.93(t,3H), 0.86(t,2H), 0.005(s,9H).

Part C. Employing the method of Example 118, Part C, but using N-[6-(4,5-diphenyl-1-[(trimethylsilyl)ethoxymethyl]-imidazole-2-yl)hexyl]-N-heptylamine, N'-(2,4-difluorophenyl)-N-[6-(4,5-diphenyl-1-[(trimethylsilyl)ethoxymethyl]-imidazole-2-yl)hexyl]-N-heptylurea was isolated as a viscous oil (1.40 g, 0.00199 mol). ¹H NMR (CDCl₃) δ 8.12(m,1H), 7.53-7.16(m,10H), 6.88(m,2H), 6.48(d,1H), 5.1(s,2H), 3.33(m,6H), 2.90(t,2H), 2.0-1.34(m,18H), 0.88(t,3H), 0.79(t,2H), 0.055(s,9H).

Part D. To a solution of N'-(2,4-difluorophenyl)-N-[6-(4,5-diphenyl-1-[(trimethylsilyl)ethoxymethyl]-1H-imidazol-2-yl)hexyl]-N-heptylurea (0.60 g, 0.000853 mol) in dry tetrahydrofuran (10 mL) under a nitrogen atmosphere, tetrabutylammonium fluoride (1M in tetrahydrofuran, 3.41 mL) was added and the reaction mixture was heated to reflux 7 hours. The reaction mixture was cooled, poured into water (50 mL) and extracted with ethyl acetate (2x50 mL). The combined organic layer was washed with water, brine, dried over magnesium sulfate and concentrated in vacuo. The product was purified by flash chromatography on silica

gel (75 mL) eluting hexane:ethyl acetate (60:40 v:v) to give the title compound as a colorless glass (0.26 g, 0.000454 mol). ^1H NMR (CDCl_3) δ 9.5-9.0 (bs, 1H), 7.87 (m, 1H), 7.5-7.2 (m, 10H), 6.83-6.7 (m, 2H), 6.4 (d, 1H), 5 3.28 (m, 4H), 2.67 (t, 2H), 1.75-1.26 (m, 18H), 0.88 (t, 3H).

Table 2



Ex. No.	R ¹	R ²	R ³	R ⁴	X	Y	n	R ⁶	mp°C
267	C ₆ H ₅	C ₆ H ₅	H	2,4-diFC ₆ H ₃	O	O	5	(CH ₂) ₆ CH ₃	
268	C ₆ H ₅	C ₆ H ₅	H	2,4-diCH ₃ OC ₆ H ₃	O	O	5	(CH ₂) ₆ CH ₃	
269	C ₆ H ₅	C ₆ H ₅	H	2,4-diFC ₆ H ₃	O	O	8	(CH ₂) ₆ CH ₃	
270	C ₆ H ₅	C ₆ H ₅	H	n-C ₃ H ₇	O	O	8	(CH ₂) ₆ CH ₃	
271	C ₆ H ₅	C ₆ H ₅	H	2,4-diFC ₆ H ₃	O	S	5	(CH ₂) ₆ CH ₃	
272	C ₆ H ₅	C ₆ H ₅	CH ₃	2,4-diFC ₆ H ₃	O	O	8	(CH ₂) ₆ CH ₃	
273	C ₆ H ₅	C ₆ H ₅	C ₆ H ₅	2,4,6-triFC ₆ H ₂	O	O	8	(CH ₂) ₆ CH ₃	
274	4-FC ₆ H ₄	4-FC ₆ H ₄	H	2,4,6-triFC ₆ H ₂	O	O	5	(CH ₂) ₆ CH ₃	
275	C ₆ H ₅	3-pyridinyl	H	2,4-diFC ₆ H ₃	O	O	5	(CH ₂) ₆ CH ₃	
276	C ₆ H ₅	C ₆ H ₅	H	2,4-diFC ₆ H ₃	S	S	5	(CH ₂) ₆ CH ₃	116-118
277	4-FC ₆ H ₄	4-FC ₆ H ₄	H	2,4-diFC ₆ H ₃	S	S	8	(CH ₂) ₆ CH ₃	
278	C ₆ H ₅	C ₆ H ₅	H	2,4-diFC ₆ H ₃	SO	O	5	(CH ₂) ₆ CH ₃	77-79
279	C ₆ H ₅	C ₆ H ₅	H	2,4-diFC ₆ H ₃	SO	O	8	(CH ₂) ₆ CH ₃	
280	C ₆ H ₅	C ₆ H ₅	H	n-C ₃ H ₇	SO	O	5	(CH ₂) ₆ CH ₃	
281	C ₆ H ₅	C ₆ H ₅	H	2,4-diFC ₆ H ₃	SO ₂	O	5	(CH ₂) ₆ CH ₃	66-68
282	C ₆ H ₅	C ₆ H ₅	H	2,4-diFC ₆ H ₃	SO ₂	O	8	(CH ₂) ₆ CH ₃	

Table 2 (continued)

Ex. No.	R ¹	R ²	R ³	R ⁴	X	Y	n	R ⁶	mp °C
283	C ₆ H ₅	C ₆ H ₅	H	n-C ₃ H ₇	SO ₂	O	8	(CH ₂) ₆ CH ₃	
284	C ₆ H ₅	C ₆ H ₅	H	n-C ₃ H ₇	SO ₂	S	5	(CH ₂) ₆ CH ₃	
285	C ₆ H ₅	C ₆ H ₅	CH ₃	n-C ₃ H ₇	SO ₂	O	5	(CH ₂) ₆ CH ₃	
286	C ₆ H ₅	C ₆ H ₅	H	2,4,6-triFC ₆ H ₂	NH	O	5	(CH ₂) ₆ CH ₃	
287	C ₆ H ₅	C ₆ H ₅	H	2,4-diCH ₃ OC ₆ H ₃	NH	O	5	(CH ₂) ₆ CH ₃	
288	C ₆ H ₅	C ₆ H ₅	H	2,4-diFC ₆ H ₃	NH	O	8	(CH ₂) ₆ CH ₃	
289	4-FC ₆ H ₄	4-FC ₆ H ₄	H	n-C ₅ H ₁₁	NH	O	4	(CH ₂) ₈ CH ₃	
290	C ₆ H ₅	C ₆ H ₅	CH ₃	C ₆ H ₅	NH	O	7	(CH ₂) ₅ CH ₃	
291	C ₆ H ₅	C ₆ H ₅	H	2,4-diFC ₆ H ₃	NCH ₃	O	5	(CH ₂) ₆ CH ₃	
292	C ₆ H ₅	C ₆ H ₅	H	2,4-diFC ₆ H ₃	NCH ₃	O	8	(CH ₂) ₆ CH ₃	
293	C ₆ H ₅	C ₆ H ₅	H	n-C ₃ H ₇	NCH ₂ C ₆ H ₅	O	6	(CH ₂) ₈ CH ₃	
294	C ₆ H ₅	C ₆ H ₅	H	2,4,6-triFC ₆ H ₂	NCH ₂ C ₆ H ₅	O	5	(CH ₂) ₆ CH ₃	
295	C ₆ H ₅	C ₆ H ₅	H	2,4-diClC ₆ H ₃	NC ₃ H ₇	O	8	(CH ₂) ₆ CH ₃	
296	C ₆ H ₅	C ₆ H ₅	H	3,4,5-triCH ₃ OC ₆ H ₂	NC ₃ H ₇	O	4	(CH ₂) ₅ CH ₃	
297	C ₆ H ₅	C ₆ H ₅	H	CH ₃	NC ₆ H ₁₃	O	5	(CH ₂) ₆ CH ₃	
298	C ₆ H ₅	C ₆ H ₅	H	2,4,6-triFC ₆ H ₂	S	S	5	(CH ₂) ₆ CH ₃	124-126
299	C ₆ H ₅	C ₆ H ₅	H	(CH ₂) ₂ CH ₃	S	S	5	(CH ₂) ₆ CH ₃	89-91
300	C ₆ H ₅	C ₆ H ₅	H	3-FC ₆ H ₄	S	S	5	(CH ₂) ₆ CH ₃	161-163
301	(CH ₃) ₂ CH	(CH ₃) ₂ CH	H	C ₆ H ₁₁	NH	O	5	(CH ₂) ₆ CH ₃	
302	(CH ₃) ₂ CH	C ₆ H ₅	H	2,4-diCH ₃ OC ₆ H ₃	CH ₂	O	5	(CH ₂) ₆ CH ₃	
303	4-CH ₃ OC ₆ H ₄	C ₆ H ₅	H	2,4,6-triFC ₆ H ₂	SO	O	5	(CH ₂) ₆ CH ₃	

Table 2 (continued)

Ex. No.	R ¹	R ²	R ³	R ⁴	X	Y	n	R ⁶	mp °C
304	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	3-FC ₆ H ₄	SO ₂	O	5	(CH ₂) ₆ CH ₃	
305	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	CH(CH ₃) ₂	O	S	5	(CH ₂) ₆ CH ₃	
306	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	C ₆ H ₅	NH	S	5	(CH ₂) ₆ CH ₃	
307	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	(CH ₂) ₇ CH ₃	CH ₂	S	5	(CH ₂) ₆ CH ₃	
308	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	2,6-diClC ₆ H ₃	O	O	5	(CH ₂) ₆ CH ₃	
309	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	CH ₃	NH	O	5	(CH ₂) ₆ CH ₃	
310	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	(C ₆ H ₄)(C ₆ H ₅)	CH ₂	O	5	(CH ₂) ₆ CH ₃	
311	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	CH ₃	2,4-diFC ₆ H ₃	SO	O	5	(CH ₂) ₆ CH ₃	
312	(CH ₃) ₂ CH	(CH ₃) ₂ CH	CH ₃	C ₆ H ₁₁	SO ₂	O	5	(CH ₂) ₆ CH ₃	
313	(CH ₃) ₂ CH	(CH ₃) ₂ CH	CH ₃	C ₆ H ₅	O	H ₂	5	(CH ₂) ₆ CH ₃	
314	C ₆ H ₅	C ₆ H ₅	H	2,4-diFC ₆ H ₃	NH	H ₂	3	(CH ₂) ₆ CH ₃	
315	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	C ₆ H ₁₁	CH ₂	H ₂	3	(CH ₂) ₆ CH ₃	
316	C ₆ H ₅	C ₆ H ₅	H	n-C ₃ H ₇	O	S	5	(CH ₂) ₆ CH ₃	
317	(CH ₃) ₂ CH	(CH ₃) ₂ CH	H	C ₆ H ₁₁	NH	S	5	(CH ₂) ₆ CH ₃	
318	(CH ₃) ₂ CH	C ₆ H ₅	H	CH(CH ₃) ₂	CH ₂	S	5	(CH ₂) ₆ CH ₃	
319	C ₆ H ₅	4-CH ₃ OC ₆ H ₄	H	C ₆ H ₅	O	H ₂	5	(CH ₂) ₆ CH ₃	
320	(CH ₃) ₂ CH	(CH ₃) ₂ CH	H	2,4-diFC ₆ H ₃	NH	H ₂	3	(CH ₂) ₆ CH ₃	
321	4-(CH ₃) ₂ NC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	H	C ₆ H ₁₁	CH ₂	H ₂	8	(CH ₂) ₆ CH ₃	
322	4-(CH ₃) ₂ NC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	H	(CH ₂) ₇ CH ₃	SO	O	5	C ₆ H ₅	
323	4-(CH ₃) ₂ NC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	H	n-C ₃ H ₇	SO ₂	O	5	(CH ₂) ₆ CH ₃	

Table 2 (continued)

Ex. No.	<u>R¹</u>	<u>R²</u>	<u>R³</u>	<u>R⁴</u>	<u>X</u>	<u>Y</u>	<u>n</u>	<u>R⁶</u>	<u>mp°C</u>
324	4-(CH ₃) ₂ NC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	H	C ₆ H ₁₁	NH	O	5	(CH ₂) ₆ CH ₃	
325	4-(CH ₃) ₂ NC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	H	CH(CH ₃) ₂	CH ₂	O	5	(CH ₂) ₆ CH ₃	
326	4-(CH ₃) ₂ NC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	H	C ₆ H ₅	CH ₂	S	5	(CH ₂) ₆ CH ₃	
327	4-(CH ₃) ₂ NC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	H	2,4-diFC ₆ H ₃	S	H ₂	3	(CH ₂) ₆ CH ₃	
328	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	C ₆ H ₁₁	S	H ₂	8	(CH ₂) ₆ CH ₃	
329	C ₆ H ₅	C ₆ H ₅	C ₆ H ₅	(CH ₂) ₇ CH ₃	S	H ₂	5	C ₆ H ₅	
330	C ₆ H ₅	C ₆ H ₅	CH ₂ CH ₃	2,4-diFC ₆ H ₃	S	H ₂	5	(CH ₂) ₆ CH ₃	
331	(CH ₃) ₂ CH	(CH ₃) ₂ CH	CH ₂ C ₆ H ₅	2,4-diFC ₆ H ₃	S	H ₂	5	(CH ₂) ₆ CH ₃	
332	4-CH ₃ SC ₆ H ₄	4-CH ₃ SC ₆ H ₄	H	2,4-diFC ₆ H ₃	S	O	8	(CH ₂) ₆ CH ₃	
333	4-CH ₃ SOC ₆ H ₄	4-CH ₃ SOC ₆ H ₄	H	C ₆ H ₁₁	O	H ₂	8	(CH ₂) ₆ CH ₃	
334	4-CH ₃ SO ₂ C ₆ H ₄	4-CH ₃ SO ₂ C ₆ H ₄	H	2,4-diFC ₆ H ₃	CH ₂	S	5	(CH ₂) ₃ CH ₃	
335	4-CH ₃ SC ₆ H ₄	C ₆ H ₅	H	2,4-diFC ₆ H ₃	NH	O	5	(CH ₂) ₈ CH ₃	
336	4-CH ₃ SOC ₆ H ₄	C ₆ H ₅	H	2,4-diFC ₆ H ₃	S	H ₂	5	CH ₃	
337	4-CH ₃ SO ₂ C ₆ H ₄	C ₆ H ₅	H	2,4-diFC ₆ H ₃	S	S	5	C ₆ H ₅	
338	C ₆ H ₅	C ₆ H ₅	H	2,4-diFC ₆ H ₃	NH	O	5	(CH ₂) ₆ CH ₃	foam
339	C ₆ H ₅	C ₆ H ₅	H	2,4-diFC ₆ H ₃	CH ₂	O	5	(CH ₂) ₆ CH ₃	glass

EXAMPLE 340

Preparation of 2,4-difluoro-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-1-N-heptylbenzeneacetamide

To a solution of N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-1-heptanamine (2.2 g, 0.005 mol), 1-hydroxybenzotriazole hydrate (0.81 g, 0.006 mol), and 2,4-difluorophenylacetic acid (1.12 g, 0.0065 mol) in N,N-dimethylformamide (50 mL) at 0° was added, portionwise as a solid, dicyclohexylcarbodiimide (1.24 g, 0.006 mol). The reaction mixture was stirred at 0° for 2.5 hours, then at ambient temperature for 72 hours. The solids were filtered and washed with chloroform. The filtrate was concentrated under vacuum and the residue (5.2 g) was chromatographed with 7:3 hexane-ethyl acetate. The resulting solid was triturated with hexane to give the title compound (2.59 g, 0.0044 mol) as a yellow oil. ¹H NMR (CDCl₃) δ 7.6-7.0(m, 11H), 6.8-6.5(m, 2H), 3.7(d, 2H, J=13.7Hz), 3.5(t, 2H, J=6.4Hz), 3.4-3.0(m, 3H), 2.9(t, 2H, J=6.1Hz), 1.8-1.1(m, 17H), 0.9(t, 3H, J=6.6Hz).

EXAMPLE 353

Preparation of N-[5-[4,5-bis(4-methoxyphenyl)-1H-imidazol-2-ylthio]pentyl]-2,4-difluoro-N-heptylbenzeneethanamine

To a solution of lithium aluminium hydride (1 N in tetrahydrofuran, 2 mL) in dry tetrahydrofuran (30 mL), a solution of N-[5-[4,5-bis(4-methoxyphenyl)-1H-imidazol-2-ylthio]pentyl]-2,4-difluoro-N-heptylbenzeneacetamide (0.70 g, 0.00107 mol) in dry tetrahydrofuran (15 mL) was added slowly. The reaction mixture was heated to reflux for 5 hours and was then allowed to cool to ambient temperature. The reaction mixture was poured into a mixture of 10% aqueous sodium sulfate (150 mL) and ice (150 mL). The resultant emulsion was filtered through

Celite® and the filtrate was extracted with ethyl acetate (3 x 100 mL). The organic layer was washed with water, brine, dried over magnesium sulfate and concentrated in vacuo to give a crude oil. The product
5 was purified by flash chromatography on silica gel (100 mL) eluting methanol: methylene chloride (5:95 v:v) to give the title compound as a viscous colorless oil (0.46 g, 0.000723 mol). ¹H NMR (CDCl₃) δ 9.2-9.15 (bs, 1H), 7.56-7.25 (m, 4H), 7.11 (m, 1H), 6.94-6.70 (m, 6H),
10 3.81 (m, 6H), 3.07 (t, 2H), 2.74-2.58 (m, 4H), 2.43 (m, 4H), 1.71 (m, 2H), 1.53-1.20 (m, 14H), 0.91 (t, 3H).

EXAMPLE 355

Preparation of N-[5-[4,5-bis(4-methoxyphenyl)-1H-imidazol-2-ylthiolpentyl]-N-heptylcyclohexaneacetamide
15 Part A. Employing the method of Example 118, Part C, but using 2-cyclohexane acetyl chloride, N-heptyl-N-(5-hydroxypentyl)-cyclohexaneacetamide was obtained as an oil (1.5 g, 0.0046 mol). ¹H NMR (CDCl₃) δ 3.70-
20 3.61 (m, 2H), 3.37-3.18 (m, 4H), 2.03 (d, 2H), 1.97-1.08 (m, 26H), 1.02-0.86 (m, 4H).


Part B. Employing the method of Example 118, Part D, but using N-heptyl-N-(5-hydroxypentyl)cyclohexaneacetamide,
25 N-(5-bromopentyl)-N-heptylcyclohexane acetamide was isolated as an oil (1.3 g, 0.00334 mol). ¹H NMR (CDCl₃) δ 3.47-3.39 (m, 2H), 3.36-3.18 (m, 4H), 2.17 (d, 2H), 1.96-0.86 (m, 30H).

30 Part C. Employing the method of Example 118, Part E, but using N-(5-bromopentyl)-N-heptylcyclohexaneacetamide, the title compound was isolated as an oil (0.47 g, 0.00075 mol). ¹H NMR (DMSO-d₆) δ 12.34 (s, 1H), 7.29 (d, 2H), 6.95 (d, 2H), 6.84 (d, 2H), 3.77 (s, 3H),

3.73(s,3H), 3.18(m,4H) 3.07(m,2H), 2.09(d,2H), 1.73-
0.81(m,30H).

Additional amides, which are listed in Table 3,
were prepared or could be prepared analogously according
5 to the procedures of Examples 340, 353 and 355.

Table 3



Ex. No.	R ¹	R ²	R ³	R ⁴	X	Y	n	R ⁶	mp °C
340	C ₆ H ₅	C ₆ H ₅	H	CH ₂ -2,4-diFC ₆ H ₃	S	O	5	(CH ₂) ₆ CH ₃	oil
341	C ₆ H ₅	C ₆ H ₅	H	CH ₂ CH ₂ CH ₃	S	O	5	(CH ₂) ₆ CH ₃	oil (a)
342	C ₆ H ₅	C ₆ H ₅	H	CH ₂ (CH ₂) ₂ CH ₃	S	O	5	(CH ₂) ₆ CH ₃	oil (b)
343	C ₆ H ₅	C ₆ H ₅	H	CH ₂ (C ₆ H ₄) (C ₆ H ₅)	S	O	5	(CH ₂) ₆ CH ₃	57-58
344	C ₆ H ₅	C ₆ H ₅	H	CH ₂ C ₆ H ₁₁	S	O	5	(CH ₂) ₆ CH ₃	oil (c)
345	C ₆ H ₅	C ₆ H ₅	H	2,4-diFC ₆ H ₃	S	O	5	(CH ₂) ₆ CH ₃	oil (d)
346	C ₆ H ₅	C ₆ H ₅	H	C ₆ H ₅	S	O	5	(CH ₂) ₆ CH ₃	oil (e)
347	(CH ₃) ₂ CH	(CH ₃) ₂ CH	H	CH ₂ -C ₆ H ₁₁	S	O	5	(CH ₂) ₆ CH ₃	oil (f)
348	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	(CH ₂) ₂ CH ₃	S	O	5	(CH ₂) ₆ CH ₃	oil (g)
349	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	CH ₂ -3,4-diClC ₆ H ₃	S	O	5	(CH ₂) ₆ CH ₃	oil (h)

Table 3 (continued)

Ex. No.	R ¹	R ²	R ³	R ⁴	X	Y	n	R ⁶	mp °C
350	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	CH ₂ -C ₆ F ₅	S	O	5	(CH ₂) ₆ CH ₃	oil (l)
351	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	CH ₂ -2,4-diFC ₆ H ₃	S	O	5	(CH ₂) ₆ CH ₃	oil (j)
352	C ₆ H ₅	C ₆ H ₅	H	(CH ₂) ₂ CH ₃	S	H ₂	5	(CH ₂) ₆ CH ₃	oil (k)
353	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	CH ₂ -2,4-diFC ₆ H ₃	S	H ₂	5	(CH ₂) ₆ CH ₃	oil
354	4-(CH ₃) ₂ NC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	H	CH ₂ C ₆ H ₁₁	S	O	5	(CH ₂) ₆ CH ₃	oil (l)
355	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	CH ₂ C ₆ H ₁₁	S	O	5	(CH ₂) ₆ CH ₃	oil
356	n-C ₃ H ₇	n-C ₃ H ₇	H	n-C ₃ H ₇	S	O	5	(CH ₂) ₆ CH ₃	
357	3-pyridinyl	3-pyridinyl	H	CH ₂ -2,4-diCH ₃ OC ₆ H ₃	CH ₂	O	5	(CH ₂) ₆ CH ₃	
358	4-pyridinyl	4-pyridinyl	H	CH ₂ -2,4,6-triFC ₆ H ₂	NH	O	5	(CH ₂) ₆ CH ₃	
359	2-CH ₃ OC ₆ H ₄	2-CH ₃ OC ₆ H ₄	H	CH ₂ -3-FC ₆ H ₄	S	H ₂	5	(CH ₂) ₆ CH ₃	
360	3-CH ₃ OC ₆ H ₄	3-CH ₃ OC ₆ H ₄	H	CH(CH ₃) ₂	O	O	5	(CH ₂) ₆ CH ₃	
361	C ₆ H ₁₁	C ₆ H ₁₁	H	C ₆ H ₅	CH ₂	O	5	(CH ₂) ₆ CH ₃	
362	C ₆ H ₅	4-(CH ₃) ₂ NC ₆ H ₄	H	(CH ₂) ₇ CH ₃	NH	O	5	(CH ₂) ₆ CH ₃	
363	2-furanyl	2-furanyl	H	2,6-diClC ₆ H ₃	S	O	5	(CH ₂) ₆ CH ₃	
364	4-(t-C ₄ H ₉)C ₆ H ₄	4-(t-C ₄ H ₉)C ₆ H ₄	H	CH ₃	O	H ₂	5	(CH ₂) ₆ CH ₃	

Table 3 (continued)

Ex. No.	R ¹	R ²	R ³	R ⁴	X	Y	n	R ⁶	mp °C
365	2-thienyl	2-thienyl	H	CH ₂ (C ₆ H ₄) (C ₆ H ₅)	CH ₂	O	5	(CH ₂) ₆ CH ₃	
366	4-HOC ₆ H ₄	4-HOC ₆ H ₄	CH ₃	2,4-diFC ₆ H ₃	NH	O	5	(CH ₂) ₆ CH ₃	
367	(CH ₃) ₂ CH	(CH ₃) ₂ CH	CH ₃	C ₆ H ₁₁	S	O	5	(CH ₂) ₆ CH ₃	
368	C ₆ H ₅ CH ₂	C ₆ H ₅ CH ₂	CH ₃	C ₆ H ₅	O	O	5	(CH ₂) ₆ CH ₃	
369	C ₆ H ₄ -2-OCH ₂ O-2'-C ₆ H ₄		H	2,4-diFC ₆ H ₃	CH ₂	H ₂	3	(CH ₂) ₆ CH ₃	
370	4-CH ₃ C ₆ H ₄	4-CH ₃ C ₆ H ₄	H	2,4-diFC ₆ H ₃	S	O	8	(CH ₂) ₆ CH ₃	
371	4-CH ₃ OC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	H	C ₆ H ₁₁	O	O	8	(CH ₂) ₆ CH ₃	
372	4-CH ₃ OC ₆ H ₄	C ₆ H ₁₁	H	CH ₂ -2,4-diFC ₆ H ₃	CH ₂	O	5	(CH ₂) ₃ CH ₃	
373	4-CH ₃ OC ₆ H ₄	(CH ₃) ₂ CH	H	CH ₂ -2,4-diFC ₆ H ₃	NH	H ₂	5	(CH ₂) ₈ CH ₃	
374	4-(CH ₃) ₂ NC ₆ H ₄	C ₆ H ₁₁	H	2,4-diFC ₆ H ₃	S	O	5	CH ₃	
375	4-(CH ₃) ₂ NC ₆ H ₄	(CH ₃) ₂ CH	H	CH ₂ -2,4-diFC ₆ H ₃	O	O	5	C ₆ H ₅	
376	C ₆ H ₄ OC ₆ H ₄		H	C ₆ H ₁₁	NH	O	3	(CH ₂) ₆ CH ₃	
377	C ₆ H ₅	4-CH ₃ OC ₆ H ₄	CH ₂ C ₆ H ₅	(CH ₂) ₇ CH ₃	NH	O	5	(CH ₂) ₃ CH ₃	
378	C ₆ H ₅	4-(CH ₃) ₂ NC ₆ H ₄	C ₆ H ₅	(CH ₂) ₇ CH ₃	S	H ₂	5	C ₆ H ₅	
379	(CH ₃) ₂ CH	(CH ₃) ₂ CH	H	2,4-diFC ₆ H ₃	S	O	5	(CH ₂) ₆ CH ₃	

Table 3 (continued)

Ex. No.	<u>R¹</u>	<u>R²</u>	<u>R³</u>	<u>R⁴</u>	<u>X</u>	<u>Y</u>	<u>n</u>	<u>R⁶</u>	<u>mp °C</u>
380	4-CH ₃ SC ₆ H ₄	4-CH ₃ SC ₆ H ₄	H	CH ₂ -2, 4-diFC ₆ H ₃	S	O	5	(CH ₂) ₆ CH ₃	
381	4-CH ₃ SOC ₆ H ₄	4-CH ₃ SOC ₆ H ₄	H	CH ₂ -2, 4-diFC ₆ H ₃	NH	O	5	(CH ₂) ₆ CH ₃	
382	4-CH ₃ SO ₂ C ₆ H ₄	4-CH ₃ SO ₂ C ₆ H ₄	H	CH ₂ -2, 4-diFC ₆ H ₃	CH ₂	O	5	(CH ₂) ₆ CH ₃	
383	C ₆ H ₅	4-CH ₃ SC ₆ H ₄	H	CH ₂ -2, 4-diFC ₆ H ₃	S	O	5	(CH ₂) ₆ CH ₃	
384	C ₆ H ₅	4-CH ₃ SOC ₆ H ₄	H	CH ₂ -2, 4-diFC ₆ H ₃	NH	O	5	(CH ₂) ₆ CH ₃	
385	C ₆ H ₅	4-CH ₃ SO ₂ C ₆ H ₄	H	CH ₂ -2, 4-diFC ₆ H ₃	CH ₂	O	5	(CH ₂) ₆ CH ₃	
386	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	CH ₃	n-C ₃ H ₇	S	O	5	(CH ₂) ₆ CH ₃	
387	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	CH ₂ C ₆ H ₁₁	SO	O	5	(CH ₂) ₆ CH ₃	
388	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	CH(CH ₃) ₂	S	O	5	(CH ₂) ₆ CH ₃	
389	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	CH ₂ C ₆ H ₅	S	O	5	(CH ₂) ₆ CH ₃	
390	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	CH ₂ -2, 4-diFC ₆ H ₃	S	S	3	(CH ₂) ₆ CH ₃	
391	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	CH ₂ C ₆ H ₁₁	S	O	8	(CH ₂) ₆ CH ₃	
392	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	(CH ₂) ₇ CH ₃	S	O	5	C ₆ H ₅	
393	4-(CH ₃) ₂ NC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	H	n-C ₃ H ₇	SO ₂	O	5	(CH ₂) ₆ CH ₃	
394	4-(CH ₃) ₂ NC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	H	C ₆ H ₁₁	S	O	5	(CH ₂) ₆ CH ₃	
395	4-(CH ₃) ₂ NC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	H	CH(CH ₃) ₂	S	H ₂	5	(CH ₂) ₆ CH ₃	

Table 3 (continued)

Ex. No.	<u>R¹</u>	<u>R²</u>	<u>R³</u>	<u>R⁴</u>	<u>X</u>	<u>Y</u>	<u>n</u>	<u>R⁶</u>	<u>mp °C</u>
396	4-(CH ₃) ₂ NC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	H	C ₆ H ₅	S	O	5	(CH ₂) ₆ CH ₃	
397	4-(CH ₃) ₂ NC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	H	2,4-diFC ₆ H ₃	SO	O	3	(CH ₂) ₆ CH ₃	
398	4-(CH ₃) ₂ C ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	H	C ₆ H ₁₁	S	O	8	(CH ₂) ₆ CH ₃	
399	4-(CH ₃) ₂ NC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	H	(CH ₂) ₇ CH ₃	SO ₂	O	5	C ₆ H ₅	
400	C ₆ H ₅	C ₆ H ₅	H	CH(CH ₃) ₂	S	O	5	(CH ₂) ₆ CH ₃	oil (m)

Footnotes To Table 3

- (a) ^1H NMR (CDCl_3) δ 11.7-11.6(bs, 1H), 7.7-7.1(m, 10H), 3.4(t, 2H, J=7Hz), 3.3-3.2(m, 2H), 2.9(t, 2H, J=7Hz), 2.35-2.25(m, 2H), 1.8-1.1(m, 18H), 1.0-0.8(m, 6H).
- 5 (b) ^1H NMR (CDCl_3) δ 11.8-11.7(bs, 1H), 7.7-7.1(m, 10H), 3.4(t, 2H, J=6.6Hz), 3.2(t, 2H, J=8.7), 2.9(t, 2H, J=6.5Hz), 2.4-2.2(m, 2H), 1.8-1.1(m, 20H), 0.85(sextet, 6H, J=4.1Hz).
- 10 (c) ^1H NMR (CDCl_3) δ 7.6-7.1(m, 11H), 3.4-2.9(m, 6H), 2.2-2.1(m, 2H), 1.8-1.0(m, 27H), 0.9-0.8(m, 3H).
- (d) ^1H NMR (CDCl_3) δ 7.6-7.2(m, 11H), 6.9-6.8(m, 2H), 3.7-3.4(m, 2H), 3.2-3.0(m, 4H), 1.9-1.0(m, 17H).
- (e) ^1H NMR (CDCl_3) δ 7.6-7.1(m, 16H), 3.6-3.4(m, 2H), 3.3-2.9(m, 4H), 1.9-1.0(m, 16H), 0.9-0.8(m, 3H).
- 15 (f) ^1H NMR ($\text{DMSO}-d_6$) δ 11.64(bs, 1H), 3.18(m, 4H), 2.98-2.74(m, 4H), 2.08(d, 2H), 1.77-0.81(m, 42H).
- (g) ^1H NMR ($\text{DMSO}-d_6$) δ 12.36(s, 1H), 7.39(d, 2H), 7.31(d, 2H), 6.95(d, 2H), 6.85(d, 2H), 3.76(s, 3H), 3.74(s, 3H), 3.28-3.03(m, 6H), 2.22(t, 2H), 1.75-1.11(m, 18H), 0.83(m, 6H).
- 20 (h) ^1H NMR ($\text{DMSO}-d_6$) δ 12.35(bs, 1H), 7.62-7.17(m, 7H), 6.95(d, 2H), 6.85(d, 2H), 3.8-3.66(m, 8H), 3.35-3.02(m, 6H), 1.78-1.14(m, 16H), 0.85(m, 3H).
- (i) ^1H NMR ($\text{DMSO}-d_6$) δ 12.33(bs, 1H), 7.37(d, 2H), 7.31(d, 2H), 6.94(d, 2H), 6.83(d, 2H), 3.82(d, 2H), 3.77(s, 3H), 3.73(s, 3H), 3.42-3.01(m, 6H), 1.81-1.16(m, 16H), 0.85(m, 3H).
- 25 (j) ^1H NMR ($\text{DMSO}-d_6$) δ 12.32(bs, 1H), 7.43-6.8(m, 11H), 3.78(s, 3H), 3.73(s, 3H), 3.65(s, 2H), 3.35-3.01(m, 6H), 1.77-1.16(m, 16H), 0.87(m, 3H).
- 30 (k) ^1H NMR (CDCl_3) δ 7.6-7.2(m, 10H), 2.1(t, 2H, J=7.4Hz), 2.5-2.3(m, 7H), 1.8-1.6(m, 2H), 1.5-1.2(m, 18H), 0.9(quintet, 6H, J=5.1Hz).
- (l) ^1H NMR ($\text{DMSO}-d_6$) δ 12.12(s, 1H), 7.31(d, 2H), 7.20(d, 2H), 6.70(d, 2H), 6.63(d, 2H), 3.18(m, 4H),
- 35

87

3.03 (m, 2H), 2.91 (s, 6H), 2.87 (s, 6H), 2.08 (d, 2H),
1.64-0.82 (m, 30H).

(m) NMR (CDCl₃) δ 11.8 (s, 1H), 7.7-7.2 (m, 1H),
3.5 (t, 2H, J=6.4Hz), 3.3-3.1 (m, 3H),
5 2.95 (t, 2H, J=6.1Hz), 2.85-2.7 (m, 1H), 1.9-1.2 (m, 14H),
1.1-1.0 (m, 6H), 0.9-0.8 (m, 3H).

EXAMPLE 401

10 Preparation of cyclohexyl [5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]heptylcarbamate

To a solution of N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-1-heptanamine (0.87 g, 0.002 mol) and sodium bicarbonate (5%, 1 mL) in toluene (10 mL) at 0° was added, dropwise, a solution of cyclohexylchloro-
15 formate (0.32 g, 0.002 mol) in toluene (5 mL). The reaction mixture was allowed to warm to ambient temperature and stirred overnight. The solvent was removed under vacuum. The residue (1.0 g) was chromatographed with 7:3 hexane-ethyl acetate to give
20 the title compound (0.61 g, 0.0011 mol) as a yellow oil. ¹H NMR (CDCl₃) δ 11.1 (bs, 1H), 7.7-7.2 (m, 10H), 4.6 (bs, 1H), 3.3 (t, 2H, J=5.1Hz), 3.2 (t, 2H, J=7.5Hz), 3.0 (t, 2H, J=5.2Hz), 1.9-1.2 (m, 26H), 0.9-0.8 (m, 3H).

25

EXAMPLE 411

Preparation of phenyl N-[5-(4,5-bis(1-methylethyl)-1H-imidazol-2-ylthiolpentyl]-N-heptylcarbamate


Part A. Employing the method of Example 118, Part B, but using phenyl chloroformate and triethylamine, phenyl
30 N-heptyl-N-(5-hydroxypentyl)carbamate was obtained as an oil (3.18 g, 0.00989 mol). ¹H NMR (CDCl₃) δ 7.40-7.06 (m, 5H), 3.68-3.63 (m, 2H), 3.42-3.27 (m, 4H), 2.08-1.95 (bs, 1H), 1.75-1.26 (m, 16H), 0.90 (t, 3H).

Part B. Employing the method of Example 118, Part C, but using phenyl N-heptyl-N-(5-hydroxypentyl)carbamate, phenyl N-(5-bromopentyl)-N-heptylcarbamate was isolated as an oil (3.8 g, 0.0099 mol). ^1H NMR (CDCl_3) δ 7.39-7.07 (m, 5H), 3.47-3.25 (m, 6H), 1.97-1.89 (m, 2H), 1.75-1.26 (m, 14H), 0.87 (t, 3H).

Part C. Employing the method of Example 118, Part D, but using phenyl N-(5-bromopentyl)-N-heptylcarbamate, the title compound was isolated as an oil (0.3 g, 0.000615 mol). ^1H NMR ($\text{DMSO}-d_6$) δ 11.07 (s, 1H), 7.35 (m, 2H), 7.18 (t, 1H), 7.05 (d, 2H), 3.31 (m, 2H), 3.20 (m, 2H), 2.95 (m, 3H), 2.8 (m, 1H), 1.67-1.06 (m, 2H), 0.86 (m, 3H).

Additional carbamates, which are listed in Table 4, were prepared or could be prepared analogously according to the procedures of Examples 401 and 411.

Table 4



Ex. No.	<u>R¹</u>	<u>R²</u>	<u>R³</u>	<u>R⁴</u>	<u>X</u>	<u>Y</u>	<u>n</u>	<u>R⁶</u>	<u>mp°C</u>
401	C ₆ H ₅	C ₆ H ₅	H	C ₆ H ₁₁	S	O	5	(CH ₂) ₆ CH ₃	oil
402	C ₆ H ₅	C ₆ H ₅	H	C ₆ H ₅	S	O	5	(CH ₂) ₆ CH ₃	oil (a)
403	C ₆ H ₅	C ₆ H ₅	H	CH ₂ CH(CH ₃) ₂	S	O	5	(CH ₂) ₆ CH ₃	oil (b)
404	C ₆ H ₅	C ₆ H ₅	H	CH ₂ CH ₃	S	O	5	(CH ₂) ₆ CH ₃	oil (c)
405	C ₆ H ₅	C ₆ H ₅	H	(CH ₂) ₇ CH ₃	S	O	5	(CH ₂) ₆ CH ₃	oil (d)
406	C ₆ H ₅	C ₆ H ₅	H	4-FC ₆ H ₄	S	O	5	(CH ₂) ₆ CH ₃	oil (e)
407	C ₆ H ₅	C ₆ H ₅	H	(CH ₂) ₂ CH ₃	S	O	5	(CH ₂) ₆ CH ₃	oil (f)
408	C ₆ H ₅	C ₆ H ₅	H	CH ₂ C ₆ H ₅	S	O	5	(CH ₂) ₆ CH ₃	oil (g)
409	4-(CH ₃) ₂ NC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	H	C ₆ H ₅	S	O	5	(CH ₂) ₆ CH ₃	oil (h)

Table 4 (continued)

Ex. No.	<u>R¹</u>	<u>R²</u>	<u>R³</u>	<u>R⁴</u>	<u>X</u>	<u>Y</u>	<u>n</u>	<u>R⁶</u>	<u>mp°C</u>
410	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	C ₆ H ₅	S	O	5	(CH ₂) ₆ CH ₃	oil (i)
411	(CH ₃) ₂ CH	(CH ₃) ₂ CH	H	C ₆ H ₅	S	O	5	(CH ₂) ₆ CH ₃	oil
412	n-C ₃ H ₇	n-C ₃ H ₇	H	n-C ₃ H ₇	S	O	5	(CH ₂) ₆ CH ₃	
413	2-pyridinyl	2-pyridinyl	H	C ₆ H ₁₁	O	O	5	(CH ₂) ₆ CH ₃	
414	3-pyridinyl	3-pyridinyl	H	2,4-diCH ₃ OC ₆ H ₃	CH ₂	O	5	(CH ₂) ₆ CH ₃	
415	4-pyridinyl	4-pyridinyl	H	CH ₂ -2,4,6-triFC ₆ H ₂	NH	O	5	(CH ₂) ₆ CH ₃	
416	2-CH ₃ OC ₆ H ₄	2-CH ₃ OC ₆ H ₄	H	3-F-C ₆ H ₄	S	H ₂	5	(CH ₂) ₆ CH ₃	
417	3-CH ₃ OC ₆ H ₄	3-CH ₃ OC ₆ H ₄	H	CH(CH ₃) ₂	O	O	5	(CH ₂) ₆ CH ₃	
418	C ₆ H ₁₁	C ₆ H ₁₁	H	C ₆ H ₅	CH ₂	O	5	(CH ₂) ₆ CH ₃	
419	C ₆ H ₅	4-(CH ₃) ₂ NC ₆ H ₄	H	(CH ₂) ₇ CH ₃	NH	O	5	(CH ₂) ₆ CH ₃	
420	2-furanyl	2-furanyl	H	2,6-diCl-C ₆ H ₃	S	O	5	(CH ₂) ₆ CH ₃	
421	4-(t-C ₄ H ₉)C ₆ H ₄	4-(t-C ₄ H ₉)C ₆ H ₄	H	CH ₃	O	H ₂	5	(CH ₂) ₆ CH ₃	
422	2-thienyl	2-thienyl	H	(C ₆ H ₄)(C ₆ H ₅)	CH ₂	O	5	(CH ₂) ₆ CH ₃	
423	4-HO-C ₆ H ₄	4-HO-C ₆ H ₄	CH ₃	2,4-diFC ₆ H ₃	NH	O	5	(CH ₂) ₆ CH ₃	
424	(CH ₃) ₂ CH	(CH ₃) ₂ CH	CH ₃	C ₆ H ₁₁	S	O	5	(CH ₂) ₆ CH ₃	

Table 4 (continued)

Ex. No.	R ¹	R ²	R ³	R ⁴	X	Y	n	R ⁶	mp°C
425	C ₆ H ₅ CH ₂	C ₆ H ₅ CH ₂	CH ₃	C ₆ H ₅	O	O	5	(CH ₂) ₆ CH ₃	
426	C ₆ H ₄ -2-OCH ₂ O-2'-C ₆ H ₄		H	2,4-diFC ₆ H ₃	CH ₂	H ₂	3	(CH ₂) ₆ CH ₃	
427	C ₆ H ₄ OC ₆ H ₄		H	C ₆ H ₁₁	NH	O	3	(CH ₂) ₆ CH ₃	
428	4-CH ₃ OC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	H	C ₆ H ₁₁	O	O	8	(CH ₂) ₆ CH ₃	
429	4-CH ₃ OC ₆ H ₄	C ₆ H ₁₁	H	CH ₂ -2,4-diFC ₆ H ₃	CH ₂	O	5	(CH ₂) ₃ CH ₃	
430	4-CH ₃ OC ₆ H ₄	(CH ₃) ₂ CH	H	CH ₂ -2,4-diFC ₆ H ₃	NH	H ₂	5	(CH ₂) ₈ CH ₃	
431	4-(CH ₃)NC ₆ H ₄	C ₆ H ₁₁	H	2,4-diFC ₆ H ₃	S	O	5	CH ₃	
432	4-(CH ₃)NC ₆ H ₄	(CH ₃) ₂ CH	H	2,4-diFC ₆ H ₃	O	O	5	C ₆ H ₅	
433	C ₆ H ₁₁	(CH ₃) ₂ CH	H	CH ₂ -2,4-diFC ₆ H ₃	CH ₂	O	5	3-FC ₆ H ₄	
434	C ₆ H ₅	4-CH ₃ OC ₆ H ₄	H	(CH ₂) ₇ CH ₃	NH	O	5	(CH ₂) ₃ CH ₃	
435	C ₆ H ₅	4-(CH ₃) ₂ NC ₆ H ₄	H	(CH ₂) ₇ CH ₃	S	H ₂	5	C ₆ H ₅	
436	(CH ₃) ₂ CH	(CH ₃) ₂ CH	H	2,4-diFC ₆ H ₃	S	O	5	(CH ₂) ₆ CH ₃	
437	4-CH ₃ SC ₆ H ₄	4-CH ₃ SC ₆ H ₄	H	2,4-diFC ₆ H ₃	S	O	5	(CH ₂) ₆ CH ₃	
438	4-CH ₃ SOC ₆ H ₄	4-CH ₃ SOC ₆ H ₄	H	2,4-diFC ₆ H ₃	NH	O	5	(CH ₂) ₆ CH ₃	
439	4-CH ₃ SO ₂ C ₆ H ₄	4-CH ₃ SO ₂ C ₆ H ₄	H	2,4-diFC ₆ H ₃	CH ₂	O	5	(CH ₂) ₆ CH ₃	
440	C ₆ H ₅	4-CH ₃ SC ₆ H ₄	C ₆ H ₅	2,4-diFC ₆ H ₃	S	O	5	(CH ₂) ₆ CH ₃	

Table 4 (continued)

Ex. No.	R ¹	R ²	R ³	R ⁴	X	Y	n	R ⁶	mp°C
441	C ₆ H ₅	4-CH ₃ SOC ₆ H ₄	CH ₂ CH ₃	2,4-diFC ₆ H ₃	NH	O	5	(CH ₂) ₆ CH ₃	
442	C ₆ H ₅	4-CH ₃ SO ₂ C ₆ H ₄	CH ₂ C ₆ H ₅	2,4-diFC ₆ H ₃	CH ₂	O	5	(CH ₂) ₆ CH ₃	
443	4-(CH ₃) ₂ NC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	CH ₃	n-C ₃ H ₇	S	O	5	(CH ₂) ₆ CH ₃	
444	4-(CH ₃) ₂ NC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	H	C ₆ H ₁₁	S	H ₂	5	(CH ₂) ₆ CH ₃	
445	4-(CH ₃) ₂ NC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	H	CH(CH ₃) ₂	S	O	5	(CH ₂) ₆ CH ₃	
446	4-(CH ₃) ₂ NC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	H	C ₆ H ₅	SO	O	5	(CH ₂) ₆ CH ₃	
447	4-(CH ₃) ₂ NC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	H	2,4-diFC ₆ H ₃	S	O	3	(CH ₂) ₆ CH ₃	
448	4-(CH ₃) ₂ NC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	H	C ₆ H ₁₁	S	O	8	(CH ₂) ₆ CH ₃	
449	4-(CH ₃) ₂ NC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	H	(CH ₂) ₇ CH ₃	SO ₂	O	5	C ₆ H ₅	
450	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	n-C ₃ H ₇	S	O	5	(CH ₂) ₆ CH ₃	
451	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	C ₆ H ₁₁	S	H ₂	5	(CH ₂) ₆ CH ₃	
452	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	CH ₃	CH(CH ₃) ₂	S	O	5	(CH ₂) ₆ CH ₃	
453	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	C ₆ H ₅	SO	O	5	(CH ₂) ₆ CH ₃	
454	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	2,4-diFC ₆ H ₃	S	O	3	(CH ₂) ₆ CH ₃	
455	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	C ₆ H ₁₁	SO ₂	O	8	(CH ₂) ₆ CH ₃	
456	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	(CH ₂) ₇ CH ₃	S	S	5	C ₆ H ₅	
457	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	CH ₂ CH(CH ₃) ₂	S	O	5	(CH ₂) ₆ CH ₃	oil(j)

Footnotes To Table 4

- (a) ^1H NMR (CDCl_3) δ 10.6(s, 1H), 7.7-7.0(m, 15H), 3.4(q, 4H, $J=4.7\text{Hz}$), 2.9(t, 2H, $J=5.8\text{Hz}$), 1.8-1.2(m, 16H), 0.95-0.75(m, 3H).
- 5 (b) ^1H NMR (CDCl_3) δ 10.9(s, 1H), 7.75-7.1(m, 10H), 3.75(d, 2H, $J=6.3\text{Hz}$), 3.3(t, 2H, $J=6.0\text{Hz}$), 3.15(t, 2H, $J=7.5\text{Hz}$), 3.0(t, 2H, $J=6.2\text{Hz}$), 2.0-1.2(m, 17H), 0.9(t, 9H, $J=3.2\text{Hz}$).
- (c) ^1H NMR (CDCl_3) δ 10.9(s, 1H), 7.75-7.1(m, 10H), 10 4.0(d, 2H, $J=6.8\text{Hz}$), 3.4-2.95(m, 6H), 1.9-1.1(m, 19H), 1.0-0.8(m, 3H).
- (d) ^1H NMR (CDCl_3) δ 10.7(s, 1H), 7.7-7.2(m, 10H), 4.1-3.9(m, 2H), 3.4-2.9(m, 6H), 1.8-1.2(m, 28H), 0.9-0.8(m, 6H).
- 15 (e) ^1H NMR (CDCl_3) δ 10.4(s, 1H), 7.7-6.8(m, 14H), 3.5-2.9(m, 6H), 1.9-1.1(m, 16H), 1.0-0.8(m, 3H).
- (f) ^1H NMR (CDCl_3) δ 10.9(s, 1H), 7.75-7.1(m, 10H), 4.0(q, 2H, $J=6.9\text{Hz}$), 3.3(t, 2H, $J=9.5\text{Hz}$), 3.2(t, 2H, $J=7.5\text{Hz}$), 3.0(t, 2H, $J=7.8\text{Hz}$), 1.8-1.1(m, 18H), 0.9(t, 3H, $J=7.2\text{Hz}$).
- 20 (g) ^1H NMR (CDCl_3) δ 10.5(s, 1H), 7.7-7.2(m, 15H), 5.05(s, 2H), 3.3(q, 2H, $J=5.7\text{Hz}$), 3.2(t, 2H, $J=7.4\text{Hz}$), 3.0(q, 2H, $J=5.4\text{Hz}$), 1.8-1.1(m, 16H), 0.9(t, 3H, $J=6.4\text{Hz}$).
- 25 (h) ^1H NMR (CDCl_3) δ 10.0-9.8(bs, 1H), 7.57-7.03(m, 9H), 6.63(m, 4H), 3.43-3.26(m, 4H), 3.09-2.86(bs, 14H), 1.81-1.25(m, 16H), 0.89(t, 3H).
- (i) ^1H NMR ($\text{DMSO}-d_6$) δ 12.34(s, 1H), 7.39-7.22(m, 6H), 7.19(t, 1H), 7.06(d, 2H), 6.94(d, 2H), 6.84(d, 2H), 30 3.77(s, 3H), 3.72(s, 3H), 3.40-3.20(m, 4H), 3.09(m, 2H), 1.75-1.17(m, 16H), 0.84(m, 3H).
- (j) NMR (CDCl_3) δ 7.6-7.3(m, 4H), 6.9-6.8(m, 4H), 3.9-3.7(m, 8H), 3.4-2.9(m, 5H), 2.0-1.2(m, 19H), 1.0-0.8(m, 9H).

EXAMPLE 458

Preparation of N'-(2,4-difluorophenyl)-N-[3,3-dimethyl-5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea

5

Part A. The method of Little, R. D. and Muller, G. W., J. Am. Chem. Soc. 1981, 103, p. 2744 was used to prepare 3,3-dimethyl-5-hydroxypentanoic acid lactone. This lactone (12.85 g, 100.3 mmol) was dissolved in toluene (100 mL) under nitrogen atmosphere, and treated with heptylamine (17.0 mL, 115 mmol). After refluxing for 18 hours, the mixture was cooled, washed with an equal volume aq. hydrochloric acid (1 N), dried over magnesium sulfate, and concentrated under vacuum. The product was purified by elution through a plug of silica gel with ethyl acetate, and the eluant was concentrated under vacuum to afford N-heptyl-3,3-dimethyl-5-hydroxypentanamide (24.0 g, 98.7 mmol, 98%) as an oil. ¹H NMR (CDCl₃) δ 6.32 (br s, 1H); 3.78 (t, 2H, J=5.7Hz); 3.22 (q, 2H, J=6.7Hz); 2.25 (s, 2H); 1.67 (t, 2H, J=5.7Hz); 1.57-1.45 (m, 2H); 1.38-1.25 (m, 8H); 1.02 (s, 6H); 0.88 (t, 3H, J=7.0Hz).

Part B. A slurry of lithium aluminum hydride (5.50 g, 145 mmol) in tetrahydrofuran (100 mL) was cooled to 0°C, and a solution of the amide prepared in Part A (11.48 g, 47.2 mmol) in tetrahydrofuran (50 mL) was added dropwise over 1 hour. The ice bath was removed, and the mixture was heated to reflux for 18 hours. After cooling to 0°C, the mixture was quenched by the slow dropwise addition of water (6 mL), aq. NaOH (18 mL, 15%), and water (18 mL). The solution was filtered through a plug of Celite®, dried over potassium carbonate, and concentrated under vacuum to afford N-heptyl-3,3-dimethyl-5-hydroxypentanamine as a clear, colorless oil

95

(7.61 g, 33.2 mmol, 70%). ^1H NMR (CDCl_3) δ 3.70(dt, 2H, $J=10.2, 7.0\text{Hz}$); 2.70-2.55(m, 2H); 2.39-2.29(m, 2H); 1.56(dt, 2H, $J=12.1, 7.0\text{Hz}$); 1.51-1.41(m, 6H); 1.36-1.24(m, 8H); 0.91(s, 6H); 0.88(t, 3H, $J=6.9\text{Hz}$).

5

Part C. A solution of the amine prepared in Part C (4.26 g, 18.6 mmol) in methylene chloride (20 mL) was cooled to 0°C , and a solution of 2,4-difluorophenyl isocyanate (2.20 mL, 18.6 mmol) in methylene chloride (20 mL) was added dropwise with stirring over 1 hour. After slow warming to ambient temperature over 18 hours, the reaction mixture was concentrated under vacuum, and the residual oil was purified by flash chromatography to afford N'-(2,4-difluorophenyl)-N-(3,3-dimethyl-5-hydroxypentyl)-N-heptylurea as a colorless oil (2.31 g, 6.01 mmol, 32%). ^1H NMR (CDCl_3) δ 7.93(br q, 1H, $J=6.2\text{Hz}$); 6.89-6.78(m, 3H); 3.76(t, 2H, $J=6.3\text{Hz}$); 3.38-3.24(m, 4H); 2.36(br s, 1H); 1.65-1.52(m, 6H); 1.36-1.24(m, 8H); 0.97(s, 6H); 0.89(t, 3H, $J=6.6\text{Hz}$).

20


Part D. A solution of the alcohol prepared in Part C (2.05 g, 5.33 mmol) in methylene chloride (30 mL) was cooled to 0°C and treated with solid carbon tetrabromide (2.14 g, 6.45 mmol). Then, a solution of triphenylphosphine (1.69 g, 6.44 mmol) in methylene chloride (20 mL) was added dropwise. After stirring for 18 hours, the mixture was concentrated under vacuum and purified by flash chromatography to afford N'-(2,4-difluorophenyl)-N-(5-bromo-3,3-dimethylpentyl)-N-heptylurea as a clear, colorless oil (1.68 g, 3.75 mmol, 70%). ^1H NMR (CDCl_3) δ 8.10-8.02(m, 1H); 6.88-6.80(m, 2H); 6.37(br d, 1H, $J=3.3\text{Hz}$); 3.44-3.38(m, 2H); 3.36-3.24(m, 4H); 1.93-1.85(m, 2H); 1.70-1.55(m, 4H); 1.40-1.25(m, 8H); 0.98(s, 6H); 0.89(t, 3H, $J=7.0\text{Hz}$).

35

Part E. A slurry of the bromide prepared in Part D (1.60 g, 3.58 mmol), 4,5-diphenyl-1H-imidazole-2-thiol (0.82 g, 3.25 mmol), potassium carbonate (0.55 g, 3.98 mmol) and tetra-n-butylammonium iodide (0.264 g, 0.71 mmol) in tetrahydrofuran (20 mL) was heated to reflux for 18 hours, then cooled, poured into water (100 mL), and extracted with methylene chloride (100 mL). The aqueous phase was neutralized to pH 6 with HCl (6 N), then reextracted with methylene chloride. The extracts were combined, dried over magnesium sulfate and concentrated under vacuum to afford the title compound as a solid, which was recrystallized to purity from ether-hexane, mp 138-9°C. ¹H NMR (CDCl₃) δ 10.98 (br s, 1H); 7.74-7.66 (m, 1H); 7.60-7.51 (br m, 2H); 7.34-7.26 (m, 2H); 7.24-7.14 (m, 6H); 6.86-6.78 (m, 1H); 6.75-6.69 (m, 1H); 6.44 (br s, 1H); 3.23-3.14 (m, 6H); 1.80-1.66 (m, 2H); 1.62-1.54 (m, 4H); 1.39-1.27 (m, 8H); 0.94 (s, 6H); 0.90 (t, 3H, J=6.6Hz).

Additional branched compounds, which are listed in Table 5, could be prepared analogously according to the procedure of Example 458.

Table 5



Ex. No.	R ¹	R ²	R ³	X	A	Y	Z	R ⁶
458	C ₆ H ₅	C ₆ H ₅	H	S	(CH ₂) ₂ C(CH ₃) ₂ (CH ₂) ₂	O	NH-2,4-diFC ₆ H ₃	(CH ₂) ₆ CH ₃ *
459	C ₆ H ₅	C ₆ H ₅	H	S	CH ₂ CH(CH ₃)(CH ₂) ₃	O	NH-2,4-diFC ₆ H ₃	(CH ₂) ₆ CH ₃
460	C ₆ H ₅	C ₆ H ₅	H	CH ₂	(CH ₂) ₃ CH(CH ₃)CH ₂	S	NH-2,4-diFC ₆ H ₃	(CH ₂) ₃ CH ₃
461	C ₆ H ₅	C ₆ H ₅	H	NH	(CH ₂) ₃ C(CH ₃) ₂ CH ₂	H ₂	NH-2,4-diFC ₆	(CH ₂) ₈ CH ₃
462	C ₆ H ₅	C ₆ H ₅	H	O	(CH ₂)CH(C ₅ H ₁₁)(CH ₂) ₂	O	CH ₂ CH(CH ₃) ₂	C ₆ H ₅
463	4-(CH ₃) ₂ NC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	CH ₃	S	CH(CH ₃)(CH ₂) ₄	S	CH ₂ CH(CH ₃) ₂	2,4-diFC ₆ H ₃
464	4-(CH ₃) ₂ NC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	H	CH ₂	CH ₂ CH=CH(CH ₂) ₂	H ₂	CH ₂ CH(CH ₃) ₂	(CH ₂) ₆ CH ₃
465	4-(CH ₃) ₂ NC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	CH ₂ CH ₃	NH	(CH ₂) ₃ CH=CH(CH ₂) ₂	O	O(CH ₂) ₇ CH ₃	(CH ₂) ₃ CH ₃
466	4-(CH ₃) ₂ NC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	CH ₂ C ₆ H ₅	O	CH ₂ C≡C(CH ₂) ₂	S	O(CH ₂) ₇ CH ₃	CH ₃
467	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	C ₆ H ₅	S	(CH ₂) ₃ C≡C(CH ₂) ₂	H ₂	O(CH ₂) ₇ CH ₃	C ₆ H ₅
468	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	CH ₂	CH ₂ CH(CH ₃)(CH ₂) ₃	O	NHCH(CH ₃) ₂	(CH ₂) ₆ CH ₃

* m.p. = 138-139°C

Table 5 (continued)

Ex. No.	R ¹	R ²	R ³	X	A	Y	Z	R ⁶
469	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	NH	(CH ₂) ₃ CH(CH ₃)CH ₂	S	NHCH(CH ₃) ₂	(CH ₂) ₃ CH ₃
470	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	O	(CH ₂) ₃ C(CH ₃) ₂ CH ₂	H ₂	NHCH(CH ₃) ₂	(CH ₂) ₈ CH ₃
471	(CH ₃) ₂ CH	(CH ₃) ₂ CH	H	S	(CH ₂) ₂ CH(C ₅ H ₁₁)(CH ₂) ₂	O	(CH ₂) ₇ CH ₃	C ₆ H ₅
472	(CH ₃) ₂ CH	(CH ₃) ₂ CH	CH ₃	CH ₂	CH(CH ₃)(CH ₂) ₄	S	(CH ₂) ₇ CH ₃	2,4-diFC ₆ H ₃
473	(CH ₃) ₂ CH	(CH ₃) ₂ CH	H	NH	CH ₂ CH=CH(CH ₂) ₂	H ₂	(CH ₂) ₇ CH ₃	(CH ₂) ₆ CH ₃
474	(CH ₃) ₂ CH	(CH ₃) ₂ CH	H	O	(CH ₂) ₃ CH=CH(CH ₂) ₂	O	OC ₆ H ₅	(CH ₂) ₃ CH ₃
475	C ₆ H ₁₁	C ₆ H ₁₁	H	S	CH ₂ C≡C(CH ₂) ₂	S	OC ₆ H ₅	CH ₃
476	C ₆ H ₁₁	C ₆ H ₁₁	C ₆ H ₅	CH ₂	(CH ₂) ₃ C≡C(CH ₂) ₂	H ₂	OC ₆ H ₅	C ₆ H ₅
477	C ₆ H ₁₁	C ₆ H ₁₁	H	NH	CH ₂ CH(CH ₃)(CH ₂) ₃	O	NH(CH ₂) ₇ CH ₃	(CH ₂) ₆ CH ₃
478	C ₆ H ₁₁	C ₆ H ₁₁	H	O	(CH ₂) ₃ CH(CH ₃)CH ₂	S	NH(CH ₂) ₇ CH ₃	(CH ₂) ₃ CH ₃
479	C ₆ H ₅	4-CH ₃ OC ₆ H ₄	H	S	(CH ₂) ₃ C(CH ₃) ₂ CH ₂	H ₂	NH(CH ₂) ₇ CH ₃	(CH ₂) ₈ CH ₃
480	C ₆ H ₅	4-CH ₃ OC ₆ H ₄	H	CH ₂	(CH ₂) ₂ CH(C ₅ H ₁₁)(CH ₂) ₂	O	CH ₂ C ₆ H ₅	C ₆ H ₅
481	C ₆ H ₅	4-CH ₃ OC ₆ H ₄	CH ₃	NH	CH(CH ₃)(CH ₂) ₄	S	C ₆ H ₅	2,4-diFC ₆ H ₃
482	C ₆ H ₅	4-CH ₃ OC ₆ H ₄	H	O	CH ₂ CH=CH(CH ₂) ₂	H ₂	CH ₂ C ₆ H ₅	(CH ₂) ₆ CH ₃

Table 5 (continued).

Ex. No.	R ¹	R ²	R ³	X	A	Y	Z	R ⁶
483	C ₆ H ₅	4-(CH ₃) ₂ NC ₆ H ₄	H	S	(CH ₂) ₃ CH=CH(CH ₂) ₂	O	OCH(CH ₃) ₂	(CH ₂) ₃ CH ₃
484	C ₆ H ₅	4-(CH ₃) ₂ NC ₆ H ₄	H	CH ₂	CH ₂ C≡C(CH ₂) ₂	S	OCH(CH ₃) ₂	CH ₃
485	C ₆ H ₅	4-(CH ₃) ₂ NC ₆ H ₄	C ₆ H ₅	NH	(CH ₂) ₃ C≡C(CH ₂) ₂	H ₂	OCH(CH ₃) ₂	C ₆ H ₅
486	4-(CH ₃) ₂ NC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	H	S	CH ₂ CH(CH ₃)(CH ₂) ₃	O	CH ₂ CH(CH ₃) ₂	(CH ₂) ₃ CH ₃
487	4-(CH ₃) ₂ NC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	H	S	(CH ₂) ₃ CH(CH ₃)CH ₂	O	O(CH ₂) ₇ CH ₃	(CH ₂) ₆ CH ₃
488	4-(CH ₃) ₂ NC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	H	S	(CH ₂) ₃ C(CH ₃) ₂ CH ₂	O	NH-2,4-diFC ₆ H ₃	(CH ₂) ₆ CH ₃
489	4-(CH ₃) ₂ NC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	H	SO	(CH ₂) ₂ CH(C ₅ H ₁₁)(CH ₂) ₂	O	NH-2,4-diFC ₆ H ₃	(CH ₂) ₈ CH ₃
490	4-(CH ₃) ₂ NC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	H	SO ₂	CH(CH ₃)(CH ₂) ₄	O	NH(CH ₂) ₂ CH ₃	(CH ₂) ₆ CH ₃
491	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	S	CH ₂ CH=CH(CH ₂) ₂	O	CH ₂ -2,4-diFC ₆ H ₃	(CH ₂) ₃ CH ₃
492	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	S	(CH ₂) ₃ CH=CH(CH ₂) ₂	O	O-2,4-diFC ₆ H ₃	(CH ₂) ₃ CH ₃
493	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	S	CH ₂ C≡C(CH ₂) ₂	O	CH ₂ -CH(CH ₃) ₂	(CH ₂) ₆ CH ₃
494	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	S	(CH ₂) ₃ C≡C(CH ₂) ₂	O	CH ₂ CH ₃	(CH ₂) ₆ CH ₃
495	4-(CH ₃) ₂ NC ₆ H ₄	4-(CH ₃) ₂ NC ₆ H ₄	H	S	(CH ₂) ₂ C(CH ₃) ₂ (CH ₂) ₂	O	CH ₂ C ₆ H ₁₁	(CH ₂) ₆ CH ₃
496	4-CH ₃ OC ₆ H ₄	4-CH ₃ OC ₆ H ₄	H	S	(CH ₂) ₂ C(CH ₃) ₂ (CH ₂) ₂	O	NHCH(CH ₃) ₂	(CH ₂) ₆ CH ₃
497	(CH ₃) ₂ CH	(CH ₃) ₂ CH	H	S	(CH ₂) ₂ C(CH ₃) ₂ (CH ₂) ₂	O	OC ₆ H ₅	(CH ₂) ₆ CH ₃
498	C ₆ H ₁₁	C ₆ H ₁₁	H	S	(CH ₂) ₂ C(CH ₃) ₂ (CH ₂) ₂	O	CH ₂ CH(CH ₃) ₂	(CH ₂) ₆ CH ₃

100

EXAMPLE 499

Preparation of N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)-pentyl]-N-heptyl-N'-phenylguanidine

5 A solution of N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptanamine (0.50 g, 0.00115 mol) and N-phenyl-S-methyl-carbamimidothioate hydrochloride (0.34 g, 0.00115 mol) in acetonitrile (10 mL) and triethylamine (0.5 mL) was heated to reflux under a
10 nitrogen atmosphere for 4 hours. The reaction was allowed to cool to ambient temperature, was diluted with ethyl acetate (50 mL), washed with 10% aqueous sodium bicarbonate (25 mL), water, brine, dried over magnesium sulfate and concentrated in vacuo to give a crude oil.
15 The product was crystallized from acetonitrile to give the title compound (0.4 g, 0.00072 mol) as a white powder, mp 135-6°. ¹H NMR (CDCl₃) δ 7.45(m,4H), 7.23(m,8H), 6.94(t,1H), 6.82(d,2H), 3.3(t,2H), 3.16(t,2H), 3.03(t,2H), 1.7-1.16(m,16H), 0.87(t,3H).

20

EXAMPLE 500

Preparation of N-[5-[4,5-bis(4-methoxyphenyl)-1H-imidazol-2-ylthio]pentyl]-N-heptyl-N'-phenylguanidine

 Employing the method of Example 499 but using
25 N-[5-[4,5-bis(4-methoxyphenyl)-1H-imidazol-2-ylthio]-pentyl]-1-heptanamine the title compound was obtained as an off white foam (0.61 g, 0.00099 mol) mp 68-72°. ¹H NMR (CDCl₃) δ 7.37(d,4H), 7.22(m,2H), 6.97(t,1H), 6.90-6.78(m,6H), 3.75(s,6H), 3.31(t,2H), 3.20(t,2H),
30 3.00(t,2H), 1.7-1.15(m,16H), 0.87(t,2H).

EXAMPLE 501

Preparation of N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-(1-methylethyl)guanidine

Employing the method of Example 499 but using
5 N-(1-methylethyl)-S-methyl-carbamimidothioate
hydrochloride, the title compound was obtained as a pale
yellow glass (0.31 g, 0.00059 mol), mp 98-101°. ¹H NMR
(CDCl₃) δ 12.75(bs, 1H), 7.85-7.68(bs, 1H), 7.55(d, 4H),
7.30-7.16(m, 6H), 6.25-6.15(bs, 1H), 4.10-3.95(m, 1H),
10 3.35(m, 2H), 3.19(m, 2H), 2.93(m, 2H), 1.55-1.10(m, 22H),
0.85(t, 3H).

Utility

The compounds of the present invention are
15 inhibitors of the enzyme acyl-CoA: cholesterol
acyltransferase and are thus effective in inhibiting
esterification and transport of cholesterol across the
intestinal wall. In addition, the compounds are useful
in preventing the formation of cholesterol ester rich
20 macrophages (foam cells) in the arterial wall through
the inhibition of cholesterol ester formation. Foam
cells are a source of the large quantity of cholesterol
ester found in atheromatous lesions as opposed to the
surrounding undiseased tissue. Thus inhibition of ACAT
25 would decrease the accumulation and storage of
cholesterol esters in the arterial wall and prevent or
inhibit the formation of atheromatous lesions.

A. Assay of the Inhibition of Acyl-CoA: Cholesterol
Acyltransferase (ACAT) in Hepatic Microsomes

30 The ability of the compounds to inhibit ACAT, the
enzyme responsible for the intracellular synthesis of
cholesteryl esters, was tested as follows. Male Sprague
Dawley rats weighing 150-300 g, were fed rat chow ad
libitum. The animals were fasted for twenty-four hours
35 prior to being sacrificed by decapitation. The livers

were perfused in situ with 50 ml of cold 0.25 M sucrose, excised, and homogenized in three volumes of 0.1 M phosphate buffer, pH 7.4, that contained 0.5 mM EDTA (ethylenediaminetetraacetic acid), 1.0 mM glutathione, 5 0.25 M sucrose and 20 mM leupeptin. Microsomes were obtained by differential centrifugation; the supernatant from an initial spin at 15,000 x g for 15 minutes was centrifuged at 105,000 x g for 1 hour to pellet the microsomes. The microsomes were suspended in 10 homogenization buffer, reisolated by centrifugation, and stored at -70°C. Microsomes were used within one month of preparation.

The control assay in a final volume of 200 μ l consisted of 200 μ g of microsomal protein, 75 μ M 14 C-oleoyl-CoA (10,000 dpm/nmol) in 0.1 M phosphate, pH 7.4, 15 that contained 1 mM glutathione. Compounds were added in 5 μ l of DMSO (dimethyl sulfoxide) and additional controls were run with DMSO only. All components, except the oleoyl-CoA, were preincubated for 15 min. at 20 37°C prior to the initiation of the reaction by the addition of oleoyl-CoA. The assay was terminated after 10 min by the addition of 4 ml of chloroform:methanol (2:1, v/v). 20,000 dpm of 3 H-cholesteryl oleate and 10 μ g of unlabeled cholesteryl oleate and oleic acid were 25 added as an internal standard and carriers, respectively. After allowing 10 min. for lipid extraction, the samples were centrifuged at 1,000 x g for 10 min. to separate the solvent layers. The chloroform layer containing the neutral lipids was 30 spotted onto a Baker SI250-Pa silica gel TLC plate and the plate developed using a hexane: diethyl ether: acetic acid (170:30:1 v/v/v) mobile phase. The lipids were visualized by their interaction with iodine vapor and the cholesteryl ester spot was scraped into a 35 scintillation vial and counted. The specific activity

of ACAT in the control incubation averaged 260 pmol/min/mg microsomal protein. The inhibition of ACAT activity by the compounds is shown in Table 6; the data are expressed as the concentration at which ACAT activity is inhibited by 50% (IC₅₀).

B. Assay of the Inhibition of Cholesterol Esterification in Mammalian Cells

The esterification of cholesterol was determined in the murine macrophage-like cell line J774.A1. Cells were seeded in 35 mm wells at a density of 300,000 cells per well in 2 mls of Dulbecco's Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS). Cells were incubated at 37°C in an atmosphere of 5% CO₂ and 93% humidity. After 24 hours the media was changed to 0.68 mls 10% FBS-DMEM containing 34 µg of acetylated human low density lipoprotein (ac-LDL) to increase the intracellular concentration of cholesterol and promote esterification. At 41 hours, various inhibitors were added to the cells in DMSO (10 µl/ml maximum). At 43 hours, the cells were pulsed with 0.1 mM ¹⁴C-oleic acid (10,000 dpm/nmol) complexed with BSA (bovine serum albumin) to follow cholesterol ester formation. The experiment was terminated at 45 hours by washing the monolayers 3 times with 3 ml of Tris-buffered saline at 4°C. The lipids were extracted by incubating the monolayers with 1.5 ml of hexane: isopropanol (3:2, v/v) for 30 min. under gentle agitation. During this period, 10,000 dpm ³H-cholesteryl linoleate and 10 µg of cholesteryl oleate were added as an internal standard and carrier respectively. The organic solvent was removed and the cells were washed with an additional 1.0 ml of hexane: isopropanol which was combined with the original extract. The cells were allowed to dry overnight, digested with 1.5 ml of 0.2 N sodium hydroxide for 1 hour and an aliquot of the solubilized

protein used for protein determination using the Lowry method. The organic extract was taken to dryness, the residue resuspended in 100 μ l of chloroform and the lipids separated on silica gel impregnated glass fiber plates using a hexane: diethylether: acetic acid (170:30:1, v/v/v) solvent system. Individual lipids were visualized with iodine and the cholesteryl ester spot cut out and transferred to scintillation vials to determine the amount of radioactivity. The conversion of oleic acid to cholesteryl ester in the control averaged 0.54 mmol/hour/mg protein and was increased upon the addition of ac-LDL to about 10.69 ± 0.69 mmol/hour/mg protein. The inhibition of esterification by the compounds is shown in Table 7; the data are expressed as the concentration at which ACAT activity is inhibited by 50% (IC₅₀). It should be noted that many of the intermediates had inhibitory activity in the in vitro ACAT assay and in the macrophage assay. For example, N-[5(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-1-heptanaminehydrochloride had IC₅₀'s of 100 nM and 6 μ M in the in vitro ACAT and macrophage assay, respectively.

C. Assay of Antihypercholesterolemic Activity in Cholesterol-fed Hamsters

Inhibition of ACAT activity in the gut reduces the absorption of cholesterol in cholesterol-fed animals. Hamsters weighing approximately 100 g, were maintained on a diet supplemented with 0.8% cholesterol. The treatment group received 1-100 mg/kg/day, p.o., of the test compound dissolved in 500 μ l of corn oil for a period of two weeks. The control group were pair-fed to the treatment group and were dosed with 500 μ l of the corn oil vehicle. At sacrifice, the hamsters were anesthetized with CO₂ and exsanguinated via cardiac puncture. Total serum cholesterol was determined on a Du Pont aca® IV. The data were expressed in terms of mg

cholesterol per 100 ml of serum (mg %). The antihypercholesterolemic activity of the compound of Example 1 is shown in Table 8.

Table 6Inhibition of In Vitro Hepatic ACAT Activity
by Various Compounds

5	Compound of Example	<u>In Vitro</u> ACAT IC ₅₀ (nM)
	1	13
	2	3
	3	8
10	4	60
	5	12
	6	3,600
	7	41
	8	10
15	9	930
	20	20
	53	17
	64	30
	71	16
20	85	60
	94	10
	97	25
	105	20
	107	1,000
25	110	60
	114	40
	118	170
	122	80
	137	76
30	160	490
	186	2,850
	188	20

Table 6 (continued)
Inhibition of In Vitro Hepatic ACAT Activity
by Various Compounds

	Compound of <u>Example</u>	<u>In Vitro</u> ACAT IC ₅₀ (nM)
5	189	70
	190	30
	192	70
	193	60
	194	1,900
10	195	40
	196	300
	197	119
	198	40
	199	20
15	200	710
	201	200
	202	220
	205	74
	204	500
20	206	40
	207	9
	208	20
	209	1,400
	210	17
25	211	32
	212	60
	258	40,000
	261	80
	262	200

Table 6 (continued)
Inhibition of In Vitro Hepatic ACAT Activity
by Various Compounds

	Compound of <u>Example</u>	<u>In Vitro</u> ACAT IC ₅₀ (nM)
5	263	40
	266	230
	276	58
10	278	8
	281	16
	298	30
	299	140
	300	130
15	338	3,500
	339	280
	340	25
	341	3
	342	30
20	343	160
	344	30
	345	60
	346	50
	347	30
25	348	700
	349	200
	350	605
	351	250
	352	300
30	353	240
	354	50
	355	10
	401	50

Table 6 (continued)
Inhibition of In Vitro Hepatic ACAT Activity
by Various Compounds

	Compound of <u>Example</u>	<u>In Vitro</u> ACAT IC ₅₀ (nM)
5	402	20
	403	35
	404	33
10	405	500
	406	10
	407	40
	408	9
	409	120
15	410	640
	411	310
	457	834
	499	3,160

20 Table 7
Inhibition of Cholesterol Esterification
in Macrophage by Various Compounds

	Compound of <u>Example</u>	Cholesterol Esterification IC ₅₀ (μM)
25	1	1.0
	2	0.8
	3	17.5
	4	4.6
30	5	2.5
	6	3.8
	7	7.5
	8	0.5
	9	11.2
35	20	54.5

Table 7 (continued)
Inhibition of Cholesterol Esterification
in Macrophage by Various Compounds

	Compound of <u>Example</u>	Cholesterol Esterification <u>IC₅₀ (μM)</u>
5	53	0.4
	64	0.6
	71	1.9
10	85	3.1
	94	0.1
	97	0.7
	105	0.3
15	107	2.3
	110	0.9
	114	3.5
	118	0.1
	122	0.3
20	137	3.4
	160	1.6
	186	6.2
	188	0.9
	189	2.2
	190	2.2
25	192	2.0
	193	2.7
	194	4.1
	195	0.4
	196	1.4
30	197	0.1
	198	0.06
	199	0.6
	200	0.8
	201	0.5

Table 7 (continued)
Inhibition of Cholesterol Esterification
in Macrophage by Various Compounds

	Compound of <u>Example</u>	Cholesterol Esterification <u>IC₅₀ (μM)</u>
5	202	0.004
	203	50.0
	204	0.4
10	205	0.003
	206	0.4
	207	0.6
	208	2.8
	209	4.8
15	210	0.8
	211	0.7
	212	1.7
	258	25.0
	259	0.9
20	260	6.0
	276	6.1
	278	1.2
	281	3.5
	298	2.5
25	299	1.2
	300	0.9
	338	3.4
	339	4.4
	340	0.2
30	341	0.1
	342	1.6
	343	1.1
	344	0.4
	345	0.3
35	346	0.5

Table 7 (continued)
Inhibition of Cholesterol Esterification
in Macrophage by Various Compounds

	Compound of <u>Example</u>	Cholesterol Esterification <u>IC₅₀ (μM)</u>
5	347	0.3
	348	0.2
	349	0.09
10	350	0.05
	351	0.04
	352	2.2
	353	0.08
	354	0.02
15	355	0.03
	401	0.4
	402	0.4
	403	0.5
	404	0.5
20	405	3.9
	406	0.6
	407	0.8
	408	1.3
	410	0.03
25	411	0.5
	457	0.1
	499	3.4

Table 8

Dose Response Evaluation of Example 1
in Hypercholesterolemic Hamsters

5	Dose (mg/kg/day)	Serum Cholesterol (mg %) ^a		Decrease (%)
		<u>Control</u>	<u>Treated</u>	
	1	400 ± 25	295 ± 12	26
	3	381 ± 17	279 ± 16	27
	10	371 ± 7	201 ± 12	46
10	30	368 ± 15	197 ± 11	46
	100	400 ± 17	62 ± 8	60

a) Values are the mean ± SEM, n=9-10 per group

15 Dosage Forms:

The compounds of the present invention can be administered orally using any pharmaceutically acceptable dosage form known in the art for such administration. The active ingredient can be supplied
 20 in solid dosage forms such as dry powders, granules, tablets or capsules, or in liquid dosage forms, such as syrups or aqueous suspensions. The active ingredient can be administered alone, but is generally administered with a pharmaceutical carrier. A valuable treatise with
 25 respect to pharmaceutical dosage forms is Remington's Pharmaceutical Sciences, 16th Edition, 1980.

In their therapeutic use as antihypercholesterolemic and/or antiatherosclerotic agents, the compounds of the invention are administered
 30 to the patient at dosage levels of 1 to 28 g per day. For a normal male adult human of approximately 70 kg of body weight, this translates into a dosage of 14 to 400 mg per kilogram body weight per day. The dosage administered will, of course, vary depending upon known
 35 factors such as the age, health, and weight of the

recipient; nature and extent of symptoms, kind of
concurrent treatment, frequency of treatment, and the
effect desired. Useful pharmaceutical dosage forms for
administration of the compounds of this invention can be
5 illustrated as follows:

Tablets

Tablets are prepared by conventional procedures so
that the dosage unit is 500 milligrams of active
10 ingredient, 150 milligrams of lactose, 50 milligrams of
cellulose and 10 milligrams of magnesium stearate.

Capsules

Capsules are prepared by conventional procedures so
that the dosage unit is 500 milligrams of active
15 ingredient, 100 milligrams of cellulose and 10
milligrams of magnesium stearate.

Syrup

		<u>Wt. %</u>
20	Active Ingredient	10
	Liquid Sugar	50
	Sorbitol	20
	Glycerine	5
	Flavor, Colorant and	as required
25	Preservative	
	Water	as required

The final volume is brought up to 100% by the
addition of distilled water.

30

115

Aqueous Suspension

		<u>Wt. %</u>
	Active Ingredient	10
	Sodium Saccharin	0.01
5	Keltrol® (Food Grade	0.2
	Xanthan Gum)	
	Liquid Sugar	5
	Flavor, Colorant and	as required
	Preservative	
10	Water	as required

Xanthan gum is slowly added into distilled water before adding the active ingredient and the rest of the formulation ingredients. The final suspension is passed
15 through a homogenizer to assure the elegance of the final products.

Resuspendible Powder

		<u>Wt. %</u>
20	Active Ingredient	50.0
	Lactose	35.0
	Sugar	10.0
	Acacia	4.7
	Sodium Carboxymethylcellulose	0.3
25		

Each ingredient is finely pulverized and then uniformly mixed together. Alternatively, the powder can be prepared as a suspension and then spray dried.

Semi-Solid Gel

		<u>Wt. %</u>
	Active Ingredient	10
	Sodium Saccharin	0.02
5	Gelatin	2
	Colorant, Flavor and	as required
	Preservative	
	Water	as required

10 Gelatin is prepared in hot water. The finely pulverized active ingredient is suspended in the gelatin solution and then the rest of the ingredients are mixed in. The suspension is filled into a suitable packaging container and cooled down to form the gel.

15

Semi-Solid Paste

		<u>Wt. %</u>
	Active Ingredient	10
	Gelcarin® (Carrageenin gum)	1
20	Sodium Saccharin	0.01
	Colorant, Flavor and	as required
	Preservative	
	Water	as required

25 Gelcarin® is dissolved in hot water (around 80°C) and then the fine-powder active ingredient is suspended in this solution. Sodium saccharin and the rest of the formulation ingredients are added to the suspension while it is still warm. The suspension is homogenized

30 and then filled into suitable containers.

Emulsifiable Paste

	<u>Wt. %</u>
Active Ingredient	30
Tween® 80 and Span® 80	6
5 Keltrol®	0.5
Mineral Oil	63.5


All the ingredients are carefully mixed together to make a homogeneous paste.

10 The term "consisting essentially of" in the present disclosure is intended to have its customary meaning; namely, that all specified materials and conditions are very important in practicing the invention but that
15 unspecified materials and conditions are not excluded so long as they do not prevent the benefits of the invention from being realized.

The foregoing disclosure includes all the information deemed essential to enable those of skill in the art to practice the claimed invention. Because the
20 cited publications and applications may provide further useful information, however, these cited materials are hereby incorporated by reference.

WHAT IS CLAIMED IS:


1. A compound of the formula



Formula (I)

wherein

R¹ and R² are selected independently from H, C₁-C₈ alkyl, C₃-C₈ branched alkyl, C₃-C₇ cycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₇-C₁₄ araalkyl, 2-, 3- or 4-pyridinyl, 2-thienyl, 2-furanyl, phenyl optionally substituted with 1 to 3 groups selected from F, Cl, Br, OH, C₁-C₄ alkoxy, C₁-C₄ alkyl, C₃-C₈ branched alkyl, CH₃S(O)_r, NO₂, CF₃, or NR⁷R⁸; or R¹ and R² can also be taken together as



where L is O, O(CH₂)_{m+1}O, or (CH₂)_m where m is 0-4;
 R³ is H, C₁-C₆ alkyl, allyl, benzyl, or phenyl optionally substituted with F, Cl, CH₃, CH₃O, or CF₃;
 R⁴ is straight chain C₁-C₈ alkyl optionally substituted with F; C₃-C₈ branched alkyl, C₃-C₇

cycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₇-C₁₄ araalkyl where the aryl group is optionally substituted with 1 to 3 groups selected from C₁-C₄ alkyl or alkoxy, F, Br, Cl, NH₂, OH, CN, CO₂H, CF₃, NO₂, C₁-C₄ carboalkoxy, NR⁷R⁸, or NCOR⁷; C₃-C₆ alkenyl or alkynyl, C₁-C₃ perfluoroalkyl, phenyl optionally substituted with 1 to 3 groups selected from C₁-C₄ alkyl, C₃-C₈ branched alkyl, C₁-C₄ alkoxy, F, Br, Cl, NH₂, OH, CN, CO₂H, CF₃, NO₂, C₁-C₄ carboalkoxy, NR⁷R⁸ or NCOR⁷; pentafluorophenyl, benzyl optionally substituted with 1 to 3 groups selected from C₁-C₄ alkyl or alkoxy, F, Br, Cl, NH₂, OH, CN, CO₂H, CF₃, NO₂, C₁-C₄ carboalkoxy, NR⁷R⁸, or NCOR⁷; 2-, 3- or 4-pyridinyl, pyrimidinyl, or biphenyl;

R⁵ is H, C₁-C₆ alkyl, or benzyl;

R⁶ is C₁-C₈ alkyl, C₃-C₈ branched alkyl, C₃-C₇ cycloalkyl, C₃-C₈ alkenyl or alkynyl, phenyl optionally substituted with 1 to 3 groups selected from C₁-C₄ alkyl or alkoxy, F, Br, Cl, NH₂, OH, CN, CO₂H, CF₃, NO₂, C₁-C₄ carboalkoxy, NR⁷R⁸, or NCOR⁷; pentafluorophenyl, benzyl optionally substituted with 1 to 3 groups selected from C₁-C₄ alkyl or alkoxy, F, Br, Cl, NH₂, OH, CN, CO₂H, CF₃, NO₂, C₁-C₄ carboalkoxy, NR⁷R⁸, or NCOR⁷;

R⁷ and R⁸ are selected independently from H or C₁-C₄ alkyl;

X is S(O)_r, O, NR⁵, CH₂;

A is C₂-C₁₀ alkyl, C₃-C₁₀ branched alkyl, C₃-C₁₀ alkenyl, or C₃-C₁₀ alkynyl;

Y is O, S, H₂, or NH;

Z is NHR⁴, OR⁴, or R⁴;


r is 0-2,

or a pharmaceutically acceptable salt thereof.

2. A compound of Claim 1 wherein

R^1 and R^2 are selected independently from C_1 - C_8 alkyl, C_3 - C_8 branched alkyl, C_3 - C_7 cycloalkyl, C_4 - C_{10} cycloalkylalkyl, C_7 - C_{14} araalkyl, 2-, 3-, or 4-pyridinyl, 2-thienyl, 2-furanyl, phenyl optionally substituted with 1 to 2 groups selected from F, Cl, Br, OH, C_1 - C_4 alkoxy, C_1 - C_4 alkyl, C_3 - C_8 branched alkyl, $CH_3S(O)_x$, NO_2 , or NR^7R^8 ; or

R^1 and R^2 can also be taken together as



where L is O, $O(CH_2)_{m+1}O$, or $(CH_2)_m$ where m is 0-4.

3. A compound of Claim 2 wherein


R^3 is H, CH_3 , phenyl;

R^6 is C_1 - C_8 alkyl, C_3 - C_8 branched alkyl, C_3 - C_7 cycloalkyl, phenyl optionally substituted with 1 to 3 groups selected from CH_3 , CH_3O , F, Br, Cl, NH_2 , OH, CN, CO_2H , CF_3 , or di(C_1 - C_4)alkylamino; or benzyl optionally substituted with 1 to 3 groups selected from CH_3 , CH_3O , F, Br, Cl, NH_2 , OH, CN, CO_2H , CF_3 , or di(C_1 - C_4)alkylamino;

X is $S(O)_x$, CH_2 ;

A is C_2 - C_{10} alkyl, C_4 - C_9 branched alkyl.

4. A compound of Claim 3, wherein R^1 and R^2 are selected independently from C_1 - C_8 alkyl, C_3 - C_8 branched alkyl, C_3 - C_7 cycloalkyl, C_4 - C_{10} cycloalkylalkyl, C_7 - C_{14} araalkyl, 2-, 3-, or 4-pyridinyl, 2-thienyl, or phenyl optionally substituted with 1 to 2 groups selected from F, Br, Cl, C_1 - C_4 alkyl, C_3 - C_8 branched alkyl, CH_3O , $CH_3S(O)_r$, NO_2 , or di(C_1 - C_4)alkylamino; or
- 5 R^1 and R^2 can also be taken together as



10

where L is O or OCH_2O ;

R^3 is H;

15 R^4 is C_1 - C_8 alkyl, C_3 - C_8 branched alkyl, C_3 - C_7 cycloalkyl, C_4 - C_{10} cycloalkylalkyl, C_7 - C_{14} araalkyl, phenyl substituted with 1 to 3 groups selected from CH_3 , F, Cl, CH_3O , CN; or benzyl optionally substituted with 1 to 3 groups selected from CH_3 , CH_3O , F, Cl, or CN;

20 R^6 is C_1 - C_8 alkyl or phenyl optionally substituted with 1 to 3 groups selected from CH_3 , CH_3O , F, Cl, or CN;

A is C_4 - C_9 alkyl;

X is $S(O)_r$.


25

5. A compound of Claim 1 wherein Y is O, S, or NH.

6. A compound of Claim 5 wherein

R^1 and R^2 are selected independently from C_1 - C_8 alkyl, C_3 - C_8 branched alkyl, C_3 - C_7 cycloalkyl, C_4 - C_{10} cycloalkylalkyl, C_7 - C_{14} araalkyl, 2-, 3-, or 4-pyridinyl, 2-thienyl, 2-furanyl, phenyl optionally substituted with 1 to 2 groups selected from F, Cl, Br, OH, C_1 - C_4 alkoxy, C_1 - C_4 alkyl, C_3 - C_8 branched alkyl, $CH_3S(O)_r$, NO_2 , or NR^7R^8 ; or

R^1 and R^2 can also be taken together as



where L is O, $O(CH_2)_{m+1}O$, or $(CH_2)_m$ where m is 0-4.

7. A compound of Claim 6 wherein

R^3 is H, CH_3 , phenyl;


R^6 is C_1 - C_8 alkyl, C_3 - C_8 branched alkyl, C_3 - C_7 cycloalkyl, phenyl optionally substituted with 1 to 3 groups selected from CH_3 , CH_3O , F, Br, Cl, NH_2 , OH, CN, CO_2H , CF_3 , or di(C_1 - C_4)alkylamino; or benzyl optionally substituted with 1 to 3 groups selected from CH_3 , CH_3O , F, Br, Cl, NH_2 , OH, CN, CO_2H , CF_3 , or di(C_1 - C_4)alkylamino;

X is $S(O)_r$, CH_2 ;

A is C_2 - C_{10} alkyl, C_4 - C_9 branched alkyl.

8. A compound of Claim 7 wherein R¹ and R² are selected independently from C₁-C₈ alkyl, C₃-C₈ branched alkyl, C₃-C₇ cycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₇-C₁₄ araalkyl, 2-, 3-, or 4-pyridinyl, 2-thienyl, or phenyl
 5 optionally substituted with 1 to 2 groups selected from F, Br, Cl, C₁-C₄ alkyl, C₃-C₈ branched alkyl, CH₃O, CH₃S(O)_r, NO₂, or di(C₁-C₄)alkylamino; or

R¹ and R² can also be taken together as



where L is O or OCH₂O;

R³ is H;

R⁴ is C₁-C₈ alkyl, C₃-C₈ branched alkyl, C₃-C₇
 15 cycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₇-C₁₄ araalkyl, phenyl substituted with 1 to 3 groups selected from CH₃, F, Cl, CH₃O, CN; or benzyl optionally substituted with 1 to 3 groups selected from CH₃, CH₃O, F, Cl, or CN;

20 R⁶ is C₁-C₈ alkyl or phenyl optionally substituted with 1 to 3 groups selected from CH₃, CH₃O, F, Cl, or CN;

A is C₄-C₉ alkyl;

X is S(O)_r.

25

9. The compound of Claim 4 which is N'-(2,4-difluorophenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea.

10. The compound of Claim 4 which is N'-(2,4-difluorophenyl)-N-[8-(4,5-diphenyl-1H-imidazol-2-ylthio)octyl]-N-heptylurea.

5 11. The compound of Claim 4 which is N-butyl-N'-(2,4-difluorophenyl)-N-[8-(4,5-diphenyl-1H-imidazol-2-ylthio)octyl]urea.

12. The compound of Claim 4 which is N'-(2,4-dimethoxyphenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea.

10 13. The compound of Claim 4 which is N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-methylurea.

14. The compound of Claim 4 which is N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-propylurea.

15 15. The compound of Claim 4 which is N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N'-(3-fluorophenyl)-N-heptylurea.

16. The compound of Claim 4 which is N'-(2,4-difluorophenyl)-N-[5-[(4,5-diphenyl-1H-imidazol-2-yl)sulfonyl]pentyl]-N-heptylurea.

17. The compound of Claim 4 which is N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-(1-methylethyl)urea.

25 18. The compound of Claim 4 which is N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-2,4-difluoro-N-heptylbenzeneacetamide.

19. The compound of Claim 4 which is N'-cyclohexyl-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea.

30 20. The compound of Claim 4 which is N'-(2,4-difluorophenyl)-N-[5-[(4,5-diphenyl-1H-imidazol-2-yl)sulfinyl]pentyl]-N-heptylurea.

21. The compound of Claim 4 which is N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylbutanamide.

22. The compound of Claim 4 which is N-[5-[4,5-bis(1-methylethyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea.

23. The compound of Claim 4 which is N-[5-[4,5-bis(1-methylethyl)-1H-imidazol-2-ylthio]pentyl]-N-heptylcyclohexaneacetamide.

24. The compound of Claim 4 which is N-[5-[4,5-bis(4-methoxyphenyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea.

25. The compound of Claim 4 which is phenyl [5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]heptylcarbamate.

26. The compound of Claim 4 which is N-[5-[4,5-bis[4-(dimethylamino)phenyl]-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea.

27. The compound of Claim 4 which is N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N'-octyl-N-phenylurea.

28. The compound of Claim 4 which is N-[5-[4,5-bis(4-methoxyphenyl)-1H-imidazol-2-ylthio]pentyl]-2,4-difluoro-N-heptylbenzeneacetamide.

29. The compound of Claim 4 which is phenyl [5-[4,5-bis(4-(dimethylamino)phenyl)-1H-imidazol-2-ylthio]pentyl]heptylcarbamate.

30. The compound of Claim 4 which is N-[5-(4,5-dicyclohexyl-1H-imidazol-2-ylthio)pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea.

31. The compound of Claim 4 which is N-[5-[4,5-bis(4-methoxyphenyl)-1H-imidazol-2-ylthio]pentyl]-N-heptyl-N'-(1-methylethyl)urea.

32. The compound of Claim 4 which is N-[5-[4,5-bis[4-(dimethylamino)phenyl]-1H-imidazol-2-ylthio]pentyl]-N-heptyl-N'-(1-methylethyl)urea.

5 33. A pharmaceutical composition comprising an effective ACAT inhibiting or antiatherosclerotic amount of a compound of Claim 1 and a pharmaceutically acceptable carrier.

10 34. A pharmaceutical composition comprising an effective ACAT inhibiting or antiatherosclerotic amount of a compound of Claim 2 and a pharmaceutically acceptable carrier.

15 35. A pharmaceutical composition comprising an effective ACAT inhibiting or antiatherosclerotic amount of a compound of Claim 3 and a pharmaceutically acceptable carrier.

36. A pharmaceutical composition comprising an effective ACAT inhibiting or antiatherosclerotic amount of a compound of Claim 4 and a pharmaceutically acceptable carrier.

20 37. A pharmaceutical composition comprising an effective ACAT inhibiting or antiatherosclerotic amount of a compound of Claim 5 and a pharmaceutically acceptable carrier.

25 38. A pharmaceutical composition comprising an effective ACAT inhibiting or antiatherosclerotic amount of a compound of Claim 6 and a pharmaceutically acceptable carrier.

30 39. A pharmaceutical composition comprising an effective ACAT inhibiting or antiatherosclerotic amount of a compound of Claim 7 and a pharmaceutically acceptable carrier.

40. A pharmaceutical composition comprising an effective ACAT inhibiting or antiatherosclerotic amount

of a compound of Claim 8 and a pharmaceutically acceptable carrier.

41. A pharmaceutical composition comprising an effective ACAT inhibiting or antiatherosclerotic amount
5 of the compound of Claim 9 and a pharmaceutically acceptable carrier.

42. A pharmaceutical composition comprising an effective ACAT inhibiting or antiatherosclerotic amount of the compound of Claim 10 and a pharmaceutically
10 acceptable carrier.

43. A pharmaceutical composition comprising an effective ACAT inhibiting or antiatherosclerotic amount of the compound of Claim 11 and a pharmaceutically acceptable carrier.

15 44. A pharmaceutical composition comprising an effective ACAT inhibiting or antiatherosclerotic amount of the compound of Claim 12 and a pharmaceutically acceptable carrier.

45. A pharmaceutical composition comprising an effective ACAT inhibiting or antiatherosclerotic amount
20 of the compound of Claim 13 and a pharmaceutically acceptable carrier.

46. A pharmaceutical composition comprising an effective ACAT inhibiting or antiatherosclerotic amount
25 of the compound of Claim 14 and a pharmaceutically acceptable carrier.

47. A pharmaceutical composition comprising an effective ACAT inhibiting or antiatherosclerotic amount of the compound of Claim 15 and a pharmaceutically
30 acceptable carrier.

48. A pharmaceutical composition comprising an effective ACAT inhibiting or antiatherosclerotic amount of the compound of Claim 16 and a pharmaceutically acceptable carrier.

49. A pharmaceutical composition comprising an effective ACAT inhibiting or antiatherosclerotic amount of the compound of Claim 17 and a pharmaceutically acceptable carrier.

5 50. A pharmaceutical composition comprising an effective ACAT inhibiting or antiatherosclerotic amount of the compound of Claim 18 and a pharmaceutically acceptable carrier.

10 51. A pharmaceutical composition comprising an effective ACAT inhibiting or antiatherosclerotic amount of the compound of Claim 19 and a pharmaceutically acceptable carrier.

15 52. A pharmaceutical composition comprising an effective ACAT inhibiting or antiatherosclerotic amount of the compound of Claim 20 and a pharmaceutically acceptable carrier.

20 53. A pharmaceutical composition comprising an effective ACAT inhibiting or antiatherosclerotic amount of the compound of Claim 21 and a pharmaceutically acceptable carrier.

54. A pharmaceutical composition comprising an effective ACAT inhibiting or antiatherosclerotic amount of the compound of Claim 22 and a pharmaceutically acceptable carrier.

25 55. A pharmaceutical composition comprising an effective ACAT inhibiting or antiatherosclerotic amount of the compound of Claim 23 and a pharmaceutically acceptable carrier.

30 56. A pharmaceutical composition comprising an effective ACAT inhibiting or antiatherosclerotic amount of the compound of Claim 24 and a pharmaceutically acceptable carrier.

57. A pharmaceutical composition comprising an effective ACAT inhibiting or antiatherosclerotic amount

of the compound of Claim 25 and a pharmaceutically acceptable carrier.

58. A pharmaceutical composition comprising an effective ACAT inhibiting or antiatherosclerotic amount
5 of the compound of Claim 26 and a pharmaceutically acceptable carrier.

59. A pharmaceutical composition comprising an effective ACAT inhibiting or antiatherosclerotic amount of the compound of Claim 27 and a pharmaceutically
10 acceptable carrier.

60. A pharmaceutical composition comprising an effective ACAT inhibiting or antiatherosclerotic amount of the compound of Claim 28 and a pharmaceutically acceptable carrier.

15 61. A pharmaceutical composition comprising an effective ACAT inhibiting or antiatherosclerotic amount of the compound of Claim 29 and a pharmaceutically acceptable carrier.

62. A pharmaceutical composition comprising an effective ACAT inhibiting or antiatherosclerotic amount
20 of the compound of Claim 30 and a pharmaceutically acceptable carrier.

63. A pharmaceutical composition comprising an effective ACAT inhibiting or antiatherosclerotic amount
25 of the compound of Claim 31 and a pharmaceutically acceptable carrier.

64. A pharmaceutical composition comprising an effective ACAT inhibiting or antiatherosclerotic amount of the compound of Claim 32 and a pharmaceutically
30 acceptable carrier.

65. A method of treating hypercholesterolemia or atherosclerosis in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of Claim 1.

66. A method of treating hypercholesterolemia or atherosclerosis in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of Claim 2.

5 67. A method of treating hypercholesterolemia or atherosclerosis in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of Claim 3.

10 68. A method of treating hypercholesterolemia or atherosclerosis in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of Claim 4.

15 69. A method of treating hypercholesterolemia or atherosclerosis in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of Claim 5.

20 70. A method of treating hypercholesterolemia or atherosclerosis in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of Claim 6.

71. A method of treating hypercholesterolemia or atherosclerosis in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of Claim 7.

25 72. A method of treating hypercholesterolemia or atherosclerosis in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of Claim 8.

30 73. A method of treating hypercholesterolemia or atherosclerosis in a mammal comprising administering to the mammal a therapeutically effective amount of the compound of Claim 9.

74. A method of treating hypercholesterolemia or atherosclerosis in a mammal comprising administering to

the mammal a therapeutically effective amount of the compound of Claim 10.

75. A method of treating hypercholesterolemia or atherosclerosis in a mammal comprising administering to
5 the mammal a therapeutically effective amount of the compound of Claim 11.

76. A method of treating hypercholesterolemia or atherosclerosis in a mammal comprising administering to
10 the mammal a therapeutically effective amount of the compound of Claim 12.

77. A method of treating hypercholesterolemia or atherosclerosis in a mammal comprising administering to
the mammal a therapeutically effective amount of the compound of Claim 13.

15 78. A method of treating hypercholesterolemia or atherosclerosis in a mammal comprising administering to the mammal a therapeutically effective amount of the compound of Claim 14.

79. A method of treating hypercholesterolemia or
20 atherosclerosis in a mammal comprising administering to the mammal a therapeutically effective amount of the compound of Claim 15.

80. A method of treating hypercholesterolemia or atherosclerosis in a mammal comprising administering to
25 the mammal a therapeutically effective amount of the compound of Claim 16.

81. A method of treating hypercholesterolemia or atherosclerosis in a mammal comprising administering to
30 the mammal a therapeutically effective amount of the compound of Claim 17.

82. A method of treating hypercholesterolemia or atherosclerosis in a mammal comprising administering to
the mammal a therapeutically effective amount of the compound of Claim 18.

83. A method of treating hypercholesterolemia or atherosclerosis in a mammal comprising administering to the mammal a therapeutically effective amount of the compound of Claim 19.

5 84. A method of treating hypercholesterolemia or atherosclerosis in a mammal comprising administering to the mammal a therapeutically effective amount of the compound of Claim 20.

10 85. A method of treating hypercholesterolemia or atherosclerosis in a mammal comprising administering to the mammal a therapeutically effective amount of the compound of Claim 21.

15 86. A method of treating hypercholesterolemia or atherosclerosis in a mammal comprising administering to the mammal a therapeutically effective amount of the compound of Claim 22.

20 87. A method of treating hypercholesterolemia or atherosclerosis in a mammal comprising administering to the mammal a therapeutically effective amount of the compound of Claim 23.

 88. A method of treating hypercholesterolemia or atherosclerosis in a mammal comprising administering to the mammal a therapeutically effective amount of the compound of Claim 24.

25 89. A method of treating hypercholesterolemia or atherosclerosis in a mammal comprising administering to the mammal a therapeutically effective amount of the compound of Claim 25.

30 90. A method of treating hypercholesterolemia or atherosclerosis in a mammal comprising administering to the mammal a therapeutically effective amount of the compound of Claim 26.

 91. A method of treating hypercholesterolemia or atherosclerosis in a mammal comprising administering to

the mammal a therapeutically effective amount of the compound of Claim 27.

92. A method of treating hypercholesterolemia or atherosclerosis in a mammal comprising administering to
5 the mammal a therapeutically effective amount of the compound of Claim 28.

93. A method of treating hypercholesterolemia or atherosclerosis in a mammal comprising administering to
10 the mammal a therapeutically effective amount of the compound of Claim 29.


94. A method of treating hypercholesterolemia or atherosclerosis in a mammal comprising administering to
the mammal a therapeutically effective amount of the compound of Claim 30.

15 95. A method of treating hypercholesterolemia or atherosclerosis in a mammal comprising administering to the mammal a therapeutically effective amount of the compound of Claim 31.

96. A method of treating hypercholesterolemia or
20 atherosclerosis in a mammal comprising administering to the mammal a therapeutically effective amount of the compound of Claim 32.


97. A process for preparing a compound of
Formula (I):

25



wherein

R^1 and R^2 are selected independently from H, C_1 - C_8 alkyl, C_3 - C_8 branched alkyl, C_3 - C_7 cycloalkyl, C_4 - C_{10} cycloalkylalkyl, C_7 - C_{14} araalkyl, 2-, 3- or 4-pyridinyl, 2-thienyl, 2-furanyl, phenyl optionally substituted with 1 to 3 groups selected from F, Cl, Br, OH, C_1 - C_4 alkoxy, C_1 - C_4 alkyl, C_3 - C_8 branched alkyl, $CH_3S(O)_r$, NO_2 , CF_3 , or NR^7R^8 ; or R^1 and R^2 can also be taken together as



where L is O, $O(CH_2)_{m+1}O$, or $(CH_2)_m$ where m is 0-4; R^3 is H, C_1 - C_6 alkyl, allyl, benzyl, or phenyl optionally substituted with F, Cl, CH_3 , CH_3O , or CF_3 ;

R^4 is straight chain C_1 - C_8 alkyl optionally substituted with F; C_3 - C_8 branched alkyl, C_3 - C_7 cycloalkyl, C_4 - C_{10} cycloalkylalkyl, C_7 - C_{14} araalkyl where the aryl group is optionally substituted with 1 to 3 groups selected from C_1 - C_4 alkyl or alkoxy, F, Br, Cl, NH_2 , OH, CN, CO_2H , CF_3 , NO_2 , C_1 - C_4 carboalkoxy, NR^7R^8 , or $NCOR^7$; C_3 - C_6 alkenyl or alkynyl, C_1 - C_3 perfluoroalkyl, phenyl optionally substituted with 1 to 3 groups selected from C_1 - C_4 alkyl, C_3 - C_8 branched alkyl, C_1 - C_4 alkoxy, F, Br, Cl, NH_2 , OH, CN, CO_2H , CF_3 , NO_2 , C_1 - C_4 carboalkoxy, NR^7R^8 or $NCOR^7$; pentafluorophenyl, benzyl optionally substituted with 1 to 3 groups selected

from C₁-C₄ alkyl or alkoxy, F, Br, Cl, NH₂, OH, CN, CO₂H, CF₃, NO₂, C₁-C₄ carboalkoxy, NR⁷R⁸, or NCOR⁷; 2-, 3- or 4-pyridinyl, pyrimidinyl, or biphenyl;

R⁵ is H, C₁-C₆ alkyl, or benzyl;

5 R⁶ is C₁-C₈ alkyl, C₃-C₈ branched alkyl, C₃-C₇ cycloalkyl, C₃-C₈ alkenyl or alkynyl, phenyl optionally substituted with 1 to 3 groups selected from C₁-C₄ alkyl or alkoxy, F, Br, Cl, NH₂, OH, CN, CO₂H, CF₃, NO₂, C₁-C₄ carboalkoxy, NR⁷R⁸, or NCOR⁷;
10 pentafluorophenyl, benzyl optionally substituted with 1 to 3 groups selected from C₁-C₄ alkyl or alkoxy, F, Br, Cl, NH₂, OH, CN, CO₂H, CF₃, NO₂, C₁-C₄ carboalkoxy, NR⁷R⁸, or NCOR⁷;

R⁷ and R⁸ are selected independently from H or C₁-C₄ alkyl;

15 X is S(O)_r, O, NR⁵, CH₂;

A is C₂-C₁₀ alkyl, C₃-C₁₀ branched alkyl, C₃-C₁₀ alkenyl, or C₃-C₁₀ alkynyl;


Y is O, S, H₂, or NH;

20 Z is NHR⁴, OR⁴, or R⁴;

r is 0-2,

or a pharmaceutically acceptable salt thereof, comprising the steps of: reacting a compound of the formula

25



where R¹, R², X, A, and R⁶, are as defined above, and R³ is as defined above, or a suitable protecting group, such as a silyl or a trityl group,

30

with

- 5 i) an isocyanate of the formula, $R^4-N=C=O$, or an activated urea of the formula $4-CH_3-C_6H_4-SO_2-NH-C(O)-NH-R^4$, where R^4 is as defined above, to yield a compound of Formula (I) above, where Y is O, and Z is NHR^4 ; or
- 10 ii) an isothiocyanate of the formula, $R^4-N=C=S$, where R^4 is as defined above, to yield a compound of Formula (I) above, where Y is S, and Z is NHR^4 ; or

- 15 iii) a chloroformate of the formula, $R^4-O-C \begin{array}{l} O \\ // \\ \backslash \\ Cl \end{array}$,

20 where R^4 is as defined above, to yield a compound of Formula (I) above where Y is O and Z is OR^4 ; or

- 25 iv) an acid chloride of the formula, $R^4-C \begin{array}{l} O \\ // \\ \backslash \\ Cl \end{array}$, or

30 other activated carboxylic acid, where R^4 is as defined above, to yield a compound of Formula (I) above where Y is O and Z is R^4 .

98. A process of Claim 97, further comprising removing any protecting group on R^3 , to yield a compound of Formula (I), where R^3 is H.

35 99. A process of Claim 97, further comprising reacting a compound of Formula (I) where Y is O with


Lawesson's reagent or diphosphorous pentasulfide to yield a compound of Formula (I) where Y is S.

100. A process of Claim 97, further comprising reacting a compound of Formula (I) where Y is O with a
 5 reducing agent such as lithium aluminum hydride or sodium borohydride, to yield a compound of Formula (I) where Y is H₂.

101. A process of Claim 97, further comprising reacting a compound of Formula (I) where X is S with a
 10 suitable oxidizing agent to yield either the sulfoxide, SO, where r is 1, or the sulfone, SO₂, where r is 2.

102. A process of Claim 97, further comprising reacting a compound of Formula (I) where R³ is H with a
 15 suitable alkylating agent such as an alkyl halide, to yield a compound of Formula (I) where R³ is C₁-C₆ alkyl, allyl, or benzyl.


103. A process comprising the steps of alkylating a compound of the formula,



20

wherein

R¹ and R² are selected independently from H, C₁-C₈
 alkyl, C₃-C₈ branched alkyl, C₃-C₇ cycloalkyl, C₄-
 25 C₁₀ cycloalkylalkyl, C₇-C₁₄ araalkyl, 2-, 3- or 4-
 pyridinyl, 2-thienyl, 2-furanyl, phenyl optionally
 substituted with 1 to 3 groups selected from F,
 Cl, Br, OH, C₁-C₄ alkoxy, C₁-C₄ alkyl, C₃-C₈
 branched alkyl, CH₃S(O)_r, NO₂, CF₃, or NR⁷R⁸; or
 30 R¹ and R² can also be taken together as




5 where L is O, $O(CH_2)_{m+1}O$, or $(CH_2)_m$ where m is 0-4;

R^3 is H, C_1 - C_6 alkyl, allyl, benzyl, or phenyl optionally substituted with F, Cl, CH_3 , CH_3O , CF_3 , or an appropriate protecting group, such as a silyl or trityl group, and

10 X is O or S,

with a compound of the formula,



15 where

M is halide or tosylate,

A is C_2 - C_{10} alkyl, C_3 - C_{10} branched alkyl, C_3 - C_{10} alkenyl, or C_3 - C_{10} alkynyl;

20 R^6 is C_1 - C_8 alkyl, C_3 - C_8 branched alkyl, C_3 - C_7 cycloalkyl, C_3 - C_8 alkenyl or alkynyl, phenyl optionally substituted with 1 to 3 groups selected from C_1 - C_4 alkyl or alkoxy, F, Br, Cl, NH_2 , OH, CN, CO_2H , CF_3 , NO_2 , C_1 - C_4 carboalkoxy, NR^7R^8 , or $NCOR^7$; pentafluorophenyl, benzyl optionally substituted


25 with 1 to 3 groups selected from C_1 - C_4 alkyl or

alkoxy, F, Br, Cl, NH₂, OH, CN, CO₂H, CF₃, NO₂, C₁-C₄ carboalkoxy, NR⁷R⁸, or NCOR⁷;

Y is O, S, H₂, or NH, and


Z is NHR⁴, OR⁴, or R⁴,

5 to yield a compound of Formula (I):



wherein

R¹ and R² are selected independently from H, C₁-C₈ alkyl, C₃-C₈ branched alkyl, C₃-C₇ cycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₇-C₁₄ araalkyl, 2-, 3- or 4-pyridinyl, 2-thienyl, 2-furanyl, phenyl optionally substituted with 1 to 3 groups selected from F, Cl, Br, OH, C₁-C₄ alkoxy, C₁-C₄ alkyl, C₃-C₈ branched alkyl, CH₃S(O)_r, NO₂, CF₃, or NR⁷R⁸; or
 10 R¹ and R² can also be taken together as



where L is O, O(CH₂)_{m+1}O, or (CH₂)_m where m is 0-4;
 R³ is H, C₁-C₆ alkyl, allyl, benzyl, or phenyl
 20 optionally substituted with F, Cl, CH₃, CH₃O, or CF₃;
 R⁴ is straight chain C₁-C₈ alkyl optionally substituted with F; C₃-C₈ branched alkyl, C₃-C₇

- cycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₇-C₁₄ araalkyl where the aryl group is optionally substituted with 1 to 3 groups selected from C₁-C₄ alkyl or alkoxy, F, Br, Cl, NH₂, OH, CN, CO₂H, CF₃, NO₂, C₁-C₄ carboalkoxy, NR⁷R⁸, or NCOR⁷; C₃-C₆ alkenyl or alkynyl, C₁-C₃ perfluoroalkyl, phenyl optionally substituted with 1 to 3 groups selected from C₁-C₄ alkyl, C₃-C₈ branched alkyl, C₁-C₄ alkoxy, F, Br, Cl, NH₂, OH, CN, CO₂H, CF₃, NO₂, C₁-C₄ carboalkoxy, NR⁷R⁸ or NCOR⁷; pentafluorophenyl, benzyl optionally substituted with 1 to 3 groups selected from C₁-C₄ alkyl or alkoxy, F, Br, Cl, NH₂, OH, CN, CO₂H, CF₃, NO₂, C₁-C₄ carboalkoxy, NR⁷R⁸, or NCOR⁷; 2-, 3- or 4-pyridinyl, pyrimidinyl, or biphenyl;
- R⁵ is H, C₁-C₆ alkyl, or benzyl;
- R⁶ is C₁-C₈ alkyl, C₃-C₈ branched alkyl, C₃-C₇ cycloalkyl, C₃-C₈ alkenyl or alkynyl, phenyl optionally substituted with 1 to 3 groups selected from C₁-C₄ alkyl or alkoxy, F, Br, Cl, NH₂, OH, CN, CO₂H, CF₃, NO₂, C₁-C₄ carboalkoxy, NR⁷R⁸, or NCOR⁷; pentafluorophenyl, benzyl optionally substituted with 1 to 3 groups selected from C₁-C₄ alkyl or alkoxy, F, Br, Cl, NH₂, OH, CN, CO₂H, CF₃, NO₂, C₁-C₄ carboalkoxy, NR⁷R⁸, or NCOR⁷;
- R⁷ and R⁸ are selected independently from H or C₁-C₄ alkyl;
- X is S(O)_r, O, NR⁵, CH₂;
- A is C₂-C₁₀ alkyl, C₃-C₁₀ branched alkyl, C₃-C₁₀ alkenyl, or C₃-C₁₀ alkynyl;
- Y is O, S, H₂ or NH;
- Z is NHR⁴, OR⁴, or R⁴;
- r is 0-2,
- and, optionally forming a pharmaceutically acceptable salt thereof.

104. A process of Claim 103, further comprising removing any protecting group on R³.

105. A process of Claim 103, further comprising reacting a compound of Formula (I) where Y is O with
5 Lawesson's reagent or diphosphorous pentasulfide to yield a compound of Formula (I) where Y is S.

106. A process of Claim 103, further comprising reacting a compound of Formula (I) where Y is O with a reducing agent such as lithium aluminum hydride or
10 sodium borohydride, to yield a compound of Formula (I) where Y is H₂.

107. A process of Claim 103, further comprising reacting a compound of Formula (I) where X is S with a suitable oxidizing agent to yield either the sulfoxide,
15 SO, where r is 1, or the sulfone, SO₂, where r is 2.

108. A process of Claim 103, further comprising reacting a compound of Formula (I) where R³ is H with a suitable alkylating agent such as an alkyl halide, to
20 yield a compound of Formula (I) where R³ is C₁-C₆ alkyl, allyl, or benzyl.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US91/03727

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC(5) C07D 233/22 U.S. CL. 548/337, 514/398						
II. FIELDS SEARCHED <div style="text-align: center; margin-top: 10px;">Minimum Documentation Searched ⁷</div> <table style="width: 100%; border: none;"> <tr> <td style="width: 25%; border: none;">Classification System</td> <td style="border: none;">Classification Symbols</td> </tr> <tr> <td style="border: none; height: 40px; vertical-align: bottom;">U.S.</td> <td style="border: none; vertical-align: bottom;">548/337, 514/398</td> </tr> </table> <div style="text-align: center; margin-top: 10px;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸</div>			Classification System	Classification Symbols	U.S.	548/337, 514/398
Classification System	Classification Symbols					
U.S.	548/337, 514/398					
CHEMICAL ABSTRACT SERVICE STRUCTURE SEARCH						
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹						
Category [*]	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³				
X	US,A, 3950353 (DURANT) published 13 April 1876 (see entire document)	1-8,21,23,28, 33-40,53,55,60, 65-72,85,87,92				
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>[*] Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>						
IV. CERTIFICATION						
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report					
23 SEPTEMBER 1991	<div style="font-size: 24pt; font-weight: bold;">04 OCT 1991</div>					
International Searching Authority	Signature of Authorized Officer					
ISA/US	 CATHERINE S. KILBY SCALZO					

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers _____, because they relate to subject matter ¹² not required to be searched by this Authority, namely:

2. ☐ Claim numbers _____, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out ¹³, specifically:

3. ☐ Claim numbers _____, because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☒ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this International application as follows:

See the attached PCT telephone memo for lack of Unity of Invention.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.

2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:


1-8, 21, 23, 28, 33-40, 53, 55, 60, 65-72, 85, 87, 92-in-part

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

☐ The additional search fees were accompanied by applicant's protest.

☐ No protest accompanied the payment of additional search fees.



where R^1 and R^2 are H, alkyl, aralkyl or phenyl
 R^6 is not pyridinyl or pyrimidinyl, X is $S(O)_r$, Y is O.

Groups (II+): other compounds

These Groups are separate and distinct since they contain widely different chemical structures which would not be considered obvious over one another.